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 Infection with Shiga toxin-producing bacteria can place patients at risk of 
developing hemolytic uremic syndrome, a toxemic condition characterized by hemolytic 
anemia, thrombocytopenia, and acute renal failure.  Though hemolytic uremic syndrome 
remains the leading cause of acute renal failure in children under the age of 5, treatment 
of this disease remains purely supportive.  In order to limit the systemic effects of Shiga 
toxin, efforts must be undertaken to target intoxicated cells.  To this end, we have focused 
on two aspects of Shiga toxin pathogenesis.  One approach relied on a high-throughput 
screen of a small compound library to identify potential inhibitors of Shiga toxin 
intracellular transport, as Shiga toxin is known to undergo a stepwise progression through 
host cells following endocytosis.  This screen identified three compounds with distinct 
effects on Shiga toxin transport.  A detailed characterization of one of these inhibitory 
compounds, golgicide A, shed insight into the role of a guanine nucleotide exchange 
factor, GBF1, in coordinating bidirectional transport through the Golgi.  Golgicide A was 
found to be a potent and specific inhibitor of GBF1 and represents a novel tool for 
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probing intra-Golgi transport.  Our second approach adapted a siRNA screen of the 
human kinome to a high-throughput format.  In an effort to identify human kinases 
involved in Shiga toxin pathogenesis, we identified the mitogen-activated protein kinase-
activated protein kinase 2 (MK2) as a kinase involved in the host stress response to Shiga 
toxin.  MK2 was activated following ribotoxic stress and contributed to the Shiga toxin-
induced acute inflammatory response.  Genetic and chemical inhibition of MK2 
significantly reduced the expression of the inflammatory cytokines IL-6 and TNFα 
following Shiga toxin exposure.  MK2 thus represents a therapeutic alternative for 
treating the immunopathological response to Shiga toxin, and future efforts at dissecting 
its role in an in vivo mouse model of hemolytic uremic syndrome will help elucidate the 
contribution of the inflammatory response to Shiga toxin-mediated disease.      
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CHAPTER I 
 
Introduction 
 2 
Scope of Dissertation 
 
 The emergence of Shiga toxin (STx)-producing bacteria, most notably E. coli 
O157:H7, and the relative lack of therapeutic options for the treatment of STx-mediated 
disease underscore the need to elucidate the mechanisms of STx pathogenesis.  While 
considerable work has enhanced our molecular understanding of intracellular STx 
transport and the activation of the host stress response to STx, therapeutic alternatives 
aimed at limiting systemic injury remain limited.  The work presented in this thesis 
focuses on a dual approach to STx inhibition, highlighting the use of high-throughput 
screens to identify inhibitors of both STx transport and of the STx-induced inflammatory 
response.  The results from these studies have helped to identify three small molecule 
inhibitors acting at distinct stages in the STx transport pathway.  Further characterization 
of one compound elucidated the function of a host guanine nucleotide exchange factor in 
mediating anterograde and retrograde transport within the Golgi.  In addition, the 
identification and characterization of a kinase implicated in the inflammatory response to 
STx offered insight into a potential therapeutic target for mitigating the 
immunopathology associated with STx-mediated disease.  Future endeavors into the role 
of this kinase in mediating the host response to STx in an in vivo model system will be 
critical to understanding the initiation and regulation of the acute inflammatory response 
to STx. 
 
“Dans les champs de l’observation, le hasard ne favorise que les esprits préparés.” 
[“In the fields of observation, chance favors only the prepared minds.”]      
- Louis Pasteur        
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Shiga Toxin and the Pathophysiology of Hemolytic Uremic Syndrome 
 Bacterial exotoxins are critical components of bacterial pathogenesis.  The 
contribution of exotoxins to microbial pathogenesis relies on their ability to damage the 
host through various mechanisms.  Apart from the pore-forming toxinss, which bind the 
plasma membrane where they oligomerize and undergo a conformational change to 
penetrate and damage the host membrane, most toxins act intracellularly to cause 
cytotoxicity.  Among the intracellular toxins, the AB family of toxins is distinguished by 
a receptor-binding B moiety that is non-covalently linked to an enzymatic A subunit.  
Toxin-mediated cytotoxicity depends on the A subunit reaching its cytosolic targets.  
Several toxins damage host cells by inhibiting protein synthesis: diphtheria toxin (DT) 
and Pseudomonas exotoxin (PE) inhibit protein synthesis through the ADP-ribosylation 
of elongation factor 21,2, whereas Shiga toxin (STx) and the plant toxin ricin inhibit 
ribosome function by cleaving an adenine residue from the 60S ribosome3-7.  Still other 
toxins, such as cholera toxin (CTx) and anthrax edema toxin, induce increases in second 
messenger levels, resulting in cytotoxicity8-10.    
   Despite increasing insight into the mechanisms underlying toxin-mediated 
disease, bacterial toxins constitute a continuing global health threat.  Of particular 
importance in the U.S. has been the recent emergence of STx-producing bacteria.  STx 
was initially identified in Shigella dysenteriae type I, though it is now commonly 
associated with strains of STx-producing Escherichia coli (STEC), among which E. coli 
O157:H7 has become the most clinically relevant.  Transmission of STEC is primarily 
foodborne, with outbreaks emanating from sources ranging from meat products to 
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vegetables.  The incidence of STEC in the U.S. varies by age group, with the highest 
incidence occurring in children under 15 years of age11.   
 In a subset of patients (3-15%), gastrointestinal infection with STEC may 
progress to extraintestinal injury, leading to hemolytic uremic syndrome12 (HUS; Figure 
1).   This toxemic syndrome is clinically defined by renal failure, thrombocytopenia, and  
 
 
Figure 1.  Progression of E. coli 0157:H7 infections in children.  Following ingestion of a contaminated vehicle, 
patients develop bloody diarrhea.  In a subset of patients (as high as 15%), intestinal colonization can progress to a 
toxemic condition known as hemolytic uremic syndrome (HUS).  Adapted from Tarr et al. 13  
 
hemolytic anemia, and it remains the leading cause of acute renal failure in children14,15.  
In addition, nearly one third of patients with HUS will experience neurologic 
complications, including irritability and altered mental status12.  While the clinical 
characteristics of HUS have become more clearly defined, treatment remains purely 
supportive.  Indeed, hemodynamic stability through electrolyte and fluid monitoring 
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represents the most important therapeutic measure in the treatment of HUS and is crucial 
in preventing progression to renal failure16.      
 The pathophysiology of HUS primarily results from STx-mediated effects, and 
extraintestinal complications of HUS appear to correlate with circulating levels of the 
toxin.  The mechanisms of STx-induced toxicity remain unclear, however.  One of the 
pathologic hallmarks of HUS is the development of thrombotic lesions within the 
intestinal and renal microvasculature that accounts for the associated hemorrhagic colitis, 
hemolytic anemia, and renal failure17.  It has been suggested that STx targeting of 
endothelial cells that line the microvasculature could account for the characteristic 
thrombotic microangiopathy associated with HUS13, and the proposed mechanisms by 
which STx is believed to induce these changes will be discussed later.  While antitoxin 
therapy through parenteral administration of anti-STx antibodies or STx-binding agents 
would seem like a logical therapeutic alternative to the more supportive and established 
measures, clinical trials have consistently showed little therapeutic benefit18.  By the time 
of HUS diagnosis, the extraintestinal injury cascade is likely underway, and antitoxin 
therapy would prove ineffective against cells that have already internalized toxin.  It 
therefore becomes imperative to inhibit STx pathogenesis in intoxicated cells to 
effectively mitigate HUS pathology and limit systemic injury.     
 
Shiga Toxin Transport  
 A direct therapeutic approach to inhibiting STx pathogenesis relies on targeting 
STx transport in intoxicated cells.  STx is a member of the AB5 family of bacterial 
exotoxins, a group of bacterial toxins with unique trafficking mechanisms.  STx, like the 
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bacterial toxin CTx and the plant toxin ricin, is unable to cross host membranes and must 
progress in a retrograde fashion following endocytosis in order to reach its cytosolic  
target (Figure 2).  Following endocytosis into an early endosome, the toxin bypasses 
lysosomal degradation and eventually reaches the endoplasmic reticulum (ER) via the  
 
 
 
Figure 2.  Intracellular transport of protein toxins.  Diagram of the stepwise progression of various protein toxins 
through the host cell.  A more detailed description of the retrograde transport of STx is included in the text.  Adapted 
from Falnes, P.O. and Sandvig, K.A.19 
 
Golgi.  Once in the ER, the catalytic A subunit is retrotranslocated across the ER 
membrane and accesses the cytosol, where it can target translationally active ribosomes 
and shut off protein synthesis.   
 The existence of a retrograde transport pathway was first uncovered by electron 
microscopic studies tracking the intracellular transport of STx20, and it has become 
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increasingly apparent that this retrograde trafficking pathway is not unique to bacterial 
toxins.  Rather, bacterial toxins are believed to hijack existing host endocytic 
mechanisms, and STx has thus emerged as a useful tool for elucidating host mechanisms 
underlying its transport.  The ability of these toxins to string together existing retrograde 
mechanisms translates into a unique system for probing host retrograde transport in its 
entirety.   
 
Toxin-receptor interactions 
 Toxin tropism and the clinical manifestations of toxicity are dictated by toxin-
receptor interactions.  Of particular interest is the binding of the STx to its lipid raft-
associated receptor, the neutral glycosphingolipid globotriaosyl ceramide (Gb3).  The 
association with lipid rafts may serve as a scaffold for the trafficking machinery and 
appears to determine the fate of endocytosed toxin.  Interestingly, STx is not associated 
with lipid microdomains in differentiated monocyte-derived cell lines, which are 
relatively resistant to STx’s cytotoxic effects21.  Though the mechanisms underlying lipid 
raft internalization remain poorly defined, STx likely subverts endogenous lipid raft 
recycling pathways22 or redirects these pathways at some stage along its transport in 
susceptible cells.   
 
Endosome-to-TGN transport 
 Following the interaction with its receptor, STx internalization consists of uptake 
into early endosomes.  In contrast to DT and the anthrax toxins, which can enter the 
cytosol directly from early endosomes in a pH-dependent manner, STx is unable to cross 
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host membranes and must rely on a more labored transport to reach its cytosolic targets.  
This membrane-bound toxin bypasses the late endocytic pathway by retrograde transport 
from early or sorting endosomes to the trans-Golgi network (TGN)23,24.  Besides cell-
type differences in clathrin-dependent endocytosis, increasing evidence suggests that STx 
is internalized through both clathrin-coated pits and clathrin-independent mechanisms, 
underscoring the multiple endocytic routes that can be accessed and exploited by the 
toxin.  Despite this complexity, STx converges on early or recycling endosomes while 
bypassing lysosomal degradation25.  Studies using STx as an endocytic marker first 
characterized an alternate pathway that could redirect internalized STxB-containing 
vesicles away from fusion with late endocytic vesicles en route to the TGN.  Several host 
molecules have been implicated in endosome-to-TGN transport, most notably members 
of the Rab family of GTP-binding proteins involved in vesicular trafficking26.  
 
Intra-Golgi transport and retrotranslocation 
   The molecular components involved in intra-Golgi toxin transport have been less 
studied than those related to endosome-to-TGN fusion, but retrograde transport within 
Golgi stacks has proven essential to toxin pathogenesis.  As with trafficking through 
other organelles, the ability of protein toxins to exploit multiple existing trafficking 
routes within the Golgi has shed insight into the essential components of these pathways.  
CTx and PE, for example, bear C-terminal KDEL or KDEL-like motifs to make use of 
the COPI-dependent, KDEL receptor recycling pathway27,28.  The molecular machinery 
recruited to COPI-containing vesicles has been extensively studied, and several proteins 
that constitutively cycle between the ER and Golgi, including ERGIC-53 and the KDEL 
 9 
receptor, are known to utilize this pathway.  STx and ricin, on the other hand, lack KDEL 
motifs and exhibit COPI-independent transport through the Golgi.  These protein toxins 
exploit a Rab6-dependent pathway, as dominant negative mutants of this small GTP-
binding protein blocked STxB delivery to the ER29.  This COPI-independent pathway is 
also used for transport to the ER of Golgi-resident glycosyltransferases.   
 The penultimate destination for STx following retrograde trafficking is the ER.  
STx has been demonstrated to undergo reverse translocation through the Sec61 
translocon in order to reach the cytoplasm.  It has been proposed that STxA, like CTx and 
ricin, is able to mimic the structure of a misfolded protein and thereby exploit the host 
translocation machinery for transport from the ER to the cytosol30.    
 Taken together, the sequential transport of STx occurs through the subversion of 
preexisting host transport pathways.  However, these pathways remain poorly 
characterized, in part due to inadequate methods to probe individual stages in toxin 
transport.  In the context of STx pathogenesis, enhanced insight into these pathways are 
significant, as it is believed that this complex retrograde pathway may allow for certain 
essential steps in toxin activation and transfer; STx has been shown to be cleaved and 
activated by host proteases31.  As a result, the necessary stepwise progression of STx 
through the cell allows for distinct stages in the toxin trafficking pathway to be targeted 
and enables the characterization of host molecules essential to this process.  Moreover, 
the ability to inhibit toxin trafficking would prove particularly useful in cells that have 
already internalized toxin, where inhibition of STx transport could potentially inhibit 
STx-mediated cytotoxicity. 
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A Small Compound Approach to Shiga Toxin Inhibition 
 In an effort to dissect and inhibit the stepwise trafficking of STx, our lab 
developed a quantitative high-throughput luciferase-based assay 32 to screen libraries of 
small compounds for their ability to block STx-mediated inhibition of protein synthesis.  
In cells constitutively expressing luciferase mRNA, the level of protein synthesis could 
be determined by measuring light output from the oxidation of D-luciferin, which is 
directly proportional to the level of luciferase translation.  It was shown that this highly 
sensitive read-out of protein synthesis could clearly distinguish toxin-susceptible cells 
exhibiting decreased levels of protein synthesis from untreated cells and cells treated with 
a combination of toxin plus anti-toxin antibodies 32.  More importantly, this assay could 
be used to reproducibly screen libraries of small compounds in a high-throughput format.   
 Previous studies aimed at identifying essential components of the retrograde 
pathways used by STx, ricin, and CTx have largely focused on standard genetic 
approaches involving overexpression of dominant negative mutants or siRNA knock-
downs of various intracellular targets.  While these studies have uncovered novel 
molecular players at various stages of toxin trafficking, they have equally revealed 
inconsistencies in their effects on various toxins.  For example, disruption of the Golgi 
apparatus had found that ricin was able to bypass the Golgi apparatus en route to the    
ER 33.  Whether these alternate routes are physiologically relevant remain to be seen, 
underscoring a limitation to genetic and irreversible manipulations of trafficking 
pathways.  These approaches have been unable to identify a single trafficking mediator or 
pathway affecting STx en route to the ER. 
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The study of microbial pathogenesis through high-throughput screens  
 Pharmacological compounds have recently gained interest as an alternative to 
genetic approaches.  In particular, small molecules provide an informative chemical 
genetic method of studying biological activity in live cells in a controlled and reversible 
manner 34.  The structural diversity of small molecules allows for the screening of large 
compound libraries for desired phenotypic effects.  As these compounds are readily 
adaptable to high-throughput screens (HTS), numerous commercially available libraries 
have been used to enhance our understanding of microbial pathogenesis and eukaryotic 
trafficking.  From a library of 12,160 compounds, 24 inhibitors of Toxoplasma gondii 
invasion were identified 35.  These included compounds that inhibited host uptake of the 
organism as well as inhibitors of Toxoplasma gliding motility and microneme-based 
secretion.  Recently, a similar screen identified a small molecule inhibitor of Vibrio 
cholera virulence 36.  50,000 compounds were screened, from which 109 compounds that 
inhibited virulence factor expression were identified.  Of these, virastatin was 
characterized and found to inhibit the transcriptional regulator ToxT, thereby suppressing 
the expression of cholera toxin and the toxin co-regulated pilus.   
 With respect to toxin trafficking, few studies have used HTS with inhibition of 
toxin trafficking as the goal.  A recent study identified potent antagonists of botulinum 
neurotoxin A by screening for small molecules that could inhibit the cleavage of vesicle 
docking proteins by the light chain metalloprotease of the toxin 37.  Though this study did 
not focus on trafficking of the toxin, another study identified a small molecule, Exo2, that 
blocked CTx transport by causing disassembly of the Golgi and a redistribution of Golgi 
proteins to the ER, similar to the effects caused by the well-known fungal metabolite 
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brefeldin A 38 (BFA).  While the mechanisms and targets of these small molecules have 
not been completely solved, these studies highlight the utility of small compounds in our 
understanding into the biology of retrograde transport and its implications on organelle 
function and organization. 
 
Identification and characterization of inhibitors of STx transport 
 A high-throughput screen of over 14,400 small compounds identified several 
potential inhibitors of Shiga toxicity.  Among these, we validated and further 
characterized two compounds, compounds 75 and 134, that reversibly inhibited Shiga 
intoxication at distinct steps along its trafficking pathway.  Our initial screening results 
validated the small molecule approach toward our understanding of essential components 
in toxin transport. 
 A subsequent screen of a small compound library consisting of biologically active 
compounds identified golgicide A (GCA), the most potent reported inhibitor of Shiga 
toxicity.  Initial characterization of this compound revealed that it inhibited endosome-to-
Golgi transport of STx by reversibly ablating the Golgi and inducing a rapid dissociation 
of COPI vesicle coats from Golgi membranes.  In addition, GCA was found to 
specifically inhibit GBF1, the guanine nucleotide exchange factor for ARF1, thereby 
inhibiting bidirectional transport through the Golgi.  More importantly, the mechanistic 
characterization of GCA highlighted the central role of GBF1 in coordinating vesicle 
transport and maintaining the structural integrity of the Golgi.  Our high-throughput 
screen of small molecule libraries thus yielded three compounds with distinct effects on 
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STx transport.  Taken together, small molecules offer a novel approach to studying STx 
transport and uncovering the host transport mechanisms that underlie it.   
  
From Chemical Genetics Back to Genetics 
 While small molecule compounds are amenable to high-throughput screening and 
allow for the reversible manipulation of cellular processes, the rate-limiting step in these 
studies is the identification of the compound’s target.  Indeed, the targets of many small 
compounds pulled out of high-throughput screens have yet to be identified, and the 
criteria for validating compound specificity are not always met.  In addition, “off-target” 
effects must be considered when using these compounds at relatively high concentrations.  
As a result, we decided to take an inherently target-based approach to studying STx 
pathogenesis.  By adapting a siRNA screen to a high-throughput format, we screened the 
human kinome for kinase and kinase-associated genes whose knock-down would protect 
against Shiga toxicity in HeLa cells.   
 
Kinases and STx transport  
 As the role of kinases in Shiga toxicity remains largely unexplored, we reasoned 
that the functional diversity of kinases would enable a multifocal approach to studying 
STx pathogenesis.  On the one hand, the role of kinases in coordinating intracellular 
transport is not new, and some studies have identified kinases essential to STx 
internalization and trafficking.  Most recently, a study showed that STx binding to the 
cell surface resulted in the activation of the Src family kinase Syk, leading to the tyrosine 
phosphorylation of several downstream endocytic components, including the clathrin 
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heavy chain 39.  Binding of STx to the Gb3 receptor in a renal tubular epithelial 
carcinoma cell line also resulted in transient phosphorylation and redistribution of various 
proteins involved in cytoskeletal rearrangements 40.  Using ezrin phosphorylation as a 
readout for the initiation of downstream signaling events, various kinases were shown to 
be involved, including the Src family kinase PTK, PI 3-kinase, and Rho-associated 
kinase, but the role of each of these in toxin trafficking beyond internalization into an 
endosome was not studied.   
 The exact mechanism by which the STxB subunit engages its Gb3 receptor 
leading to receptor kinase activation and cytoskeletal reorganization remains to be seen.  
It is believed that the clustering of bound receptors within lipid rafts provides a scaffold 
for toxin internalization and enhances the toxin’s interaction with trafficking machinery.  
Whether the kinases that function in toxin internalization also contribute to subsequent 
steps in toxin trafficking, including endosome fusion with the TGN or intra-Golgi 
transport, is not known.  As toxins subvert existing host trafficking pathways, a 
characterization of kinases at distinct steps in toxin trafficking will likely reveal the role 
of kinases in mediating intracellular membrane trafficking.  
 
Kinases and the stress response to STx 
 Equally important is the critical role of kinases in mediating the stress response to 
STx.  Perhaps the most studied kinases involved in STx-induced stress pathways are 
members of the mitogen-activated protein kinase (MAPK) family.  MAPKs are signal-
transducing enzymes involved in a variety of regulatory roles in eukaryotes, including 
inflammation, differentiation, and apoptosis 41.  The p38 MAPK (p38) plays a central role 
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in the response to various insults, including UV radiation, cytokines, and toxic stress 42.  
In the context of STx-mediated damage, numerous studies have clearly defined the role 
of p38 in inciting inflammatory cytokine release from toxin-treated cells 43,44.  One study, 
for example, showed that sequence-specific damage to 28S rRNA by STx stimulated a 
ribotoxic stress response that resulted in p38 activation 45.  
 The contribution of the stress response to HUS pathology remains a debated topic 
in the field.  Some studies have suggested a direct role for STx in the thrombotic 
microangiopathy of HUS.  Of note, intravenous injection of STx into the mesenteric 
arteries of rats induced hemorrhagic lesions46.  Another study found that STx treatment of 
human glomerular endothelial cells decreased the expression of fibrinolysis factor47.  
Taken together, it has been proposed that STx contributes to HUS by directly injuring 
vascular endothelium and inducing a pro-coagulant state through the stimulation of 
endothelial thrombotic factors13.  Moreover, STx-induced cytotoxicity of endothelial cells 
may expose a collagen-rich subendothelial matrix conducive to clot formation.   
 Other lines of evidence support the view that much of the systemic and focal 
pathology is immune-mediated.  STx has been shown to upregulate endothelial cell 
cytokine expression in vitro, and pretreatment of endothelial cells with TNFα or IL-1β 
enhanced sensitivity to STx by upregulating Gb3 receptor expression48.  Exposure of 
endothelial cells to cytokines in vitro also upregulated surface expression of the leukocyte 
adhesins ICAM-1 and VCAM-149.  Clinically, increased cytokine levels have been 
detected in urine samples of HUS patients50.  It has thus been hypothesized that HUS 
could be considered an immunopathologic response to STx, though the immune 
mediators of this response remain to be identified.           
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   A synthesis of the two prevailing theories behind HUS pathology would claim 
that this toxemic syndrome results from a combination of direct toxic effects and toxin-
elicited immunopathology.  The dual role of kinases in regulating STx transport and STx-
mediated cell injury thus makes them an ideal target for studying STx pathogenesis.  In 
particular, the ability to limit the inflammatory response to STx through inhibition of 
immunomodulatory kinases would prove crucial to reducing Shiga toxicity and provide a 
therapeutic alternative for the treatment of HUS.    
    
Role of MAP kinase-activated protein kinase 2 (MK2) in the STx-induced inflammatory 
response 
 Though the mechanisms behind STx activation of immune signaling cascades 
remain unclear, a crucial component is the ability of kinases to propagate the stress signal 
and initiate a cellular response.  As a result, kinases are tempting therapeutic targets for 
limiting STx-mediated cellular injury.  For example, inhibition of p38 activation 
decreased cytokine release following exposure of macrophages to STx 51.  However, p38 
inhibition may have limited therapeutic potential, given the ability of p38 to activate 
various downstream kinases involved in diverse cellular functions.  Indeed, mice 
deficient in p38 are not viable post-natally 52-54, and in human clinical trials p38 
inhibition has been met with unanticipated side effects 55.  Moreover, inhibition of p38 
kinase activity by overexpression of dominant negative p38 isoforms 56 or by treatment 
with chemical inhibitors 57 has made probing of specific p38-dependent signaling 
pathways particularly difficult.  Effectors downstream of p38 might therefore be more 
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specific and functionally relevant to the inflammatory signals induced in response to   
STx 58.   
 The mitogen-activated protein kinase-activated protein kinase 2 (MK2) has been 
recently shown to contribute to the inflammatory response 59.  MK2 is a member of the 
MK subfamily of calcium/calmodulin-dependent kinases that was originally identified as 
an in vivo substrate of p38 60.  Activation of MK2 by p38 results primarily in the 
subsequent phosphorylation of its two main substrates, heat shock protein 27 (Hsp27) and 
tristetraprolin (TTP).  Of note, TTP has been shown to mediate the degradation of 
cytokine mRNA transcripts bearing AU-rich elements (ARE) in their 3’-UTR.  
Phosphorylation of TTP by MK2 leads to sequestration of TTP and stabilization of 
cytokine mRNAs including, but not limited to, IL-6 and TNFα.  As a result, MK2 
contributes to the inflammatory response through the post-transcriptional stabilization of 
 
Figure 3.  MK2-mediated post-transcriptional stabilization of cytokine mRNAs.  Shown is a schematic of the role 
of MK2 in stabilizing cytokine mRNA transcripts containing AU-rich elements (ARE).  Phosphorylation of TTP by 
MK2 leads to its sequestration by 14-3-3 proteins and subsequent stabilization of cytokine mRNAs.  In its 
unphosphorylated state, TTP binds to the ARE of cytokine mRNAs and directs their degradation.  The phosphatase 
PP2A promotes mRNA degradation by dephosphorylating TTP.  TTP, tristretraprolin; MK2, mitogen-activated protein 
kinase-activated protein kinase 2; PP2A, protein phosphatase 2A.  Adapted from http://www.dkfz.de/en/posttrans-
genreg/Research.html. 
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cytokine mRNAs (Figure 3).  Although MK2 has been implicated in an in vivo 
inflammatory response to LPS 59, the role of MK2 in STx-mediated toxicity has yet to be 
explored.   
 From a high-throughput siRNA screen of the human kinome, knock-down of 
MK2 was found to protect against Shiga toxicity.  Subsequent characterization of MK2 
revealed that MK2 activation depends on catalytically active STx following damage to 
the ribosome.  Chemical and genetic inhibition of MK2 significantly reduced the in vitro 
cytokine response to STx, further implicating MK2 as an important modulator of Shiga 
toxicity. 
 
Mouse model for assessing the In vivo role of MK2 in Shiga toxicity    
 The paucity of adequate animal models that recapitulate the pathological features 
of HUS has made it particularly difficult to correlate and validate in vitro findings in an 
in vivo setting.  Though administration of intravenous STx in primates did reproduce 
elements of HUS pathology61, the development of small animal models has proven less 
fruitful.  In particular, murine models of HUS, until recently, failed to produce 
glomerular thrombotic microangiopathy, a clinical hallmark of HUS and a major 
contributor to acute renal failure.  Moreover, some of these studies employed bacterial 
endotoxin, or lipoplysaccharide (LPS), in combination with STx and obtained varying 
results that depended on the dose and time of administration62.  Pretreatment with LPS 
has been shown to be protective against Shiga toxicity, while later LPS administration 
enhanced certain elements of STx-induced pathology63. 
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 Recently, a mouse model of HUS using endotoxin-free STx treatment was 
validated64.  Mice injected intra-peritoneally with three sublethal STx doses over the 
course of a week developed anemia, glomerular thrombotic microangiopathy, and acute 
renal failure  (Figure 4).              
A)                 B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Mouse model of hemolytic uremic syndrome.  Shown are two figures taken from Sauter, A.D., et al. 
(2008).  (A) Injection of mice with 3 injections of 1 ng STx2/20 g body weight (3x1) exhibit decreased renal function, 
as observed by increased serum levels of blood urea nitrogen (BUN) and creatinine compared to saline-treated controls 
(S).  (B) Mice injected with 3 sublethal doses of STx2 (3x1) show increased renal deposition of fibrin/fibrinogen 
compared to saline-injected mice or mice injected with a single, 5-ng/20g body-weight dose (1x5).  Shown are kidney 
sections stained immunohistochemically for fibrin/fibrinogen.  Bar, 20 µm.            
    
       
 We have adopted this model in order to assess the contribution of the 
inflammatory response to HUS pathology.  Given our identification of MK2 as a 
significant kinase in the immune response to STx, we plan to investigate the contribution 
of MK2 to Shiga toxicity in vivo.  More generally, the immunopathological contribution 
to HUS will be studied through MK2 deletion, as MK2 has been previously shown to 
modulate the inflammatory response in other pathological states59.  To that end, we are in 
the process of adapting the recently validated murine model of HUS to MK2-deficient 
mice and will compare the development of HUS pathology to wild-type mice.  A detailed 
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assessment of the systemic pathologic features of HUS in wild-type versus MK2-deficent 
mice will allow us to more clearly define the contribution of the immune system to the 
development of HUS.        
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CHAPTER II 
Identification and characterization of small molecules 
that inhibit intracellular toxin transport 
 30 
OVERVIEW 
 The intracellular transport pathway utilized by Shiga toxin (STx) was first 
discovered in 1992, and this unique retrograde trafficking mechanism has since been 
validated in other toxins, including cholera toxin and ricin.  The ability of these protein 
toxins to string together existing host transport mechanisms and direct their transport to 
intracellular targets makes them ideal probes for studying host retrograde transport in its 
entirety.  Standard genetic approaches, including overexpression of dominant negative 
mutants or knock-down of candidate genes by siRNA, have been undertaken to identify 
components essential to these pathways.  Most of these studies have produced 
inconsistent effects on toxin transport, underscoring the complexity of these pathways 
and the need for novel approaches to systematically investigate dynamic endocytic and 
trafficking mechanisms.  To this end, our lab has turned to small molecules as a means of 
reversibly manipulating STx trafficking.  Using a luciferase-based assay for determining 
susceptibility to STx, we screened a library of over 14,000 small molecule compounds of 
unknown function in order to identify inhibitors of Shiga toxicity.  Further 
characterization of inhibitors identified from the screen led to the discovery of two 
compounds, 75 and 134, that reversibly blocked STx transport at distinct stages in the 
STx trafficking pathway.  Though the targets of these small compounds have yet to be 
identified, this study validated the small molecule approach to toxin inhibition and 
provided a preliminary framework for identifying potential therapeutics in the treatment 
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of toxin-mediated diseases.  The work describing these studies is presented in this chapter 
and published in Infection and Immunity†
 
.         
SUMMARY 
 Shiga toxin (STx), cholera toxin (CTx), and the plant toxin ricin are among 
several toxins that reach their intracellular destination via a complex route.  Following 
endocytosis, these toxins travel in a retrograde direction through the endosomal system to 
the trans-Golgi network (TGN), Golgi, and endoplasmic reticulum (ER).  There, the 
toxins are transported across the ER membrane to the cytosol where they carry out their 
toxic effects.  Transport via the ER from the cell surface to the cytosol is apparently 
unique to pathogenic toxins, raising the possibility that various stages in the transport 
pathway can be therapeutically targeted.  We have applied a luciferase-based high-
throughput screen to a chemical library of small molecule compounds in order to identify 
inhibitors of STx.  We report two novel compounds that protect against STx and ricin 
inhibition of protein synthesis and demonstrate that these compounds reversibly inhibit 
bacterial transport at various stages in the endocytic pathway.  One compound 
(compound 75) inhibited transport at an early stage of STx and CTx transport and also 
provided protection against diphtheria toxin, which enters the cytosol from early 
endosomes.  In contrast, compound 134 inhibited transport from recycling endosomes 
through the Golgi and only protected against toxins that access the ER.   Small molecule 
compounds such as these will provide insight into the mechanism of toxin transport and 
                                               
† Saenz, J.B., Doggett, T.A., and Haslam, D.B.  2007.  Identification and characterization of small 
molecules that inhibit intracellular toxin transport. Infect. Immun. 75: 4552-4561. 
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lead to the identification of compounds with therapeutic potential against toxins routed 
through the ER.  
 
INTRODUCTION 
 Bacterial and plant toxins are significant agents of human disease and potential 
vehicles for bioterrorism.  Though diverse in their intracellular targets, a common and 
essential step in their virulence is the ability to reach the cytosol, where most toxins exert 
their enzymatic effects.  The bacterial exotoxins Shiga toxin (STx) and cholera toxin 
(CTx), as well as the plant toxin ricin, have drawn particular interest for their unique 
retrograde transport following endocytosis.  Members of the AB toxin group, these toxins 
consist of a receptor-binding B subunit and an enzymatic A subunit.  In contrast to 
anthrax and diphtheria toxins, AB toxins that enter the cytosol directly from early 
endosomes in a pH-dependent manner1, these membrane-bound toxins bypass the late 
endocytic pathway by retrograde transport from early or sorting endosomes to the trans-
Golgi network (TGN) 2,3.  From the TGN, they traffick through the Golgi to the 
endoplasmic reticulum (ER), where they are subsequently translocated through the 
Sec61p channel into the cytosol via ER quality control mechanisms 4-6.  It is believed that 
this complex retrograde transport may allow for certain essential steps in toxin activation 
and transfer; STx has been shown to be cleaved and activated by host proteases 7.  
Similarly, the ability to reach the ER may enable a chaperone-facilitated transfer to the 
cytosol, as previously reported for CTx, ricin, and STx 4,6,8,9. 
 The existence of a retrograde transport pathway was first uncovered by electron 
microscopic studies tracking the intracellular transport of STx 10.  Since that time, several 
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toxins, in addition to CTx and ricin, have likewise been found to transit through the ER 
en route to the cytoplasm.  Given the importance of these pathways to intoxication by 
diverse pathogenic agents, a number of investigations have been directed at identifying  
host molecules involved in toxin transport.  Previous studies aimed at identifying 
essential components of the retrograde pathways of STx, ricin, and CTx have largely 
focused on the Rab family of small GTP-binding proteins.  Members of the Rab family 
cycle between their GTP and GDP-bound forms, related to their functions as regulators of 
vesicular traffic 11.  Standard genetic approaches involving overexpression of dominant 
negative mutants or siRNA knock-downs of various Rabs have revealed the complexity 
of toxin trafficking pathways.  Inhibition of Rab7 and Rab9, which are involved in 
lysosome targeting pathways, had no effect on ricin and STx trafficking 12,13.  In contrast, 
inhibition of Rab6a’, involved in endosome-to-TGN transport, inhibited STx transport 
from endosomes through the Golgi 14-16 but had no effect on ricin transport or 
intoxication 17.  Similarly, overexpression of a dominant-negative Rab11, implicated in 
recycling endosome-to-TGN transport, resulted in impaired STx transport but had no 
effect on ricin 3,12.  Rab22, like Rab6a’, has been implicated in endosome-to-TGN 
transport, though inhibition of Rab22 function has had inconsistent results on retrograde 
toxin transport 18.  Though these pathways still remain poorly characterized, the 
sequential retrograde progression utilized by these toxins has translated into a unique 
system for probing host endocytic mechanisms.   
 In an effort to dissect and inhibit the stepwise trafficking of STx, we have 
developed a quantitative and highly sensitive, high-throughput luciferase-based assay to   
screen a library of small molecule compounds for their ability to block Stx-mediated 
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inhibition of protein synthesis 19.  Because STx transport involves a multi-step 
progression through the cell, we predicted that inhibitory compounds could be identified 
at distinct stages along the retrograde trafficking pathway and could potentially be 
directed at specific molecular targets.  From an initial screen of 14,400 small compounds, 
we identified several potential inhibitors.  Among these, we characterized two 
compounds (compounds 75 and 134) that reversibly inhibit Shiga intoxication and act at 
distinct steps along the toxin trafficking pathway.  Our results demonstrate the utility of a 
small molecule approach to elucidating toxin transport pathways and will lead to the 
identification of novel therapeutic approaches targeting diseases caused by ER-routed 
toxins. 
 
RESULTS 
High-throughput screen for compounds that inhibit STx activity in host cells.  
Several toxins damage host cells by inhibiting protein synthesis.  Diphtheria toxin 
(DT) and Pseudomonas exotoxin (PE) inhibit protein synthesis through the ADP-
ribosylation of elongation factor 2 20,21, whereas STx and the plant toxin ricin inhibit 
ribosome function by cleaving an adenine residue from the 60S ribosome 22-26.  Still other 
toxins, such as CTx and anthrax edema toxin, induce increases in second messenger 
levels, resulting in cytotoxicity 27-29.  In order to quantify the effects of various protein 
synthesis-inhibiting toxins on host cells, we had  previously established a luciferase-
based assay that could readily determine the susceptibility of various cell lines to Stx, 
ricin, DT, and PE30.  In cells constitutively expressing an mRNA encoding destabilized 
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firefly luciferase, luciferase enzyme activity served as a surrogate measure of protein 
synthesis.       
This assay was adapted to a high-throughout screen (HTS) and applied to a screen 
of small molecule compounds that inhibit toxin susceptibility.  The ICCB facility at 
Harvard University contains a number of commercial libraries consisting of synthetic and 
natural products.  An initial screen of biological compounds with known effects yielded 
positive hits such as brefeldin A (BFA) and D,L-threo-1-phenyl-2- decanoylamino-3-
morpholino-1-propanol  (PDMP; data not shown), two compounds previously shown to 
inhibit STx susceptibility through distinct mechanisms 31,32 and serving as positive 
controls for the detection of STx-inhibitory compounds.  In addition, the assay detected 
known inhibitors of the proteasome, such as MG-132.  This was an expected result, as the 
discriminatory power of the assay is dependent on rapid degradation of luciferase 
following translation30.      
 We next screened the ChemDiv 3 library at the ICCB facility, consisting of 
14,400 compounds of unknown function.  The compounds included in this library were 
selected for their structural diversity, chemical stability, and “drug-like properties.”  As 
these compounds were commercially available and their functions currently undefined, 
we reasoned that novel inhibitors could be identified.  Among these were selected the top 
1% of compounds yielding the highest luciferase signal in the presence of toxin, all of 
which resulted in a signal at least twice baseline.  As the initial screen lacked a 
counterscreen to exclude compounds affecting luciferase turnover, each compound was 
subsequently tested for its effect on luciferase signal following cycloheximide treatment.  
Cycloheximide-mediated inhibition of protein synthesis is independent of intracellular 
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transport, and its mechanism of ribosomal inactivation is distinct from that of STx 33.  
Therefore, compounds that provided protection against cycloheximide-mediated 
inhibition of luciferase signal must be acting in a toxin-independent manner (e.g., by 
inhibiting luciferase degradation), and these were excluded from further analysis.  After 
excluding compounds that affected cycloheximide-induced suppression of luciferase 
signal, eight compounds with toxin-specific effects were selected for further analysis.   
Notably, subsequent screens have incorporated a cycloheximide counterscreen in order to 
exclude compounds with toxin-independent effects prior to secondary analysis (Figure 1). 
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Figure 1. A sample plate from the high-
throughput screen.  Vero cells were 
transduced with pAD-Luc, seeded in 384-well 
plates, and incubated for 1 h with various 
known biological compounds, followed by 
treatment with Shiga toxin (STx; 1 ng/ml) or 
cycloheximide (CHX; 2 mg/ml) for 5 h.  
SuperLight Reagent was added, and relative 
light output (RLU) was determined.  Replicates 
(up/down arrowheads) of STx- or CHX-treated 
samples are presented by sample number, and 
the insets demonstrate Z’ and Z factors 
calculated for each replicate plate.  Since each 
plate contains 16 negative controls (wells 
treated with STx or CHX but lacking 
compound) and 16 positive controls (wells 
treated with neither toxin, CHX, nor 
compound), the Z’- and Z-factors can be 
calculated for each plate.  The Z’-factor (a 
measure of the ability of an assay to distinguish 
positive controls from negative controls) ranged 
from 0.61 to 0.74.  The Z-scores (the ability of 
an assay to distinguish true hits from negative 
controls) ranged from 0.46 to 0.62 for the 
known biologicals, and, as expected, varied 
depending on the composition of the library.  
An assay having Z’- and Z-scores greater than 
0.5 is considered excellent for HTS    purposes 
34.  In contrast to proteasomal inhibitors MG-
132 and 3,4-dichloroisocoumarin, which were 
positive on STx- and CHX-treated replicates, 
some compounds scored as positives on the 
STx-treated plates and were negative on the 
CHX-treated plates (circles), including 
brefeldin A (BFA), a known inhibitor of STx 
intracellular transport.  
 
 
Secondary analysis to determine potency and efficacy of inhibitory compounds 
 The optimal protective concentration for each identified hit was determined using 
a radioactive assay for protein synthesis 35 that was modified for medium-throughput 
analysis in a multi-well format (see Methods).  As some of these compounds could 
exhibit non-specific effects at increased concentrations, the lowest concentration 
providing significant protection against STx compared to untreated Vero cells was 
considered to be optimal.  Compounds classified as inhibitors showed half-maximal 
CHX
0 25 50 75 100 125 150 175 200 225 250 275 300 325 350 375
0
1000000
2000000
3000000
4000000
MG-132
Positive
controls
Negative controls
CHX #1
z'= 0.677865
z= 0.58207
CHX #2
z'= 0.637963
z= 0.534609
3,4-dichloroisocoumarin
Sample Number
STx
0 25 50 75 100 125 150 175 200 225 250 275 300 325 350 375
0
1000000
2000000
3000000
4000000
Brefeldin A
AG1478
Thapsigargin
MG-132
A-23187
STx #2
z' = 0.631
z = 0.462
3,4-dichloroisocoumarin
STx #1
z' = 0.616
z = 0.455
Sample Number
R
L
U
 38 
activity between 10 to 50 µM (data not shown).  Compounds were used above their half-
maximal concentrations but below their maximal concentrations for all subsequent assays 
(25 µM for compound 75 and 50 µM for compound 134). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
log DT IC50 = 0.08 
log DT IC50 = 0.36  
 
log Stx IC50 = -1.6 
log Stx IC50 = 0.41 (**)  
 
log Ricin IC50 = -0.85 
log Ricin IC50 = 0.67 (**)  
 
log STx IC50 = -2.0 
log STx IC50 = -0.85 (*)  
log Ricin IC50 = -1.6 
log Ricin IC50 = 0.18 (**)  
 
-4 -3 -2 -1 0 1 2
0
25
50
75
100
125
150
log[STx] (ng/mL)
%
 p
ro
te
in
 sy
nt
he
si
s
-1.0 -0.5 0.0 0.5 1.0 1.5 2.0
0
25
50
75
100
125
log[Ricin] (ng/mL)
%
 p
ro
te
in
 s
yn
th
es
is
-3 -2 -1 0 1 2 3
0
25
50
75
100
125
log[DT] (ng/mL)
%
 p
ro
te
in
 sy
nt
he
si
s
-4 -3 -2 -1 0 1 2
0
25
50
75
100
125
150
log[STx] (ng/mL)
% 
pro
tei
n s
yn
the
sis
-1.0 -0.5 0.0 0.5 1.0 1.5 2.0
0
25
50
75
100
125
150
log[Ricin] (ng/mL)
%
 pr
ot
ein
 sy
nt
he
sis
-3 -2 -1 0 1 2 3
0
25
50
75
100
125
log[DT] (ng/mL)
%
 pr
ot
ein
 sy
nt
he
sis
log DT IC50 = 0.02  
log DT IC50 = 1.3 (**)  
 
Figure 2.  Protective effects of inhibitory compounds against STx, ricin, and DT.  (A, B) Protein synthesis 
levels for control (black line, no compound) and compound-treated (red line) Vero cells were determined 
using the radioactive amino acid incorporation assay (see Methods).  Percent protein synthesis is expressed as 
the amount of radioactive amino acid incorporation in control or compound-treated cells at a given toxin 
concentration as a percentage of radioactive amino acid incorporation in cells lacking toxin treatment.  Toxin-
response curves, toxin IC50 values, and statistical comparisons between control and compound-treated cells 
were calculated (see Methods).  Data points (mean ±SD) represent triplicate data at the indicated toxin 
concentration from one representative experiment.  (A) Compound 134 (50 µM; left panels) protects against 
STx- and ricin-mediated decreases in protein synthesis.  Toxin IC50 values for STx and ricin in compound-
treated cells were found to be statistically different (*, p<0.05) from control cells.  (B) Compound 75 (25 µM; 
right panels) protects against STx-, ricin-, and DT-mediated decreases in protein synthesis.  Toxin IC50 values 
for all three toxins in compound-treated cells were found to be highly statistically different (**, p<0.01) from 
those in control cells. 
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The ability of these compounds to protect against increasing STx concentrations 
was expressed as toxin IC50, the concentration of toxin needed to reduce protein synthesis 
by 50% (see Methods).  Using these criteria, compounds 75 and 134, at their respective 
optimal concentrations, exhibited the greatest protective effects among the hits identified 
from the initial screen.  Both compounds showed statistically significant increases in STx 
IC50 compared to cells containing no compound (Figure 2).   
At higher concentrations, these compounds exhibited up to 1,000-fold increases in 
Stx IC50 (not shown).   Neither of these compounds affected luciferase degradation in the 
presence of cycloheximide (not shown).  An initial characterization of compounds 
showing highly protective effects against STx led us to consider whether these 
compounds could protect against other toxins that inhibit protein synthesis.  Both 
compounds 75 and 134 similarly showed statistically significant increases in ricin IC50 
(Figure 2; p<0.01).   Protection against both STx and ricin was also greater than 
previously observed protective effects using an overexpressed dominant negative mutant 
of Rab6, a small GTP-binding protein found to be essential to STx transport through the 
Golgi 17. 
 Interestingly, compound 134 failed to show a statistically significant effect 
against DT-mediated protein synthesis inhibition (Figure 2A), while compound 75 
demonstrated greater protection (Figure 2B).  Vero cells lacking compound treatment 
demonstrated a similar susceptibility profile to DT as to STx and ricin.  STx and ricin, 
following endocytosis, are known to traffick from an endosomal compartment to the ER 
via the Golgi 36.  DT, however, directly accesses the cytosol from early endosomes, as the 
low endosomal pH is believed to allow for a conformational change in the holotoxin and 
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promote shuttling of the A moiety across the endosomal membrane 20.  The lack of 
protection against DT suggests that compound 134 affects toxin transport at a post early-
endosome stage but has no effect on trafficking from plasma membrane to the early 
endosomal compartment.  In contrast, the protective effect of compound 75 against all 
three toxins suggests that this compound affects transport mechanisms common to all 
three pathways, presumably at an earlier stage in endocytosis than the site of action of 
compound 134. 
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Effects of compounds 75 and 134 
on toxin transport 
 In order to determine the site 
at which inhibitory compounds were 
affecting toxin activity, the 
endocytosis and transport of 
fluorescent STx and CTx B-subunits 
(STxB and CTxB, respectively) 
were examined.  The retrograde 
transport of protein toxins is 
believed to occur exclusively from 
early and/or recycling endosomes 37.  
In order to determine whether 
endocytosis and trafficking of STxB 
to early and recycling endosomes 
were affected by compound 134, 
STxB transport was compared to 
fluorescently-labeled transferrin (Tf), 
which is known to accumulate in 
recycling endosomes at 22oC due to a 
block in recycling endosome-to-TGN 
transport at this temperature 15.  
DMSO 75 (25 µM) 134 (50 µM) 
STxB 
Merge 
Tf 
A) 
+ 
DMSO 75 (25 µM) 134 (50 µM) 
+ 
Tf 
Merge 
CTxB 
  B) 
Figure 3.  Compound 75 impedes STxB/CTxB and transferrin 
ligand trafficking to recycling endosomes.  (A) Vero cells were 
incubated with AlexaFluor 594-labeled STxB (1 µg/ml) and 488-
labeled Tf (1 µg/ml)  for 1 h at 4°C in serum-free medium, then 
shifted to 22°C for an additional hour and developed for 
immunofluorescence, as described in Methods.  In control (0.5% v/v 
DMSO) and compound 134-treated cells, STxB reaches a 
perinuclear, Tf-positive compartment previously described as 
recycling endosomes (cross).  In compound 75-treated cells, 
however, no perinuclear staining was observed, and Tf and STxB 
were confined to early endosomes (punctate staining).  (B) Neither 
CTxB  nor Tf reaches the perinuclear Tf-positive recycling 
endosome compartment in 75-treated Vero cells compared to control 
and 134-treated cells.  Results are representative of two similar 
experiments.  Images were obtained at 1000X magnification.  Tf, 
transferrin; blue, nuclei.  
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Consistent with previous reports, STxB colocalized with Tf-positive compartments in 
control cells at 22°C (Figure 3A).  STxB trafficking to Tf-positive compartments in 134-
treated cells was not significantly different than in control cells, showing a similar level 
of colocalization with the perinuclear recycling endosome compartment (Figure 3A, 
cross).  Similar results were seen with CTxB, which also accumulated in a Tf-positive 
perinuclear compartment. 
(Figure 3B, cross).  In 
addition, compound 134 did 
not affect binding of CtxB 
or STxB to the cell surface 
(Figure 4), suggesting that 
this compound was not 
occupying toxin receptor 
binding sites or significantly 
decreasing receptor 
expression.  Taken together 
with the relative lack of 
protection of compound 134 
against DT-mediated protein 
synthesis inhibition (Figure 
2A), these results 
collectively suggest that 
No toxin STxB-488 
(No compound) 
STxB-488 
+ Compound 75  
STxB-488 
+ Compound 134  
2.0
 
36.1 
45.0 
35.9 
Figure 4.  Compound treatment does not downregulate Gb3 receptor 
expression.  (A-D) Vero cells were grown to confluency and shifted to 4ºC for 
15 min.  STxB-488 was added at 1µg/mL, and cells were kept at 4ºC for an 
additional 45 min to allow for STxB binding to Gb3 receptors.  Cells were 
washed 5 times with cold PBS prior to scraping the cells into 750 µL of cold 
PBS.  STxB-positive cells were sorted by FACS (M1 gate), and the proportion 
of STxB-positive cells relative to the total number of cells (% total) was 
determined by CellQuest 9 (Becton-Dickinson).  For compound-treated cells, 
compound was added at the indicated concentrations at 37ºC for 30 min prior to 
the binding of STxB at 4ºC.  Neither compound 75 (C) nor 134 (D) decreased 
the proportion of STxB-positive cells compared to DMSO-treated cells (B) at 
the indicated concentrations.  (A) represents untreated Vero cells lacking STxB.  
A) B) 
C) D) 
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compound 134 maintains STx and CTx transport to recycling endosomes.  
Compound 75, like compound 134, did not inhibit STxB binding to its receptor or 
decrease receptor expression (Figure 4).  However, treatment with compound 75 
appeared to inhibit transport of both STxB/CTxB and Tf to perinuclear recycling 
endosomes.  Most of the toxin and Tf were located in peripheral vesicular structures 
(Figure 3), likely early endosomes.  These results, in addition to those demonstrating 
effects of compound 75 on DT susceptibility, collectively suggest that this compound 
inhibits STx and CTx transport to recycling endosomes. 
Immunohistochemical analysis of compound-treated cells revealed morphological 
changes to the Golgi (not shown).  The dispersal of the Golgi apparatus is a 
morphological effect that has been observed under several conditions that impair 
retrograde and intra-Golgi transport 38.  To exclude the possibility that the effects of these 
compounds were non-specific to intracellular toxin transport, we sought to rule out  
processes that are known to have effects on Golgi morphology.  In particular, during the 
process of apoptosis, the Golgi becomes fragmented 39.  In order to rule out that 
compounds 75 and 134 were inducing Golgi fragmentation through apoptosis, ATP levels 
in compound-treated cells were compared to those in untreated cells or cells treated with 
staurosporine, a known apoptosis-inducing agent40.  Treatment with compounds 75 and 
134 failed to deplete ATP levels over 24 hours as was observed following staurosporine  
 44 
 
treatment, suggesting that the compounds were not cytotoxic or apoptosis-inducing at the 
specified concentrations over the time course studied (Figure 5A).  In addition, 
compound-treated cells consistently showed a more punctate and swollen Golgi 
compared to the more tubulated Golgi in staurosporine-treated cells (Figure 5B).  The 
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Figure 5.  Biochemical and morphologic effects of compound treatment are distinct from those produced 
by apoptosis-inducing or Golgi-disturbing agents.  (A) Compound treatment does not deplete ATP levels.  
Vero cells were incubated with compounds 75, 134, staurosporine, or DMSO for up to 24 h at 37ºC at the 
indicated concentrations.  ATP levels were determined by the CellTiter-Glo Luminescent Cell Viability Assay 
(see Methods).  Luminescence (relative light units) is linearly related to ATP levels in viable cells.  Results 
(mean ±SD) are triplicate data for each time point from one representative experiment.  (B) Compound 134 
produces changes in Golgi morphology distinct from those generated by known apoptosis-inducing 
(staurosporine, anisomycin) or Golgi-disturbing agents (nocodazole, brefeldin A).  Vero cells were treated for 1 h 
with the specified compounds at the indicated concentrations prior to incubation with 1 µg/mL Alexa Fluor 488-
labelled CTxB at 4ºC for 1 h.  Toxin was internalized for 1 h at 37ºC.  Cells were fixed, permeabilized, and 
stained with an antibody against the Golgi marker giantin.  Compound 75 produced a similar dispersal of the 
Golgi as seen with compound 134 (not shown).  BFA, brefeldin A; blue, nuclei.  Images were obtained at 1000X 
magnification. 
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Golgi morphology of compound-treated cells also differed from the characteristic Golgi 
architecture of cells treated with anisomycin, a peptidyl transferase inhibitor shown to 
induce apoptosis in HeLa cells 41.  Other small molecule compounds known to affect 
Golgi morphology include nocodazole 38, a microtubule-disrupting agent, and brefeldin 
A, a known trafficking inhibitor that causes complete dispersal of the Golgi 42.  The 
morphological effects on the Golgi for compounds 75 and 134 were distinct from each of 
these (Figure 5B).  As a result, effects on the Golgi, induced by these compounds as early 
as 30 minutes following compound treatment (not shown), were consistently distinct 
from the characteristic morphological and biochemical changes observed with known 
apoptosis-inducing and Golgi-disturbing agents.   
As another means of determining and quantifying the effect of compounds 75 and 
134 on toxin transport from early endosomes to the TGN, sulfation of a STxB construct 
bearing a tandem of C-terminal sulfation sites (STxB-Sulf2) was evaluated.  Sulfation of 
endogenous proteins occurs in the TGN, and sulfation of internalized STxB-Sulf2 has 
shown that it trafficks through this compartment 43.  Trafficking of fluorescently-labeled 
STxB-Sulf2 (Figure 6A, green) showed similar Golgi localization as native STxB-594 in 
untreated cells (Figure 6A, red) and thus could serve as a suitable assay for toxin 
trafficking through the TGN.  Consistent with its effect at an early stage in toxin 
trafficking, compound 75 inhibited STxB sulfation to 47 % of compound-negative 
samples (Figure 6B).  By contrast, compound 134 modestly reduced sulfation (72% of 
control) over the 3-hour incubation.  Sulfation of endogenous proteins, as assessed by 
total [35S] incorporation, was unaffected by compound treatment, implying that the 
compounds were not inhibiting sulfotransferase enzymatic activity (not shown).  
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Together with previous 
results, these results are 
consistent with compound 75 
inhibiting transport at an 
early stage in endocytosis and 
compound 134 blocking 
transport at a post-recycling 
endosome stage (including 
recycling endosome-to-TGN 
transport). 
 
Compounds 75 and 134 
reversibly target toxin 
retrograde transport.  
Small molecule 
compounds may act by 
reversible or irreversible 
mechanisms.  In general, irreversible inhibitors act by covalent interaction with or 
modification of target molecules, such as through oxidation or acylation.  Reversible 
compounds often act as competitive inhibitors of enzymatic activity or of protein-target 
interactions.  Morphological effects on the Golgi produced by compound 75 and 134 
treatment were found to be reversible.  Following washout of the compounds, the Golgi 
reassembled in compound-treated cells at a time point at which BFA-treated cells 
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Figure 6.  Compounds 75 and 134 affect trafficking of STxB 
through the trans-Golgi network (TGN).  (A) A STxB construct 
containing a tandem of sulfation sites and a histidine tag for purification 
(see Methods) was used to track STxB transport through the TGN in 
Vero cells.  (B) The degree of sulfation of the STxB-Sulf2 construct 
was determined as described in Methods.  % signal indicates the band 
density relative to the band signal in DMSO-treated cells from one 
representative experiment.  Results are representative of two similar 
experiments.  Compound 75 was used at 25 µM and 134 at 50 µM.  
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maintained an altered Golgi morphology (Figure 7A).  More importantly, Vero cells lost 
protection against STx following washout of either compound (Figure 7B). 
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Figure 7.  Effects of compounds on Golgi structure are reversible.  (A) Vero cells were treated with 
compounds 75 (25 µM), 134 (50 µM), or BFA (25 µg/mL) for 1 h at 37ºC, followed by washing with prewarmed 
media and an additional incubation at 37ºC in media alone for the indicated times.  Cells were fixed, 
permeabilized, and stained with anti-giantin (green) and anti-TGN46 (red) antibodies. Control indicates cells 
treated with DMSO (0.5% v/v) and fixed 2 h after washing as with compound-treated cells. (B) Vero cells were 
pretreated with compounds 75 (left) and 134 (right) for 1 h at 37ºC at the concentrations used in (A), followed by 
washing with prewarmed media and an additional incubation at 37ºC in media alone for 2 h.  Cells were then 
treated with STx for 4 h and assessed for levels of protein synthesis using the radioactive amino acid 
incorporation assay, as described in Methods.  Black line, untreated; red line, compound treatment with no 
washout; red dotted line, compound treatment with washout.  BFA, brefeldin A.  
B) 
30 
60 
120 
Compound 
75 
Compound 
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      BFA Control Time after 
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(min) 
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Effects of compounds on anterograde transport 
The toxin trafficking pathway, from early endosomes to the ER via the Golgi, is 
almost the mirror inverse of the biosynthetic and secretory pathways. The degree of 
overlap between the retrograde and anterograde pathways, however, remains largely 
unresolved.  Since no host molecules have been shown to traffic from endosomes all the 
way to the ER, the ability to track bacterial toxins and identify compounds that 
potentially block their transport allows us to specifically probe the retrograde pathway in 
its entirety.   
To study the effects of these compounds on general anterograde transport, the 
sequential trafficking of a temperature-sensitive VSVG-GFP (tsO45) fusion protein 44 in 
transiently transfected Vero cells was examined.  In cells incubated at 42°C, the VSVG-
GFP protein was seen to be retained within the ER.  An hour following a shift to 32°C, 
the VSVG-GFP protein had made an anterograde progression to the Golgi (Figure 8A).  
Compounds 75 and 134 also maintained VSVG-GFP transport from the ER to the Golgi, 
as evidenced by colocalization of VSVG-GFP with TGN46 as early as 1 h following the 
shift to 32°C (Figure 8A, yellow).  BFA has been shown to impede ER to Golgi transport 
42, and cells treated with BFA showed a dispersed Golgi with VSVG-GFP restricted to 
the ER over the time course studied.  We conclude that both compounds 75 and 134 
preserve ER-to-Golgi transport of VSVG-GFP, suggesting that generalized anterograde 
transport mechanisms from the ER to the Golgi remain unaffected.   
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To examine the 
effects of compounds 75 
and 134 on the secretory 
pathway beyond the Golgi, 
the secretion of a GFP 
construct bearing an amino-
terminal neuropeptide Y 
secretion signal (NPY-
GFP) was assessed by 
ELISA.  In contrast to BFA 
and compound 75, 
compound 134 had a 
minimal effect on NPY-
GFP secretion (Figure 8B, 
86% and 89% GFP 
secretion compared to 
untreated cells at 1 and 2h, 
respectively).  Compound 
75 decreased GFP secretion 
to a similar extent as BFA, 
a known inhibitor of 
anterograde transport.  It 
should be noted that NPY-GFP secretion was only reduced by approximately 50% after 1 
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Figure 8.  Effects of compound treatment on anterograde transport.  (A) 
Both compounds 75 and 134 maintain ER-to-Golgi transport.  Anterograde 
transport of VSVG-GFP (green) was assessed by immunofluorescence in Vero 
cells transiently transfected with pCDM8.1 expressing VSVG-GFP ts045, as 
described in Methods.  Following fixation at indicated times, cells were 
permeabilized and labeled with anti-TGN46 (red).  (B) Compound 75 and BFA 
decrease post-Golgi secretion of NPY-GFP.  NPY-GFP secretion at 1  and 2 h 
following CHX treatment was assessed by ELISA of cell supernatants.  Mean 
absorbance values for control wells containing DMEM alone were subtracted 
from sample wells.  Results (mean ±SD) are pooled data from one representative 
experiment.  BFA, brefeldin A; OD, optical density.  
B) 
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h of BFA.  This likely represents the pool of protein that had already reached the Golgi 
prior to BFA or compound 75 treatment.  We conclude that, when compared to its effects 
on retrograde transport of toxin, compound 134 exhibits a less pronounced and less 
significant effect on the anterograde secretory pathway. 
 
DISCUSSION 
A luciferase-based assay for determining cell susceptibility to STx-mediated 
inhibition of protein synthesis was adapted to HTS and used to screen a chemical library 
of small compounds.  Compounds 75 and 134 showed marked potency and selectivity 
against intracellular toxin transport.  Both compounds demonstrated strong protective 
effects against STx and ricin, and compound 75 was shown to equally protect against DT.  
We thus report two novel compounds demonstrating efficacy against multiple bacterial 
toxins, with toxin IC50 values nearly an order of magnitude greater than previously 
reported values using knock-down approaches for toxin inhibition 17,45.     
Screens at the ICCB have recently identified small molecule inhibitors of 
Toxoplasma invasion and Vibrio cholera virulence.  From a library of 12,160 
compounds, 24 inhibitors of Toxoplasma gondii invasion were identified 46.  These 
included compounds that inhibited host uptake of the organism as well as inhibitors of 
Toxoplasma gliding motility and microneme-based secretion.  Effective doses of these 
compounds ranged from 3 to 100 µM.  Recently, a similar screen identified a small 
molecule inhibitor of Vibrio cholera virulence 47.  50,000 compounds were screened, 
from which 109 compounds that inhibited virulence factor expression were identified.  Of 
these, a compound named virastatin inhibited the transcriptional regulator ToxT, thereby 
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suppressing the expression of cholera toxin and the toxin co-regulated pilus.  The 
minimal inhibitory concentration of virastatin against CTx expression ranged from 3 to 
40 µM, depending on the bacterial strain.  As a result, recent screens underscore the 
utility of small molecule assays in the identification of compounds that inhibit microbial 
virulence or block intracellular trafficking pathways.    
The ability of compound 134 to specifically protect against STx and ricin but not 
DT suggested that it targeted a step common to the transport of STx and ricin but distinct 
from the DT transport pathway.  Since DT is known to access the cytosol directly from 
an endosomal compartment 20, compound 134 was presumed to act on a site downstream 
of the early endosome.  However, compound 134 had little to no effect on toxin 
colocalization with a perinuclear, Tf-positive compartment previously reported as 
recycling endosomes 48, implying that toxin transport to early/ recycling endosomes was 
unaffected.  If we consider that toxin transport to the Golgi was delayed compared to 
control cells and that the sulfation of STxB-Sulf2 was modestly reduced, it seems likely 
that compound 134  inhibits toxin transport at a post-recycling endosome stage (including 
recycling endosome-to-TGN transport).  Compound 75, on the other hand, consistently 
impeded toxin localization to the recycling endosome and exhibited a more pronounced 
effect on transport through the TGN, as evidenced by the decreased sulfation of STxB-
Sulf2.  We thus conclude that compounds 75 and 134 are conferring toxin-protective 
effects by disrupting transport at distinct steps along the toxin trafficking pathway.     
Both compounds produced a fragmented Golgi phenotype and delayed, but did 
not inhibit, toxin transport to this disrupted compartment.  Toxin transport to the ER, 
though significantly reduced compared to control cells, was apparent by 
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immunofluorescence (not shown), suggesting that toxin transport through the Golgi was 
not completely blocked.  Consistent with these findings, these compounds, at the 
inhibitory concentrations used, did not completely protect susceptible cells against toxin-
mediated decreases in protein synthesis, as has been observed following BFA     
treatment 49.  The strong protective effect of BFA, however, comes at the expense of a 
collapsed Golgi structure and disrupted anterograde transport 38.  Morphological analysis 
of compound-treated cells revealed dispersed Golgi-derived vesicles, but their 
pronounced toxin-protective effects were distinct from apoptosis-inducing or cytotoxic 
agents.   
More importantly, the disrupted Golgi membranes showed competent anterograde 
trafficking in compound 134-treated cells, implying that this compound was 
preferentially targeting components of the retrograde pathway.  A similar Golgi 
fragmentation has been observed in HeLa cells depleted of Cog3p, and the disrupted 
Golgi membranes were equally capable of anterograde trafficking of VSVG protein 50.  
Though it also exhibited a strong protective effect against toxin-mediated protein 
synthesis inhibition, compound 75 appeared to have a more pronounced effect on  the 
post-Golgi trafficking of NPY-GFP.  Nonetheless, the identification of two compounds 
preferentially targeting the retrograde pathway could represent a useful tool in elucidating 
similarities and differences between anterograde and retrograde trafficking.      
A previous study examining toxin transport found that disruption of the Golgi 
apparatus by the expression of a temperature-sensitive mutant of ε-COP did not inhibit 
ricin transport in Chinese hamster ovary cells, and it was concluded that ricin was 
capable of bypassing the Golgi apparatus altogether through a normally inaccessible 
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route 51.  Though we cannot rule out the possibility that compound treatment is inducing 
an alternate toxin trafficking pathway, it seems unlikely that toxin is bypassing the Golgi 
to any appreciable extent in compound-treated cells, given that STxB and CTxB still 
traffic to the disrupted Golgi apparatus.  Rather, our results indicate that an intact Golgi is 
required for efficient STx trafficking and toxicity.  The reversibility of compound effects 
on Golgi structure concomitant with the loss of protection against STx following Golgi 
reassembly suggest that STx transits retrogradely through the Golgi using a pathway that 
is equally responsible for maintaining Golgi structure.   
In contrast to standard genetic approaches that have been extensively employed to 
understand the retrograde pathways used by bacterial and plant toxins, small compounds 
provide an informative chemical genetic method for studying intracellular toxin transport 
in a controlled and reversible manner 52.  Pharmacological agents derived from small 
compounds have enhanced our understanding into the biology of retrograde transport and 
its implications on Golgi organization 38.  Retrograde flow through the Golgi is believed 
to balance anterograde flow in order to establish a membrane equilibrium while 
maintaining Golgi polarity 53.  It has been suggested that components regulating 
retrograde trafficking of glycolipid toxin receptors could also serve a role in the 
retrograde recycling of Golgi membranes 54.  Indeed, it remains to be seen if the recycling 
of different resident Golgi proteins is being directly or indirectly targeted by protein 
toxins and, more importantly, whether the inhibitory effects of either or both of these 
compounds is targeting this host membrane recycling machinery.  Future studies with 
fluorescently modified or biotinylated compounds that can be efficiently tracked and used 
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to identify molecular targets will elucidate our understanding of toxin subversion of 
retrograde, membrane recycling pathways.    
 Our study identifies two small compounds that protect against toxin-mediated 
inhibition of protein synthesis by selectively and reversibly disrupting toxin trafficking.  
As the mechanisms underlying endocytic transport become clearer, the ability to 
manipulate and alter these pathways through small molecules will serve as an invaluable 
tool in probing both the retrograde and anterograde trafficking mechanisms. 
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MATERIALS AND METHODS 
Reagents and antibodies 
Small chemical compounds were purchased from ChemDiv and reconstituted to 5 
mg/mL stocks in DMSO.  All compounds were checked for purity by mass spectroscopy.  
Shiga-like toxin 1 (referred to as STx1 in the text) and diphtheria toxin were from List 
Biological Laboratories, and ricin was from Sigma.  Recombinant Alexa Fluor 488-
labeled CTxB, Alexa Fluor 594-labeled human transferrin, SlowFade Gold mounting 
reagent with or without DAPI, and Alexa Fluor-labeled goat or donkey anti-IgG 
secondary antibodies were obtained from Molecular Probes.  Rabbit anti-p115 and mouse 
anti-GM130 were purchased from BD Transduction Laboratories.  Rabbit anti-giantin 
was from Covance, sheep anti-human TGN46 from Serotec.  Dulbecco’s Modified 
Eagle’s Medium (DMEM), Eagle’s Minimum Essential Medium (EMEM), streptomycin, 
and penicillin were from BioWhittaker.  Non-essential amino acids (NEAA) were 
purchased from Mediatech.  Cycloheximide, DMSO, brefeldin A, nocodazole, 
anisomycin, and staurosporine were from Sigma.  Trans [35S] was purchased from MP 
Biomedicals, and [35S]O4 was obtained from American Radiolabeled Chemicals.    
 
Cell culture 
 Vero  and HeLa cells were grown and maintained at 37ºC and 5% CO2.  Vero 
cells were maintained in DMEM supplemented with 10% fetal calf serum (FCS, Sigma), 
100 µg/mL streptomycin, 100 U/mL penicillin, and 1% NEAA.  HeLa cells were 
maintained in EMEM supplemented with 5% FCS, 100 µg/mL streptomycin, 100 U/mL 
penicillin, and 1% NEAA. 
 57 
Purification of Shiga toxin B subunit (STxB) 
 Recombinant STx-B was isolated from periplasmic extracts of E. coli BL21(DE3) 
cells (Invitrogen) containing the expression vector pT7B5-1, as previously described 35.  
Briefly, periplasmic extracts were subjected to anion-exchange chromatography on a Q-
sepharose column (Pharmacia), and pentameric STxB was isolated following further 
purification of the Q-sepharose peak on a Superdex 75R 10/30 gel filtration column 
(Pharmacia).  Fractions containing STxB were identified by SlotBlot (Hoefer) using a 
polyclonal rabbit anti-STxB antibody 35, and positive fractions were combined and 
concentrated to 1 mg/ml using Ventricon Plus-20 filters (Millipore).  STxB purity was 
verified by SDS-PAGE on a 4-20% Tris-HCl gel stained with Coomassie Blue.  
AlexaFluor-488 and -594 conjugation was performed following the manufacturer’s 
recommendations (Molecular Probes). 
 
Luciferase-based assay for measuring protein synthesis 
 The luciferase-based assay has been described 19 and was applied to a high-
throughput screen of small molecules consisting of known biological as well as unknown 
compounds at the ICCB facility at Harvard University.  The luciferase protein has been 
modified by Promega by the addition of a PEST sequence, resulting in its short 
intracellular half-life 55.  The luciferase-PEST cDNA was cloned into an adenoviral 
expression plasmid 19, and high titer viral stocks were generated (pAD-Luc).  Vero or 
HeLa cell monolayers were transduced  with pAD-Luc (MOI of 200) and incubated for 
24 h at 37oC in 5% CO2, then seeded into 384-well black polystyrene plates (Corning) at 
1 x104 cells/well for an additional 24 h.  Cells were then treated for 30 min at 37ºC with 
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known biological and unknown compounds at 5 mg/mL.  STx was added at 1 ng/mL, and 
cells were incubated for an additional 4 h at 37ºC.  To determine luciferase expression, 
the SuperLight Luciferase Reporter Gene Assay was used according to the 
manufacturer’s instructions (BioAssay Systems), and light output was detected using an 
LMax 1.1L luminometer (Molecular Devices).  To be considered protective, the 
compound must increase the luciferase signal at least 2-fold above the mean observed 
from cells treated with toxin alone.  Compounds maintaining luciferase expression levels 
in the presence of cycloheximide alone (100 µM) were excluded from further analysis. 
 
Radioactive amino acid incorporation assay 
 Experiments measuring radioactive [35S] incorporation were used to confirm 
positive hits from the luciferase-based high-throughput screen.  This assay was adapted to 
a multi-well format to enable testing on a large number of samples.  Vero cells were 
cultured overnight at 37oC in 5% CO2 in 96-well plates at 2.5 x 104 cells/well, whereupon 
media was removed and replaced with either prewarmed media (plus 0.5% DMSO v/v) or 
media containing compound.  Following a 1 h incubation at 37oC, toxin was added to 
wells in triplicate, and cells were shifted to 37°C for an additional 4 h.  The media was 
then removed from all wells and replaced with media containing Trans [35S] label at 10 
µCi/mL.  Cells were incubated at 37oC for 45 min, then washed with PBS (pH 7.4) and 
lysed (1 mg/mL BSA, 0.2% deoxycholic acid, 0.1% SDS, 20mM Tris pH 7.4) at 4oC for 
12 h.   Proteins from the lysed cells were TCA-precipitated (final concentration 15%), 
transferred to multi-screen HA plates (Millipore), and the filters were washed with ice-
cold 20% TCA.   Filters were then removed from the plate, placed in 2 mL Bio-Safe II 
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scintillation fluid (RPI), and [35S] incorporation quantitated using a beta counter 
(Beckman).  Independent experiments were performed at least three times for potent 
compounds, and data were analyzed using Prism v4.0 software (2003). 
 
Toxin and transferrin internalization 
 For toxin trafficking experiments, Vero cells were grown in chamber slides (2.5 x 
104 cells/chamber) and treated with medium containing DMSO, compound, or known 
agents at indicated concentrations for 1 h at 37oC, then placed on ice for 15 min prior to 
the addition of toxin.  Toxin was bound for 45 min at 4°C, followed by washing of 
unbound toxin with ice-cold PBS (pH 7.4).  Fresh, prewarmed media was added, and 
cells were shifted to 37oC for the indicated times to allow for toxin internalization.  In 
transferrin trafficking experiments, cells were pretreated with compounds in serum-free 
culture medium, and transferrin and toxin were bound to cells at 4°C for 1 h, followed by 
a shift to 22oC for 1 h.  For all immunofluorescence experiments, cells were fixed in 4% 
paraformaldehyde in cold PBS, permeabilized in culture medium containing 0.1% Triton-
X100, and blocked with culture medium containing 0.1% BSA (w/v), all at room 
temperature.  All primary and secondary (Alexa Fluor 488, 594, or 555-labeled donkey 
anti-IgG) antibodies were diluted in blocking buffer.  Cells were rinsed thoroughly in 
PBS prior to mounting in SlowFade Gold reagent with or without DAPI.  Fluorescence 
imaging used EpiFluorescence (Zeiss) microscopy. 
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Expression and trafficking of VSVG-GFP 
Vero cells were transiently transfected with VSVG-GFP ts045, as previously 
described for other cell lines 44.  Briefly, 106 Vero cells were transfected with 20 µg of 
pCDM8.1 expressing VSVG-GFP ts045 and a Lipofectamine2000 (Invitrogen) mixture 
in antibiotic-free medium (DMEM with 10% FCS), followed by overnight incubation at 
37oC in 5% CO2.  Cells were collected and placed into chamber slides (Lab-Tek) for an 
additional 8-10 h at 37oC before their transfer to 42oC for 12-16 h.  Cells were then 
treated with compounds or brefeldin A (25 µg/mL) in prewarmed, antibiotic-free medium 
for 1 h at 42oC before their transfer to 32oC.  Thirty minutes prior to the shift to 32oC, all 
chambers were treated with cycloheximide (100 µM) to prevent de novo protein 
synthesis.  Cells were fixed following various incubation times at 32°C.  Fixation, 
permeabilization, staining, and imaging were performed as described for toxin and 
transferrin internalization experiments. 
 
Cell viability assay 
 The viability of cells treated with compound was evaluated using the CellTiterGlo 
Lumninescent Cell Viability Assay (Promega), a luciferase-based assay.  Vero cells (5 x 
104 cells/well) were added to 96-well plates and grown at 37oC in 5% CO2 overnight.  
Media was then removed and replaced with either prewarmed media with DMSO or 
compound in triplicate.  Following incubation at 37°C for various times, an equal volume 
of CellTiter Reagent (50 µL) was added according to the manufacturer’s instructions, and 
light output was measured using the Lmax 1.1L luminometer.  Independent experiments 
were performed three times. 
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Assessment of NPY-GFP secretion 
 Approximately 5 x 106 Vero cells were infected overnight at 37ºC in 5% CO2 
with pAD-NPY-GFP.  Cells were then washed, trypsinized, and seeded into each well of 
a 6-well plate (~1 x 106 cells/well).  The next day, media was removed, and cells were 
washed twice with serum-free media.  Media was subsequently replaced with serum-free 
DMEM containing DMSO or compounds for 30 min at 37ºC.  Cells were all treated with 
cycloheximide (100 µM) to inhibit de novo protein synthesis and to synchronize NPY-
GFP trafficking.  At various time points following cycloheximide treatment, supernatants 
were collected, and GFP secretion was assessed by ELISA as described in the 
manufacturer’s instructions (Pierce).  ELISA plates were analyzed by the Gen5 software 
program (BioTek) using the Synergy 2 spectrophotometer (BioTek).  Mean absorbance 
for control wells containing DMEM alone were subtracted from sample wells before 
analysis.   
 
Cloning and expression of StxB-Sulf2-His6 
 In order to add overlapping sulfation sites to the carboxyl terminus of Stx B-
subunit, the STxB gene from pNAS-13 35 was amplified with primers Sulf1, 5’-
GGTGCTCAAGGAGTATTGTGTAATATGAAAAAAACATTATTAATA-GC-3’ and 
Sulf-2, 5’GGATTCAGCGAAGTTATTTTTCGTGGAGAGGAACCTGAG- 
TATGGAGAAGAGGAACCTGAGTATGGAGAAAGCGGCCGAAAAAAGTAGGC-
G-3’, which encodes the two overlapping sulfation sites added to STxB by  Johannes et 
al.56.  The amplified product was ligated into expression plasmid pCRT7-TOPO 
(Invitrogen).  Sequencing of one such product revealed a nucleotide deletion at base 312 
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of the STxB coding region, such that the sulfation sites were intact and the frame-shift 
resulted in read-through in frame into the pCRT7 flanking sequence encoding a V5 
epitope, a histidine tag, and a stop codon.  This protein was found to be expressed at a 
high level from BL21 (DE3) cells and was used in future studies.  The protein was 
expressed from BL21 (DE3) cells by the addition of 0.1 M IPTG (Fischer) to cultures 
growing at late log phase.  After 2 h incubation at 30oC, the bacteria were harvested by 
centrifugation, and periplasmic extract was prepared by osmotic lysis.  The material was 
mixed with 2 mL Ni-NTA resin (Qiagen) and incubated overnight at 4oC with rocking.  
The resin and periplasmic extract were then applied to an empty column, the beads were 
washed with several column volumes of PBS, followed by PBS containing imidazole at 
25, 50, 250 and 500 mM.  The STxB-Sulf2-His protein, which remained associated with 
the column at 500 mM imidazole, was released by the addition of 5 ml 2M imidazole in 
PBS.  The eluted protein was dialyzed twice against PBS (pH 7.4), aliquoted, and stored 
at 4ºC.  In order to demonstrate that addition of the sulfation, V5, and histidine tags did 
not affect binding and transport of the toxin, STxB-Sulf2-His was labeled with 
AlexaFluor-488 following the manufacturer’s instructions (Molecular Probes).  Vero 
cells were incubated with 1 µg/mL each of  STxB-Sulf2-His-488 and  wild-type STxB 
labeled with AlexaFluor-594.  After binding at 4ºC for 1 h, the cells were washed and 
warmed to 37ºC for 1 h, fixed with 4% paraformaldehyde, and visualized by 
epifluoresence microscopy.    
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Sulfation of STxB-Sulf2-His 
 Vero cells were seeded overnight at 37ºC in 5% CO2 (1 x 106 cells/well).  The 
next day, media was replaced with serum-free DMEM lacking sulfate (Washington 
University Tissue Culture Support Center), and cells were incubated for an additional 3.5 
h at 37ºC.  Media was replaced with sulfate-free DMEM containing DMSO or compound 
for 30 min at 37ºC, then replaced with prewarmed sulfate-free media containing 1 
mCi/mL [35S]O4 for 3 h at 37ºC.  Wells were washed with cold PBS (pH 7.4) and lysed 
with PBS containing 1% Triton X-100.  The protein concentration of post-nuclear 
supernatants were determined by the BCA Protein Assay Kit (Pierce), and 250 µg lysates 
were added to 40 µL Ni-NTA Superflow beads and rotated at 4ºC overnight.  The next 
day, beads were spun down at 5,000 rpm for 5 min, and the unbound fraction was 
collected.  Total [35S]-incorporated counts were determined by measuring radioactive 
counts from TCA-precipitated proteins of unbound lysates.  Beads were washed once 
with PBS containing 1% Triton X-100 and twice with PBS.  Beads were resuspended in 
imidazole (1.5 M in PBS), and eluates were denatured with 1X SDS gel-loading buffer 
(50 mM Tris HCl, 100 mM β-mercaptoethanol, 2% SDS, 0.1% bromophenol blue, 10% 
v/v glycerol) and boiling.  Eluates were resolved on a 10-20% Tris-HCl denaturing gel, 
fixed, and developed overnight in a Phosphorimager cassette.     
 
Statistics 
 Data are expressed as mean ± SD.  Toxin IC50 values were determined by a 
nonlinear regression curve fit to the observed data as determined by Prism v4.0 (2003), 
and statistical differences between toxin IC50 values were calculated by the F test.  
 64 
Differences were considered statistically significant for p ≤ 0.05 (*) or highly statistically 
significant for p ≤ 0.01 (**). 
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CHAPTER III 
Golgicide A reveals essential roles for 
GBF1 in Golgi assembly and function 
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OVERVIEW 
 In contrast to some members of the AB toxin family, the bacterial exotoxin Shiga 
toxin (STx) undertakes a more labored route to reach its intracellular target in host cells.  
Following endocytosis into an early endosome, the membrane-bound STx is transported 
in a retrograde manner to the endoplasmic reticulum (ER) via the Golgi.  It has been 
proposed that STx exploits underlying host mechanisms to gain access to the cytosol, 
where it can exert its enzymatic effects.  Though the stepwise progression of STx through 
the cell has become more clearly defined, the host molecules essential to distinct steps in 
STx transport remain largely unidentified.  In addition, no host molecules have been 
shown to be transported from endosomes all the way back to the ER.  As a result, STx 
has become a useful probe for studying the retrograde pathway in its entirety.  Using a 
recently developed high-throughput assay for screening compound libraries for potential 
inhibitors of STx transport, we identified Golgicide A (GCA), a potent and highly 
specific inhibitor of Shiga toxicity.  Further characterization of GCA found that it 
strongly protects against Shiga toxicity by inhibiting GBF1, a cis-Golgi-localized guanine 
nucleotide exchange factor for ADP-ribosylation factor 1 (ARF1).  A more detailed 
structural analysis suggested a putative binding site of GCA on GBF1 that could be 
critical for GDP/GTP exchange on ARF1.  More importantly, GCA represents a novel 
tool for preferentially targeting ARF1 at the cis-Golgi and for studying the role of GBF1 
in mediating host trafficking within the Golgi.  The work describing these studies is 
 75 
presented in this chapter and published in Nature Chemical Biology†
 
.  The contributions 
of the authors to different sections of the project are indicated.   
SUMMARY 
 The small GTPase ADP-ribosylation factor 1 (ARF1) plays a critical role in 
regulating secretory traffic and membrane transport within the Golgi of eukaryotic cells.  
ARF1 is activated by Golgi-localized guanine nucleotide exchange factors (ARFGEFs), 
which confer spatiotemporal specificity to vesicular transport.  From a phenotypic screen 
aimed at identifying small molecule inhibitors of Shiga toxin (STx) trafficking, we 
identified a novel compound, golgicide A (GCA), that reversibly caused Golgi 
disassembly while maintaining endocytic transport to recycling endosomes.  The 
morphological effects on the Golgi resemble those caused by the fungal metabolite 
brefeldin A (BFA), but further characterization reveals that GCA specifically targets 
coatomer protein I (COPI)-dependent transport within the Golgi while maintaining 
adaptor protein 1 (AP-1)-mediated trafficking.  More specifically, the phenotypic effects 
of GCA mimicked overexpression of the dominant-negative GBF1-E794K mutant.  
However, overexpression of a GBF1 point mutant (GBF1-M830L) conferred resistance 
to GCA and reversed the effects of GCA on the Golgi, indicating that GCA specifically 
disrupts COPI-dependent trafficking by targeting the cis-Golgi-localized ARFGEF, 
GBF1.  As a specific and reversible inhibitor of GBF1, GCA will serve as a useful 
alternative to BFA for examining the role of GBF1 in maintaining Golgi structure and 
function. 
                                               
† Saenz, J.B., Sun, W.J., et al.  2009.  Golgicide A reveals essential roles for GBF1in Golgi assembly and 
function. Nat. Chem. Biol. 5: 157-165. 
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INTRODUCTION 
 The family of small GTP-binding proteins known as ADP-ribosylation factors 
(ARFs) mediate eukaryotic vesicular transport and membrane trafficking 1.  Mammalian 
ARFs fall into three categories based on sequence similarity: class I (ARF1-3), class II 
(ARF4 and ARF5), and class III (ARF6) 2.  The most extensively characterized of the 
ARFs, ARF1 is a major regulator of vesicular transport within the cis/medial-Golgi as 
well as between the trans-Golgi network (TGN) and endosomes.  A member of the Ras 
superfamily of small GTPases, ARF1 cycles between its inactive, GDP-bound form, and 
an active, GTP-bound state.  Inactive ARF1-GDP is primarily cytosolic and can associate 
weakly with Golgi membranes, whereas active ARF1-GTP coordinates coated vesicle 
assembly following its tight interaction with membranes 3.   
 Activation of ARF1 at the Golgi is catalyzed by ARF1-specific guanine 
nucleotide exchange factors (ARFGEFs) that confer spatiotemporal specificity to 
vesicular transport.  The ARFGEFS are further divided into two families consisting of the 
large brefeldin A (BFA)-susceptible molecules, which localize to the Golgi and TGN, 
and the smaller BFA-resistant ARNO-family GEFs, which predominantly localize to 
endosomes 4,5.  Crucial to their guanine nucleotide exchange activity is a highly 
conserved region of roughly 200 amino acids known as the Sec7 domain, whose central 
hydrophobic groove binds to nucleotide-free ARF16,7.  Activation of ARF1 at the cis-
Golgi is catalyzed by the mammalian ARFGEF Golgi BFA resistance factor 1 (GBF1), 
while ARF1 is activated at the TGN by the ARFGEFs BIG1 and BIG2 (Figure 1)8-12.  
Following activation by GBF1, ARF1-mediated COPI coat recruitment enables vesicle 
transport between the Golgi and endoplasmic reticulum (ER) 13.  Activation by BIG1 and 
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BIG2 results in ARF1 recruitment of adaptor protein 1 (AP-1), a protein implicated in 
clathrin vesicular transport from the Golgi to endosomes, AP-3, involved in clathrin 
vesicular transport from the Golgi to lysosomes and vacuoles, AP-4, an adaptor protein 
functioning at the TGN, and Golgi-associated, gamma adaptin ear containing, ARF-
binding proteins (GGA 1-3), monomeric proteins involved in trafficking from the TGN 
and within the endosomal compartment  14-19.  ARF1 has also been demonstrated to 
modulate phospholipase D activity, thus affecting membrane compositional integrity and 
continuous remodeling of the Golgi 20.  
 The crucial role of 
ARFGEFs in vesicular 
transport has been 
highlighted by the effects 
of BFA, a heterocylic 
lactone that inhibits ARF1 
activation at the cis- and 
trans-Golgi (TGN) by 
stabilizing an abortive 
complex between ARF1-
GDP and its cognate 
ARFGEF 21.  At the cis-
Golgi, BFA inhibits ARF1 
activation by GBF1 and 
AP-1 COPI 
ARF1-GDP 
BIG1/BIG2 GBF1 
ARF1-GTP ARF1-GTP 
TGN 
Golgi 
ER ERGIC 
 
 
Figure 1.  Schematic 
diagram of Golgi-
localized ARFGEFs.  
ARF1 exists in the 
cytoplasm in its inactive, 
GDP-bound form.  At the 
cis-Golgi, the ARFGEF 
GBF1 catalyzes GDP/GTP 
exchange on ARF1, 
thereby activating it.  
Activated ARF1 (ARF1-
GTP) recruits COPI coat 
protein, which mediates 
ER-to-Golgi and intra-
Golgi transport.  At the 
trans-Golgi (TGN), GTP 
exchange on ARF1 is 
catalyzed by the TGN-
localized ARFGEFs 
BIG1/BIG2.  Activated 
ARF1 recruits AP-1 coat 
protein, which mediates 
bidirectional transport 
between endosomes and 
the TGN.  ARF1, ADP-
ribosylation factor 1; 
GBF1, Golgi BFA-
resistance factor 1; 
BIG1/2, BFA-inhibited 
guanine nucleotide 
exchange factors 1/2; AP-
1, adaptor protein 1; 
COPI, coat protein I; ER, 
endoplasmic reticulum; 
ERGIC, ER-Golgi 
intermediate compartment.  
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blocks COPI-dependent trafficking that is essential to maintaining Golgi integrity.  This 
results in a redistribution of Golgi membranes and proteins to the ER.  Similarly, 
inhibition of BIG1/BIG2 at the TGN halts AP-1-dependent TGN-endosome trafficking 
and leads to a fusion of both compartments.  In addition to its effects on ARFGEF 
activity, BFA has other less-characterized effects on intracellular transport molecules, 
including inhibition of BARS and Golgi-associated phospholipase D activities 22-24.  
 Recently, the function of individual ArfGEFs has been explored. Among the 
ARFGEFs, GBF1 has been studied most intensively, either by siRNA-mediated  
silencing 10,25-27 or by the expression of dominant-negative forms 9,11,28,29.   The 
phenotypic and functional effects of these perturbations have not been in complete 
agreement but nevertheless demonstrate crucial roles for GBF1 in intra-Golgi transport.  
We describe here the discovery and characterization of a potent, highly specific, and 
rapidly reversible small molecule inhibitor of GBF1 function. This compound, which we 
called Golgicide A (GCA), reveals diverse roles for GBF1 in maintaining structure and 
function of the Golgi and trans-Golgi network. 
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RESULTS 
Golgicide A (GCA) is a potent and highly effective inhibitor of Shiga toxin activity. 
 From a high-throughput screen for small molecules that inhibit the effect of 
bacterial toxins on host cells 30,31, we identified a compound that potently and effectively 
protected Vero cells from Shiga toxin (STx).  STx inhibits protein synthesis by 
inactivating an adenine residue on the 28S ribosome.  To quantify the effects of STx on 
protein synthesis, a luciferase-based assay was used to screen the Harvard ICCB facility’s 
ChemDiv4 library, composed of approximately 14,000 commercially available small 
molecule compounds selected for their structural diversity, chemical stability, and “drug-
like” properties.  GCA (Figure 1A) was identified as protective by the initial high-
throughput screen, maintaining light output at least 3 standard deviations above STx-
treated Vero cells lacking compound (not shown).  The potency of GCA, determined 
from the compound IC50 (the compound concentration resulting in 50% inhibition of STx 
activity in STx-treated Vero cells; see Methods) was found to be 3.3 µM (Figure 1B).  At 
a GCA concentration of 10 µM, the STx IC50, or the STx concentration required to 
reduce protein synthesis by 50%, was significantly increased over untreated cells (Figure 
1C).  This protection was similar to that observed with BFA, which has been considered 
the most efficacious STx-protective agent. 
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Other compounds identified in this screen acted through the inhibition of intracellular 
toxin transport 32, leading us to examine the effect of GCA on toxin trafficking and on 
intracellular organelle morphology.   
 Immunofluorescence experiments demonstrated dramatic effects of GCA on the 
Golgi and TGN.  Whereas the Golgi remains as a tightly organized perinuclear ribbon in 
untreated cells, GCA caused complete dispersal of the Golgi marker giantin.  This effect 
was seen at concentrations as low as 5 µM (not shown).  Within two minutes of GCA  
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Figure 2.  GCA is a potent and effective inhibitor of STx susceptibility.  (A) Structure of GCA.  (B) 
Vero cells were pretreated for 30 min at 37ºC with varying concentrations of GCA, followed by 
incubation with STx (1 ng/mL) for 4 h at 37ºC.  Percentage protein synthesis indicates the amount of 
radioactive amino acid incorporation in GCA-treated cells as a percentage of radioactive amino acid 
incorporation in cells lacking STx treatment.  Protein synthesis levels and compound-response curves 
were determined as described in Methods.  (C) Protein synthesis levels for control (solid line; no 
compound) or GCA-treated (dotted line; 10 µM) Vero cells were determined using the radioactive amino 
acid incorporation assay as described in (B).  Percentage protein synthesis is expressed as the amount of 
radioactive amino acid incorporation in untreated or GCA-treated cells at a given toxin concentration as a 
percentage of radioactive amino acid incorporation in cells lacking STx treatment.  Toxin IC50 values for 
GCA-treated cells were significantly increased over control cells (p<0.01; see Methods).  For (A) and 
(B), data points (mean ±SD) represent triplicate data at the indicated compound or toxin concentrations, 
respectively, from one representative experiment.  STx, Shiga toxin; GCA, Golgicide A.  
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addition, giantin labeling became extensively tubulated and had completely dispersed by 
15 min (Figure 3A).   These morphological effects were highly reminiscent of those 
B) 
Figure 3. GCA causes tubulation and dispersal of the Golgi and TGN. (A) Vero cells were treated with 
GCA (10 μM) for the indicated times prior to fixation and labeling with anti-TGN46 (red) and anti-giantin 
(green) antibodies.  Both the TGN and medial-Golgi begin to disassemble within 5 min of treatment.  
Insets demonstrate giantin-positive tubules (arrowheads) at the indicated times.  White scale bars, 20 μm.  
Yellow scale bars, 5 μm.  (B) BFA and GCA disperse the medial-Golgi marker giantin to a partially 
punctate pattern adjacent to ERES. Vero cells were treated with BFA (10 μg/ml) or GCA (10 μM) for 60 
min, then fixed and labeled with antibodies against giantin (red) or Sec31 (green).  Both compounds cause 
giantin redistribution into a hazy and punctate pattern.  Giantin-positive punctate structures are closely 
approximated to Sec31-labeled ERES.  White scale bars, 10 μm.  Yellow scale bars, 5 μm.  BFA, brefeldin 
A; TGN, trans-Golgi network; ERES, endoplasmic reticulum exit sites. 
BFA GCA 
Giantin 
Sec31 
Merge 
BFA GCA 
0 min 2 min 5 min 10 min 15 min 20 min 
TGN46 
Giantin 
Merge 
t = 5 min t = 10 min 
 A) 
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caused by BFA 33,34.  The distribution of cis-Golgi (GM130 and p115; not shown) and 
medial-Golgi (giantin; Figure 3B) markers were essentially identical following either 
GCA or BFA treatment.   
 Treatment with GCA resulted in a diffuse and punctate distribution of the medial-
Golgi marker giantin. The punctate structures were in contact with Sec31-positive foci, 
indicative of their association with ER exit sites (ERES; Figure 3B).  These findings were 
also similar to BFA treatment, which causes Golgi matrix proteins to concentrate at 
ERES35.  Effects of these compounds on the TGN, however, were subtly different.  
Whereas BFA induced the formation of tubules derived from TGN and endosomes, GCA 
caused the TGN to disperse into small vesicles that subsequently disseminated 
throughout the cell (Figure 3A). 
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 The morphologic effects of GCA did not result from disruption of microtubules or 
actin cytoskeleton (Figure 4).  Finally, the effects of GCA were found to be rapidly 
reversible.  Within 15 minutes of removing the compound, the Golgi and TGN began to 
reassemble (Figure 5A).  The effects of GCA on protein secretion (Figure 5B) were 
likewise found to be completely  reversible within 1 h of compound removal. 
Tubulin 
DAPI 
DMSO (0.5% v/v) GCA (10 µM) Cytochalasin B (25 µM) 
Actin 
DMSO (0.5% v/v) GCA (10 µM) Nocodazole (5 µg/mL) 
A) 
B) 
Figure 4.  GCA does not affect microtubular or actin cytoskeletons.  (A) Vero cells were treated for 30 min at 
37ºC with DMSO, GCA, or nocodazole at the indicated concentrations prior to fixation and immunostaining, as 
described in Methods.  At 10 µM, GCA had no observable effects on microtubules, while nocodazole, an inhibitor of 
microtubule polymerization, produced drastic morphological effects. (B) Vero cells were treated with DMSO, GCA, 
or cytochalasin B at the indicated concentrations and developed for immunofluorescence, as in (A).  GCA showed no 
effects on actin microfilaments compared to DMSO-treated cells, while the actin-depolymerizing agent cytochalasin 
B induced significant changes to actin morphology.  
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GCA depletes COPI at the cis-Golgi with no effect on AP-1 or GGA3 at TGN. 
 While the mechanisms behind the dramatic morphological changes induced by 
BFA have not been completely elucidated, the effects of BFA on both the cis/medial-
Golgi and the TGN are in part due to the specific inhibition of ARFGEFs acting at both 
of these compartments 1,36.  BFA inhibits GBF1 activity within the Golgi by stabilizing 
an abortive complex between ARF1-GDP and the catalytic Sec7 domain of GBF1 37, 
thereby disrupting COPI-mediated retrograde transport and resulting in a redistribution of 
Golgi contents into the ER.  At the TGN, BFA forms a similar complex between ARF1-
GDP and the TGN-localized BIG1/2, inhibiting anterograde transport beyond the      
TGN 38,39.  As a result of the delocalization of various vesicular transport mediators at the 
TGN, including clathrin coat and the adaptor proteins AP-1, AP-3, and GGA3 22, the 
A) 
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Figure 5.  The effects of GCA are rapidly reversible.  (A) 
Vero cells were treated with GCA (10 µM) for 1 h.  To 
remove GCA, cells were washed three times with PBS and 
incubated at 37ºC in media alone for various times (t = 0, 15, 
30, and 60 min) prior to fixation and labeling with an anti-
giantin antibody.  The medial-Golgi (green) reassembles by 
60 min following GCA removal.  (B) The effects of GCA on 
protein secretion are reversible.  Vero cells were transduced 
with adenovirus expressing NPY-GFP and were treated with 
DMSO or GCA for 1 h at the indicated concentrations.  In 
cells with compound washout, DMSO or GCA was removed 
as described in (A), and cells were incubated in media alone 
for 1 h.  The amount of secreted GFP was assessed 2 h later 
by ELISA (see Methods).  GCA treatment alone inhibits 
NPY-GFP secretion, while NPY-GFP secretion was restored 
to control levels following GCA removal.  NPY-GFP, GFP 
construct bearing a neuropeptide Y secretion signal; O.D., 
optical density.  
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TGN tubulates and subsequently fuses with a proportion of endosomes.  The dual 
targeting by BFA of both Golgi- and TGN-localized ARFGEF activity thus appears to 
underlie many of its morphological effects.               
 Consistent with previous reports 40-42, COPI delocalization preceded Golgi 
collapse in BFA-treated cells: within 5 min following BFA treatment, β-COP staining 
was diffuse (Figure 6D), and this dispersal preceded morphologic changes to Golgi 
structure, as evidenced by juxtanuclear staining with the Golgi structural marker GM130 
(Figure 6B).  In addition, BFA almost immediately induced AP-1 (Figure 6E) and GGA3 
(Figure 6F) dispersal from TGN membranes.  Since compound GCA had similar effects 
on the cis/medial-Golgi to BFA (Figures 6A-B), we compared the effects of these 
compounds on COPI, AP-1 and GGA3 localization.  GCA treatment equally resulted in a 
rapid loss of COPI from the Golgi complex prior to its collapse.  However, AP-1 (Figure 
6E) and GGA3 (Figure 6F) remained associated with the TGN until the Golgi and TGN 
began to disperse.  Taken together, GCA and BFA have similar phenotypic effects on 
medial- and cis-Golgi which correlate with rapid dispersal of COPI from Golgi 
membranes.  In contrast, these two compounds have differing morphologic effects on the 
TGN and distinct effects on AP-1 and GGA3 localization.  This led us to investigate 
whether GCA specifically targeted a cis/medial-Golgi-localized molecule that could 
explain the compartment-specific effects. 
 
 
 86 
  
GCA treatment phenotypically mimics overexpression of dominant negative GBF1. 
 Given GCA’s distinct effects on cis/medial-Golgi, we hypothesized that GCA 
could be specifically targeting GBF1, the ARFGEF responsible for ARF1 activation and 
COPI recruitment to cis-Golgi membranes, while maintaining BIG1/BIG2-mediated 
activation and AP-1/GGA3 vesicle coat recrtuitment at the trans-Golgi (Figure 1).  
Consistent with this possibility, we found that expression of GBF1-E794K, a catalytically 
 
BFA GCA DMSO 
A) 
GCA DMSO E) BFA GCA DMSO 
TGN46 
GGA3 
Merge 
F) 
D) 
Merge 
β-COP 
GM130 
TGN46 
Merge 
AP-1 
BFA 
BFA GCA DMSO 
Giantin 
GM130 
TGN46 
B) 
C) 
Figure 6.  GCA disperses Golgi structure and inhibits recruitment of COPI coat while maintaining AP-1 and 
GGA3 coat recruitment to the TGN.  (A-C) Vero cells were treated with DMSO (0.5% v/v), GCA (10 µM), or 
BFA (10 µg/mL) for 1 h prior to fixation and staining with the indicates antibodies (see Methods).  GCA and BFA 
treatment resulted in the dispersal of giantin (medial-Golgi) and GM130 (cis-Golgi).  (D-F) Vero cells were treated 
for 5 min with the indicated compounds (at concentrations used in A-C) and stained with the indicated antibodies.  
Both GCA and BFA cause rapid dispersal of COPI (D), but, unlike BFA, GCA maintains AP-1 (E) and GGA3 (F) 
localization.  Blue, nuclei.  
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inactive, dominant-negative GBF1 9, resulted in dispersal of β-COP from Golgi 
membranes and disruption of TGN and medial-Golgi structure (Figure 7A), 
phenotypically similar to the effects of GCA.   This GBF1 mutant was previously shown 
to localize to the ER-Golgi intermediate compartment (ERGIC) 9: indeed, wild-type 
GBF1 colocalized with ERGIC-53, a marker for this compartment, following GCA 
treatment (Figure 7B).  Moreover, overexpression of the TGN-localized ARFGEF, BIG1,  
partially reversed BFA’s morphologic effects on the TGN (Figure 7C), consistent with 
previous studies highlighting BFA’s dual inhibition of ARFGEFs at the cis/medial- and 
A) B) 
Merge 
GBF1-EK 
β-COP 
GBF1-EK 
TGN46 
GBF1-EK 
Giantin 
ERGIC-53 
Merge 
GBF1-WT 
GCA 
DMSO BFA GCA 
TGN46 
BIG1-HA 
Merge 
C) 
Figure 7.  Treatment with GCA phenotypically resembles overexpression of inactive GBF1.  (A) 
Vero cells overexpressing the GBF1-E794K (GBF1-EK) mutant show dispersed COPI, giantin, and 
TGN staining.  Arrowheads indicate GBF1-EK-overexpressing cells.  (B) GCA treatment (10 µM) of 
cells overexpressing wild-type GBF1 (GBF1-WT) causes trapping of GBF1 in the ERGIC, as shown 
by colocalization with the ERGIC marker, ERGIC-53.  (C) BIG1 overexpression partially rescues the 
effects of BFA (10 µg/mL) on the TGN but fails to reconstitute TGN morphology in GCA (10 µM)-
treated cells.  ERGIC, ER-Golgi intermdiate compartment; Blue, nuclei. 
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trans-Golgi 25.  However, BIG1 overexpression did not rescue the morphological effects 
on the Golgi in GCA-treated cells.  These results point to a phenotypic similarity between 
GCA treatment and overexpression of catalytically inactive GBF1 and support the 
possibility that GBF1 is the target of GCA. 
 
A single nucleotide substitution in canine GBF1 results in resistance to GCA†
 In the course of examining the effect of GCA on several cell types, we found that 
Madin-Darby canine kidney (MDCK) cells were resistant to GCA, as evidenced by a lack 
of effect of this compound on Golgi morphology and  β-COP localization (Figure 8A), 
viability (not shown), and protein secretion (not shown).  The Golgi apparatus of MDCK 
. 
                                               
† The identification of a GBF1 mutant that was resistant to GCA was carried out by William Sun, and the 
following section highlights those findings. 
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A) 
B) 
Figure 8. MDCK 
cells are resistant to 
GCA.  (A) MDCK 
and Vero cells were 
left untreated or 
treated for 1 h with 
GCA (10 μM). GCA 
did not affect β-COP 
distribution in 
MDCK cells, whereas 
both were dispersed 
in GCA-treated Vero 
cells.  (B) The Sec7 
domain of GBF1 was 
amplified from 
MDCK cDNA (see 
Methods). The 
sequences of four 
resulting clones were 
compared to 
published mammalian 
orthologues. A 
methionine for 
leucine substitution 
was identified in the 
canine peptide (black 
arrow). 
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cells has also been reported to be resistant to the effects of BFA43-45.  Given that BFA is 
known to bind within the highly-conserved Sec7 domain of Golgi-associated ARFGEFs 
and that we suspected GBF1 to be the target of GCA, we examined the possibility that 
differences in the canine GBF1 Sec7 domain accounted for MDCK cell resistance to both 
compounds.  We amplified, cloned, and sequenced the canine GBF1 Sec7 domain.  
Analysis of several independent clones revealed a leucine substitution for methionine at 
residue 832 of the full-length protein (numbering corresponds to the human GBF1 
sequence).  Comparison with all other mammalian GBF1 homologues revealed this 
substitution to be unique to the canine gene (Figure 8B).  Interestingly, mutagenesis of 
the corresponding methionine to leucine in the yeast ARFGEF  homologue Gea1 and the 
human GBF1 resulted in resistance to BFA32, 37,46. 
 The M832L substitution was introduced into the hamster GBF1, and the effect of 
its expression on GCA 
susceptibility was examined in 
transfected cells.  Vero cells 
expressing this mutant were highly 
resistant to GCA, as evidenced by 
maintenance of COP localization, 
TGN morphology, and cis-Golgi 
structure, even at compound 
concentrations as high as 100 µM 
(Figure 9).  As described later, 
TGN46 GM130 β-COP 
Merge 
GBF1-ML 
Merge Merge 
GBF1-ML GBF1-ML 
Figure 9.  Overexpression of the GBF1-ML mutant protects 
against GCA’s effects on Golgi morphology.  Vero cells were 
transiently transfected with GBF1-M832L (GBF1-ML) and treated 
for 1 h with GCA (100 µM) prior to staining with the indicated 
antibodies.  GCA has little to no effect on Golgi morphology in cells 
overexpressing GBF1-ML (arrowheads). 
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expression of GBF1-M832L rescued the functional effects of GCA on secretion and on 
retrograde toxin transport.  The ability of this mutant to fully protect Vero cells against 
the phenotypic and functional effects of this compound indicate that GCA specifically 
targets GBF1 and does not have evident “off-target” effects.    
 
Molecular modeling of GCA selectivity for GBF1†
 The results presented thus far suggest that GCA has high selectivity for GBF1 and 
does not affect BIG1.  The mechanism of GCA specificity for GBF1 was investigated by 
 
                                               
† Molecular modeling of the GCA-GBF1 interaction was carried out by Badry Bursulaya and Nathanael 
Gray.  Functional characterization of the GBF1 loop mutants was carried out by David Haslam, and the 
following section highlights those findings. 
GCA 
GBF1 ARNO 
BFA 
GBF1 ARNO 
A) 
B)  
Figure 10.  Molecular modeling of the potential GCA-GBF1 interaction identifies a tripeptide loop that 
could account for GCA’s selectivity for GBF1.  (A) Sequence alignment of the Sec7 domains of various 
human ARFGEFs identifies the M832 residue (arrowhead) and a tripetide loop (asterisk) present in GBF1 but 
absent from the other human ARFGEFs.  (B) (left) GCA (yellow) and BFA (magenta) were docked onto the 
BFA binding pocket on GBF1 (blue) and ARNO (magenta).  GCA, but not BFA, contacts a tripeptide loop on 
GBF1 that is absent in ARNO.  The structures of GCA and BFA are also provided (middle panel).  (right) 
The GBF1 Sec7 domain (residues 693 to 887) was threaded onto the previously reported ARNO-ARF1-BFA 
complex.  Only the Sec7 domains of GBF1 (blue) and ARNO (purple) are shown.  The asterisk highlights the 
tripeptide loop on GBF1 that is lacking in ARNO.    
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molecular modeling and  site-directed mutagenesis.  The GBF1 Sec7 domain was 
modeled in complex with ARF1 using the published structure of the ARF1-ARNO-BFA 
complex47.  Although there is considerable sequence divergence between GBF1 and 
BIG1/BIG2 (Figure 10A), the predicted tertiary structure of the GBF1 Sec7 domain is 
very similar to that of ARNO (Figure 10B).  When the ARNO-ARF1 and predicted 
GBF1-ARF1 complexes were compared, the BFA-interacting regions of the interfacial 
cleft were virtually identical.  Nevertheless, the observation that the GBF1-M832L 
mutant was resistant to both BFA and GCA suggested that these compounds may bind 
within the same GBF1-ARF1 interfacial region.  When GCA was docked into this 
pocket, it was found to extend past the BFA-binding region to contact a tripeptide loop 
that exists in GBF1 and is lacking in other ARFGEFS, including ARNO, BIG1 and BIG2 
(Figure 10B, asterisk).   
 The contribution of the GBF1 tripeptide extension to GCA susceptibility was 
investigated by mutagenesis.  Deletion of residues 845 to 848 or substitution of alanines 
for all three residues resulted in resistance to GCA, as indicated by the ability of these 
mutants to maintain Golgi morphology in the presence of the compound (Figure 11A).  
However, as expected, these mutants remained susceptible to BFA, as this loop lies 
outside the BFA-binding pocket and would not be expected to contribute to BFA 
susceptibility (Figures 10B and 11A).  Further mutagenesis of individual residues 
revealed that substitution of alanine for arginine 843, glutamine 845 or asparagine 846 
resulted in loss of susceptibility to GCA (Figure 11B) while none of these residues were 
required for BFA susceptibility (not shown).  Lysine 844, which protrudes from the 
opposite side of the GBF1 loop, did not affect GCA susceptibility.  In summary, these 
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results reveal that GCA susceptibility is dependent upon residues within a tripeptide 
found within the GBF1 Sec7 domain. 
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GCA prevents GBF1-mediated GTP exchange on ARF1. 
 GBF1 activates ARF1 by catalyzing GDP/GTP exchange on Golgi membranes8,11.  
In order to assess the effect of GCA on GBF1 activity, in vivo ARF1-GTP levels were 
quantified in cells treated with either BFA or GCA.  This assay took advantage of the 
ability of immobilized GGA3 to specifically pull down ARF1-GTP from cellular 
extracts48.  GCA treatment significantly reduced levels of ARF1-GTP, with an 
approximate 33% decrease compared to DMSO-treated controls (Figure 12A).  BFA, on 
the other hand, reduced ARF1-GTP levels to nearly 25% of control levels.  This is 
consistent with BFA’s more promiscuous effects on ARFGEFs at the cis/medial-Golgi 
and TGN compared to GCA’s more specific targeting of GBF1.   
 To confirm that the observed decrease in ARF1-GTP levels were specific to GCA 
inhibition of GBF1, cells were transduced with an adenoviral construct expressing the 
previously identified GBF1-ML mutant (Figure 9; see Methods).  Overexpression of the 
GCA-resistant GBF1-ML mutant restored ARF1-GTP levels in GCA-treated cells to 
control levels (86%) but had a marginal effect on restoring ARF1-GTP levels in BFA-
treated cells (45%).  Because adenoviral transduction did not result in overexpression in 
100% of the cells (Figure 12B), overexpression of the GBF1-ML mutant was likely 
unable to completely restore ARF1-GTP to control levels.  Nonetheless, overexpression 
of a GCA-resistant GBF1 mutant attenuated GCA’s inhibitory effect on GBF1-mediated 
GTP exchange on ARF1.  Moreover, the ability to rescue ARF1-GTP levels was 
Figure 11.  A distinct tripeptide loop in GBF1 accounts for GCA’s selecticvity for GBF1.  (A) Vero cells 
were transfected with wild-type GBF1 (GBF1-WT) or GBF1 mutants prior to a 1-h treatment with GCA (10 µM) 
or BFA (10 µg/mL).  Cells overexpressing the GBF1-M830L mutant (Figure 9) or the loop mutants (GBF1-Δ3 
and GBF1-AAA) are protected against the effects of GCA on the Golgi.  Overexpression of the loop mutants 
shows no protection against the effects of BFA.  (B) Site-directed mutagenesis of specific residues within the 
GBF1 tripeptide loop shows that R843, Q845, and N846 are critical to GCA susceptibility, while K844 appears to 
not be involved in binding to GCA.  GBF1-Δ3, GBF1 mutant lacking the tripeptide loop; GBF1-AAA, GBF1 
mutant with tripeptide replaced with three consecutive alanine residues (see Methods).  Blue, nuclei.     
 94 
dampened in BFA-treated cells, presumably because BFA targets ARFGEFs besides 
GBF1.  Together, these results further confirm that GCA specifically targets GBF1 and 
inhibits this ARFGEF’s GDP/GTP exchange function.  More importantly, these results 
provide an estimate of the relative contribution of GBF1 and other ARFGEFs on ARF1 
activation.  These data would suggest that, in Vero cells growing under tissue culture 
conditions, GBF1 accounts for approximately 30% of activated ARF1 and BIG1/BIG2 
for 45%, with the remainder attributed to BFA-resistant ARFGEFs. 
 
B) 
Figure 12.  GCA specifically 
inhibits GBF1-mediated activation 
of ARF1.  (A) Vero cells left 
untransduced (No transduction) or 
transduced with an adenoviral 
construct overexpressing the GBF1-
ML mutant were treated with DMSO 
(0.5% v/v; None), BFA (10 µg/mL), 
or GCA (10 µM) for 1 h.  Intracellular 
ARF1-GTP levels were assessed (see 
Methods).  Percentages indicate band 
intensity as a percentage of DMSO-
treated controls.  Graphs indicate 
mean (±S.D.) from three independent 
experiments, and statistical analyses 
are provided in Methods.  (B) Vero 
cells were transduced with an 
adenoviral construct overexpressing 
GBF1-ML (GBF-1) prior to a 1-h 
treatment with GCA (10 µM).  Cells 
were subsequently stained with 
antibodies against the HA epitope 
(red) and giantin (green).  
Approximately 85% of transduced 
cells express detectable GBF1-ML.  
Blue, nuclei.  
A) 
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GBF1 inhibition arrests protein secretion†
 Having demonstrated that GCA was a specific inhibitor of GBF1 function, we 
used this compound to examine the role of GBF1 in secretory transport.  Previous studies 
with a dominant negative mutant indicated that GBF1 function was required for 
maturation of ER-Golgi intermediate vesicles to a transport-competent state10,11.  Recent 
studies with siRNA-mediated inhibition suggested that GBF1 was required for 
anterograde transport of membrane-anchored cargo but was not required for secretion of 
soluble molecules10.   
 
 To assess the role of GBF1 in secretion of membrane-anchored proteins, we 
examined the effect of GCA on transport of a GFP-tagged, temperature sensitive VSV-G 
mutant, tsVSVG-GFP49.  At the non-permissive temperature of 40oC, this protein is 
retained and accumulates in the ER.  Following a shift to the permissive temperature 
(32oC), tsVSVG-GFP transits through the ERGIC to the Golgi and ultimately to the 
plasma membrane.  Cells were transfected either with tsVSVG-GFP alone or co-
transfected with plasmid encoding GBF1-WT or GBF1-M832L, and the fate of tsVSV-G 
was followed in GCA-treated cells.  In untreated cells, tsVSVG-GFP was transported 
from the ER to Golgi within 60 min and was located predominantly at the plasma 
membrane by 4 h (Figure 13A).  GCA treatment, however, caused tsVSVG-GFP to be 
partially retained in a reticular, ER-like distribution as well as in diffuse punctate 
structures.  GBF1-WT overexpression did not overcome the block in tsVSVG-GFP 
secretion in GCA-treated cells, whereas co-transfection with GBF1-M832L restored 
tsVSVG-GFP transport to the plasma membrane.   
                                               
† Experiments involving the effects of overexpression of a GCA-resistant mutant on protein secretion were 
carried out by David Haslam, and this section highlights those findings. 
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 Expression of the GCA-resistant GBF1 loop mutants also restored transport of 
(tsVSVG-GFP) to the plasma membrane in the presence of GCA (not shown).  GCA 
treatment did not completely block tsVSVG-GFP transport from the ER, as this protein 
was also found in peripheral punctate structures after a 60-min incubation.  These 
0 
1h 
4h 
h 
VSV-G GBF1-WT VSV-G 
GBF1-ML  +  GCA 
GBF1-ML VSV-G 
Untreated GBF1-WT  +  GCA 
GCA 
VSV-G 
ERGIC-53 
Figure 13.  GBF1 mediates anterograde transport of 
membrane-bound proteins.  (A) Transport of tsVSVG-GFP 
was monitored, at the various indicated times, in control cells 
(Untreated) and cells overexpressing wild-type (GBF1-WT) or 
GCA-resistant mutant GBF1 (GBF1-ML).  Where indicated, 
cells were treated with GCA (10 µM) for 1 h prior to 
immunostaining.  Overexpression of GBF1-ML restores 
VSVG trafficking to the cell surface.  (B) VSVG-GFP is 
retained in the ERGIC following a 4-h treatment with GCA (10 
µM).  In Vero cells transfected with tsVSVG-GFP and treated 
with GCA, VSVG-GFP colocalizes with ERGIC-53-positive 
foci.  Right panel indicates merged, magnified area of white 
box.  Blue, nuclei.   
A) 
B) 
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Figure 14.  GCA inhibits secretion of soluble cargo.  Cells were 
transduced either with adenovirus expressing NPY-GFP alone or co-
transduced with NPY-GFP plus adenovirus expressing GBF1-WT or 
GBF1-ML.  Cells were either left untreated or were exposed to GCA 
(10 mM) for 1 h.  Secreted GFP concentration was assessed by ELISA 
(see Methods).  GCA treatment decreases NPY-GFP secretion in 
untransduced cells (dotted), while overexpression of GBF1-ML (blue), 
but not GBF1-WT (red), restores NPY-GFP secretion to levels in 
untransduced, untreated cells (black).  
structures were identified as the ERGIC by their labeling with anti-ERGIC53, indicating 
that tsVSVG-GFP was capable of transport from the ER to the ERGIC in cells lacking 
GBF1 function. (Figure 13B).   
 To monitor the secretion of soluble cargo proteins, we expressed GFP bearing a 
neuropeptide Y secretion signal (NPY-GFP)50.  This protein is secreted from Vero cells 
with a half life of approximately 60 min, as judged by pulse chase experiments32.  Vero 
cells expressing NPY-GFP demonstrated markedly decreased GFP secretion in the 
presence of GCA (Figure 14).  If inhibition of NPY-GFP secretion in GCA-treated cells 
was solely due to the inhibition of GBF1 function, then expression of the GCA-resistant 
GBF1-M832L mutant should 
restore protein secretion to 
levels seen with untreated 
cells.  Whereas cells 
transduced with GBF1-WT 
failed to transport NPY-GFP 
to the plasma membrane in 
the presence of GCA, the 
expression of GBF1-M832L 
restored NPY-GFP transport 
through the Golgi to the 
plasma membrane (Figure 
14).  Together, these data 
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indicate that GBF1 function is required for secretion of a soluble  protein (NPY-GFP) as 
well as membrane-associated cargo (tsVSVG-GFP). 
 
GBF1 is involved in retrograde toxin transport 
 The stepwise intracellular trafficking of bacterial toxins has been frequently used 
to probe host endocytic transport mechanisms31.  STx transport to the TGN from 
endosomes can be quantified by assessing its sulfation by resident tyrosyl-protein 
sulfotransferases at the TGN51,52.  We examined the effect of GCA on endosome-to-TGN 
transport using a STxB subunit that bears overlapping tyrosine sulfation sites (STxB-
Sulf2)32.    Treatment with GCA markedly attenuated toxin sulfation (Figure 15A).  
Expression of GBF1-WT failed to rescue the transport of STxB-Sulf2 to the TGN, while 
expression of GBF1-M832L completely restored toxin sulfation to control levels in 
GCA-treated cells.  These results would suggest that GBF1 function is required for toxin 
transport from endosomes to the TGN, though we cannot rule out the possibility that 
inhibition of GBF1 prevents formation of a fully functional TGN to which STxB is 
targeted.  We equally cannot rule out whether GCA alters the optimal pH required for 
sulfotransferase activity at the TGN. 
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To rule out the possibility that GCA non-specifically inhibited endocytic transport 
GBF1-WT GBF1-ML 
None GCA 
Control 
None GCA None GCA 
STxB-
Sulf2 
A) GCA DMSO 
Tf 
CTxB 
Merge 
B) 
0 10 20 30 40 50 60
0
10
20
30
40
50
60
70
80
90
100
110
Untreated
GCA (10 µM)
Half life (min)
C) 
0 30 60
0
2
4
6
8
10
12
14
16
Time (min)
%
 D
eg
ra
de
d
D) 
Figure 15.  GCA impedes endosome-to-TGN transport of STx.  (A) Transport of STx to the TGN was assessed 
by quantifying the degree of sulfation of a STxB construct bearing a tandem of sulfation sites (STxB-Sulf2; see 
Methods).  GCA treatment inhibited STxB-Sulf2 sulfation, while overexpression of the GCA-resistant mutant 
GBF1-ML, but not wild-type GBF1 (GBF1-WT), restored it.  (B) GCA does not affect toxin transport to 
early/recycling endosomes.  Vero cells were treated with DMSO (0.5% v/v) or GCA (10 µM) for 1 h, and the 
transport of fluorescently-tagged cholera toxin B subunit (CTxB) and transferrin (Tf) was assessed at 22º C.  GCA 
treatment has no effect on CTxB colocalization to Tf-positive endosomes.  Blue, nuclei.  (C) GCA treatment does 
not affect the kinetics of transferrin recycling.  Vero cells were left untreated or were treated with GCA for 1 h.  
Cells were allowed to internalize AlexaFluor-488 labeled transferrin for 60 min.  Fresh media containing quenching 
anti-AlexaFluor-488 antibodies were added, and at various times the cells were harvested and fixed (see Methods).  
Each time point represents triplicate data (mean ±S.D.).  All data were fitted by nonlinear regression assuming one 
phase decay, and half-lives (in min; inset) were calculated using GraphPad Prism.  (D) GCA treatment does not 
affect lysosomal degradation of bovine serum albumin (BSA).  Vero cells were incubated with 1 µCi/ml [125I]-BSA 
at 37ºC in serum-free media containing no compound (untreated; solid line), BFA (10 µg/mL; red), or GCA (10 
µM; dotted line).  Supernatants were collected at 30 or 60 min, and TCA-soluble (degraded BSA) and –insoluble 
(undegraded BSA) counts were measured (see Methods).  % Degraded refers to the percentage of degraded BSA 
(TCA-soluble counts) as a fraction of total BSA (TCA-soluble + TCA-insoluble counts).  Radiolabeled Vero cells 
were also held at 4ºC for 1 h prior to TCA precipitation of cell supernatants to account for BSA degradation in the 
absence of endocytosis.  This value was subtracted from all samples prior to analysis.  BFA, brefeldin A.     
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from the cell surface, we assessed the effects of endocytic transport of various ligands to 
recycling endosomes.  Treatment with GCA did not affect accumulation of the cholera 
toxin B subunit (CTxB) in transferrin (Tf)-positive recycling endosomes at 22ºC (Figure 
15B), a temperature shown to block endosome-to-TGN transport53.  GCA treatment 
equally maintained the kinetics of transferrin recycling similar to untreated Vero cells 
(Figure 15C). 
  In addition, the degradation kinetics of radiolabeled bovine serum albumin was 
unaffected by GCA treatment, suggesting that generalized transport to lysosomes is 
unaffected in GCA-treated cells (Figure 15D).  This observation was further supported by 
a lack of effect of GCA on LDL-BODPY transport to lysosomes by immunofluorescence 
(not shown).  Together, these results suggest that GCA maintains endocytic transport to 
recycling endosomes and lysosomes. 
 GCA was initially identified in a high-throughput screen for its ability to inhibit 
the effects of STx on mammalian cells.  Figures 15A-B indicate that retrograde toxin 
transport was arrested within the endocytic compartment.  To determine whether the 
effects of GCA on toxin transport were due solely to GBF1 inhibition, we examined the 
ability of GBF1-M832L to restore toxin susceptibility to GCA-treated cells.  Cells were 
transduced with the appropriate GBF1 constructs and treated with GCA.  GCA strongly 
protected against STx in control cells and those transduced with GBF1-WT (Figure 16).  
In contrast, GCA was unable to protect against Shiga toxicity in cells overexpressing the 
GCA-resistant GBF1-M832L, indicating that the effects of GCA relied on GBF1 
inhibition. Taken together, these results indicate that GBF1 function is not required for 
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transport of bacterial toxins to recycling endosomes, but this ARFGEF is required for 
retrograde transport of STx from endosomes to the TGN and Golgi.  
 
  DISCUSSION 
 We have described the identification and characterization of GCA, a potent, 
highly effective, and rapidly reversible inhibitor of intra-Golgi transport.  Initial 
characterization of GCA revealed that it induced a BFA-like disruption of the Golgi.  
Unlike BFA, GCA specifically inhibited COPI coat recruitment to the cis/medial-Golgi 
while maintaining AP-1/GGA3 targeting to the TGN.  The pleiotropic effects of GCA 
resulted from specific inhibition of the cis/medial-Golgi-localized ARFEGEF, GBF1.  
GCA thus represents a useful probe of the intracellular function of GBF1 in mediating 
vesicle transport and organelle integrity and will serve as a useful alternative to the more 
promiscuous transport inhibitor BFA. 
 The phenotypic effects of GCA were similar to those induced by expression of a 
catalytically inactive, dominant negative GBF1 (GBF1-E794K).  Canine cells were found 
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Figure 16.  Overexpression of a GCA-resistant mutant restores STx susceptibility to Vero cells.  Inhibition of 
Shiga toxicity by GCA is completely reversed in cells expressing GBF1-ML.  Cells were either left untransduced or 
transduced with adenovirus expressing wild-type GBF1 (GBF1-WT) or a GCA-resistant GBF1 (GBF1-ML).  Cells 
were then treated with either GCA (solid line) or no compound (dotted line) prior to exposure to increasing 
concentrations of STx.  After a 4-h incubation, protein synthesis was assessed (see Methods).  Data points represent 
triplicate data (mean ±S.D.) from one representative experiment.  
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to be resistant to the effects of GCA, and characterization of the canine GBF1 gene 
revealed a methionine for leucine substitution corresponding to residue 832 of the human 
GBF1.  When introduced into the hamster GBF1, this substitution resulted in complete 
resistance to the phenotypic and functional effects of GCA.  This residue is located 
within an alpha-helix of the Sec7 domain and forms part of a hydrophobic interfacial cleft 
that recognizes ARF1 in its GDP-bound state 7,54.  Interestingly, BFA binds within this 
cleft and substitution of methionine 832 to leucine results in BFA resistance46.  
Therefore, our finding that GBF1-M832L is also resistant to GCA suggests that these two 
compounds bind within the same interfacial cleft.   However, unlike BFA, which inhibits 
BIG1 and BIG2 in addition to GBF1, GCA is highly specific for GBF1.  Molecular 
modeling and mutagenesis studies revealed that a tripeptide loop present within the GBF1 
Sec7 domain and absent from all other known ARFGEFS, accounts for the selectivity of 
GCA for its target.  These structural findings may allow for the design of GCA analogues 
that specifically inhibit BIG1, BIG2, and related ARFGEFs. 
 We demonstrated that GCA inhibits ARF1 activation, and this effect is largely 
rescued by the expression of GBF1-M832L, indicating that GCA directly inhibits GBF1 
function.  We found that transport of  tsVSVG-GFP was arrested in the ERGIC, 
indicating that GBF1 function was not required for exit of cargo from the ER but was 
required for transport past the ERGIC.  These results are similar to those found with 
expression of a dominant negative GBF1 and by siRNA-mediated inhibition of GBF1 
expression, which also found that GBF1 function was not required for exit of secreted 
molecules from the ER but was required for maturation of ER-Golgi transport 
intermediates and transport of tsVSVG-GFP past this compartment55.  Inhibition of GBF1 
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function with GCA also blocked secretion of a soluble cargo protein.  These results differ 
from a recent report that siRNA-mediated inhibition of GBF1 expression had no effect on 
the secretion of soluble cargo, though transport of transmembrane proteins was 
impaired10.  Golgi morphology in these cells was relatively mildly affected, which was 
unexpected given the dramatic effects of BFA treatment, expression of dominant 
inhibitory GBF1, or inhibition of COPI expression or function.  From these siRNA 
studies, GBF1 function and COPI recruitment were speculated to have relatively little 
role in secretion of soluble proteins and in the maintenance of medial-Golgi structure.  
We propose instead that the relatively milder effects of siRNA on Golgi morphology and 
secretion of soluble proteins resulted from less than complete inhibition of GBF1 
expression. 
 The role of GBF1 in retrograde transport to the Golgi has not previously been 
investigated.  We show that GCA treatment maintains endocytic transport from the cell 
surface to endosomes and lysosomes, suggesting that GBF1 function is not required for 
these pathways.  However, GBF1 inhibition trapped bacterial toxins at the endosomal 
level, and these vesicles were unable to fuse with a dispersed TGN.  These findings 
indicate that GBF1 function is required for endosome-to-TGN transport.  It is currently 
not known whether GBF1 function is essential to maintenance of an intact TGN to which 
endosome-derived vesicles can be targeted.  Inhibition of GBF1 at the cis/medial-Golgi 
could impede anterograde transport of soluble and membrane-bound proteins crucial for 
TGN membrane homeostasis.  These possibilities would be amenable to investigation 
using GCA.     
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 Small molecule inhibition offers several advantages over RNAi or transfection 
with dominant-negative mutants, most notably in its ability to rapidly inhibit protein 
function in essentially all treated cells independent of transfection efficiency.  A 
reversible small molecule inhibitor offers the ability to dynamically monitor the role of 
protein function and affords the opportunity to examine mechanisms of recovery from 
perturbations in protein function.  Moreover, RNAi cannot completely inhibit protein 
expression, and in some cases small amounts of residual protein are sufficient to maintain 
normal function and phenotype.  However, an inherent caveat shared by RNAi, dominant 
negative expression, and small molecules is the possibility of non-specific or “off- target” 
effects.  Demonstrating the specificity of small molecules can be relatively difficult, as 
these compounds often exhibit non-specific effects at higher concentrations.   In the case 
of RNAi, specificity is often proven by expressing an siRNA-resistant version of the 
targeted gene and demonstrating reversal of the phenotypic effects.  We have taken a 
similar approach to prove that GCA is highly specific for GBF1.  Expression of the 
GBF1-M832L mutant renders cells completely resistant to the effects of this compound, 
indicating that the phenotypic and functional effects of GCA do not result from non-
specific effects.  
 Phenotypic screens aimed at identifying inhibitors of endocytic 
and secretory transport have uncovered small molecules that are highly useful probes of 
intracellular transport.  Exo156 and Exo257 were uncovered from an image-based 
screen for inhibitors of secretory transport and exhibited Golgi-disruptive effects.  Studies 
with Exo2 revealed that treatment with this compound ablated the Golgi but maintained 
TGN integrity and suggested the existence of an alternative pathway for cholera toxin 
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transport.  Exo1 exhibited BFA-like effects on ARF1 dissociation from Golgi 
membranes, but unlike BFA, it did not interfere with ARFGEF activity. The molecular 
targets of Exo1 and Exo2 have yet to be elucidated.  A high-throughput screen for 
inhibitors of dynamin GTPase activity discovered dynasore, a particularly useful probe 
for studying the dynamics of dynamin-mediated clathrin coat formation58,59.  Similarly, 
secramine was identified as a novel tool for dissecting the functions of Cdc42 and 
possibly other RhoGTPases60.  Finally, SecinH3, an inhibitor of the cytoadhesins, was 
recently identified, and its use revealed a role for these BFA-insensitive ARFGEFs in 
insulin signaling61.  Together, these studies underscore the utility of small molecules as 
alternative biological probes for dynamic intracellular processes.   
 The discovery of a small molecule inhibitor of GBF1 allowed us to demonstrate 
an essential role for GBF1 in anterograde and retrograde traffic through the Golgi and its 
requirement for maintenance of Golgi and TGN structure.  Given its specificity, efficacy, 
and reversibility, GCA provides a unique and powerful means of elucidating the 
mechanisms underlying assembly and transport within the Golgi. 
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MATERIALS AND METHODS 
Antibodies and reagents   
 Compound GCA  was purchased from ChemDiv, reconstituted to 10 mM in 
DMSO, and stored at -20oC.  Chemical characterization of GCA, along with validation of 
the structural isomers responsible for its activity, have been reported62.  Shiga-like toxin 1 
(List Biological Laboratories), trans [35S] (MP Biomedicals), and [35S]O4 (American 
Radiolabeled Chemicals) were also used.  Antibodies included rabbit anti-giantin 
polyclonal (Covance), rabbit anti-hemagglutinin polyclonal (Sigma-Aldrich), mouse anti-
GM130 (BD Transduction), rabbit anti-human TGN38 (Santa Cruz), rabbit anti-βCOP 
(ABR), mouse anti-ERGIC-53 (Axxora), and fluorescently-labeled secondary antibodies 
(Molecular Probes).  DMSO, BFA, cytochalasin B, and nocodazole were from Sigma.   
 
Cell Lines and Cell Culture.  
 Vero (African green monkey kidney, CRL-1587), MDCK (Madin-Darby canine 
kidney, CCL-34), and 293A-HEK (Human embryonic kidney, CRL-1573) cells were 
obtained from the American Type Tissue Culture Collection (Manassas, VA).  293A cells 
were obtained from Invitrogen.  Vero cells were maintained in DMEM supplemented 
with 10% fetal calf serum and 1% nonessential amino acids at 37oC under 5% CO2.  
MDCK cells were maintained in EMEM supplemented with 10% fetal calf serum and 1% 
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nonessential amino acids at 37oC under 5% CO2.  293A cells were maintained in EMEM 
with 10% heat-inactivated horse serum.   
 Transient transfections were performed using Lipofectamine 2000 (Invitrogen) in 
OptiMem media, following the manufacturer’s recommendations.  Following overnight 
incubation at 37oC under 5% CO2, cells were collected into chamber slides (Lab-Tek, 
Campbell, CA) or appropriate dishes and incubated for 24 h before experimentation. 
 
Radioactive protein synthesis assay 
 The luciferase-based high-throughput screen to identify inhibitors of STx 
trafficking has previously been described32,63.  Similarly, confirmation of positive hits 
from the ChemDiv4 library screen was assessed by a previously described radioactive 
[35S] incorporation assay adapted to a multi-well format32.  Briefly, Vero cells cultured 
overnight at 37oC and 5% CO2 in 96-well plates (2.5 x 104 cells/well) were treated with 
0.5% DMSO (v/v) or media containing GCA or BFA at the indicated concentrations.  
Following a 0.5-h incubation at 37oC, toxin was added to wells in triplicate, and cells 
were shifted to 37°C for an additional 4 h.  Medium containing trans [35S] label at 10 
µCi/mL was added, and cells were incubated at 37oC for 45 min, washed with PBS (pH 
7.4), and lysed (1 mg/mL BSA, 0.2% deoxycholic acid, 0.1% SDS, 20mM Tris pH 7.4) at 
4oC for 12 h.   Proteins from the lysed cells were TCA-precipitated (final concentration 
15%), transferred to multi-screen HA plates (Millipore), and the filters were washed with 
ice-cold 20% TCA.   Filters were then removed from the plate, placed in 2 mL Bio-Safe 
II scintillation fluid (RPI), and [35S] incorporation quantitated using a beta counter 
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(Beckman).  Independent experiments were performed at least three times for GCA and 
BFA, and data were analyzed using Prism v4.0 software (2003). 
 
Immunofluorescence.  
 For all immunofluorescence experiments, cells were fixed in 4% 
paraformaldehyde in cold PBS, permeabilized with 0.1% Triton X-100 in PBS, blocked, 
then  probed with primary and secondary (Alexa Fluor 488 or 594-labeled donkey anti-
IgG) antibodies diluted in blocking buffer (DMEM containing 10% fetal calf serum plus 
1 mg/mL BSA).  Cells were rinsed thoroughly in PBS prior to mounting in SlowFade 
Gold reagent containing DAPI (Molecular Probes).  Fluorescence imaging used 
epifluorescence (Zeiss) microscopy. 
 
Toxin and transferrin internalization.   
 For CTxB and transferrin trafficking experiments, Vero cells grown in chamber 
slides (2.5 x 104 cells/chamber) were treated with serum-free medium containing DMSO, 
GCA, or BFA at the indicated concentrations and times at 37oC.  Following the binding 
of toxin and transferrin at 4ºC, cells were shifted to 19oC for 1 h to allow for toxin 
internalization.  Cells were processed for immunofluorescence as described above. 
 
Expression and trafficking of tsVSVG-GFP.  
 Vero cells were transiently transfected with VSVG-GFP ts045 using 
Lipofectamine 2000 (Invitrogen).  In some experiments, cells were co-transfected with 
GBF1-HA WT or M832L plasmids.  After overnight incubation at 37oC in 5% CO2, cells 
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were collected and placed into chamber slides (Lab-Tek) for an additional 8-10 h at 37oC 
before their transfer to 42oC for 12-16 h.  Cells were then treated with cycloheximide 
(100 µg/mL) to prevent de novo protein synthesis and either no compound,  GCA (10 
µM), or BFA (10 µg/mL), then transferred to 32oC.  Cells were fixed following various 
incubation times at 32°C.  Fixation, permeabilization, staining, and imaging were 
performed as described for immunofluorescence experiments. 
 
Cloning and sequence analysis of canine GBF1 Sec7 domain   
 Total RNA was isolated from approximately 107 MDCK cells by silica membrane 
binding (RNeasy, Qiagen), and contaminating chromosomal DNA was removed by 
DNase treatment (Qiagen).  The cDNA was prepared from isolated RNA with random 
primers and SuperScript II reverse transcriptase (Invitrogen) according to the 
manufacturer’s instructions.  The Sec7 domain of the canine GBF1 gene was amplified 
from MDCK cDNA using primers 5’-cgattttcctgtctcctgccagatccacggg-3’ and 5’-
ccacacatagttctcccgaaccaagcc-3’  and the resulting product cloned into pcDNA3.1/V5/His.  
Four resulting clones were sequenced and compared to their human, hamster, and murine 
counterparts. 
 
Site-directed mutagenesis 
 The hamster GBF1 cDNA (a gift from Paul Melançon, University of Alberta, 
Edmonton, AB) was used as template for constructing HA-tagged wild-type and mutant 
cDNA.  GBF1-HA was generated by PCR using primers GBF1-HA (5’-
gccgcgctagcctgaggcat agtcaggcacgtcataaggatagccgttgacttcagaggtgggaatagggtctgtag-3’) 
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and the upstream GBF1 primer (5’-gacaggtttgccaagatggtggataagaatatt tacatc-3’).  The 
resulting PCR product was cloned into pcDNA3.1D/V5-His-TOPO (Invitrogen) under 
control of the cytomegalovirus (CMV) promoter.  The insert was sequenced to ensure its 
fidelity. 
 The GBF1 mutants were generated using the QuikChange II XL Site-Directed 
Mutagenesis Kit (Stratagene). Mutagenic primers were E794K sense 
(5’gccttccgtttgcccgggaaggcaccagttattcacaggttgc-3’), E794K antisense 
(5’gcaacctgtgaataactggtgccttcccgggcaaacggaaggc-3’), M832L sense 
(5’ggcctatgctgtcatcttgcttaatactgaccagc-3’), and M832L antisense 
(5’gctggtcagtattaagcaagatgacagcataggcc-3’).  Mutant clones were sequenced to ensure 
their fidelity. 
 
Preparation of adenovirus expressing GBF1-HA and GBF1-HA mutants  
 Adenovirus expressing GBF1-HA constructs, canine Arf1 switch mutants, and 
NPY-GFP were prepared by cloning the appropriate cDNA into plasmid pENTR-11, then 
transferring the cDNA insert to plasmid pAD/CMV/DEST using the Clonase II reaction 
(all from Invitrogen).  Crude adenoviral stocks were isolated from transfected 293A cells, 
which were then used to generate high titer stocks.  Each was aliquoted and frozen at  
-80oC until used for transduction.  Control experiments were performed with each stock 
to determine conditions resulting in optimal transduction efficiency. 
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NPY-GFP secretion assay  
 The NPY-GFP assay was similar to that previously reported32, with slight 
modifications.  Briefly, 106 Vero cells were transduced overnight at 37ºC in 5% CO2 with 
pAD-NPY-GFP.  Cells were then washed, trypsinized, and seeded into a 96-well plate 
(~1 x 104 cells/well).  The next day, the cells were washed once with PBS then incubated 
at 37ºC with media containing DMSO, BFA (10 µg/mL), or GCA (10 µM).  Supernatants 
were collected at various times thereafter.  GFP quantitation was performed by ELISA 
using anti-GFP coated plates (Pierce) and rabbit anti-GFP in solution.  Mean absorbance 
for control wells containing DMEM alone were subtracted from sample wells. 
Calculation of GFP concentration was performed by interpolation from a recombinant 
GFP (rGFP; Boehring Manneheim) standard curve. 
 
ARF1-GTP pulldown assay   
 Human ARF1 bearing a carboxy-terminal HA epitope tag was amplified from a 
human liver cDNA (Invitrogen) using flanking primers 5’-gtccttccacctgtccacaagcatgggg-
3’ and 5’-ccgcgctagcctgaggcatagtcaggcacgtcataaggatagccgttcttctggttccggagctgattg 
gacagcc-3’.  The resulting product was ligated into plasmid pCDNA3.1/V5/His.  
Nucleotide sequencing was performed to verify fidelity of the HA-tagged wild-type 
cDNA.  Following overexpression, the localization of ARF1 was tracked by indirect 
immunofluorescence using a mouse anti-V5 (Invitrogen) primary antibody, followed by 
staining with the corresponding secondary antibody.   
 The VHS and GAT domains from human GGA3 were amplified from a human 
cDNA library using primers 5- ggccgaattcatggcggaggcggaaggggaaagc-3’ and 5’- 
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ccggctcgagtcagtcaggcagggttaaggtagccacctcg-3’  The resulting product was initially 
cloned into plasmid pcDNA3.1/V5/His and sequenced to ensure its fidelity.  The product 
was then released by digestion with EcoRI and XhoI and ligated into similarly digested 
plasmid pGEX-6p1.  Expression of the recombinant GGA3-GST protein was induced by 
the addition of IPTG and the protein purified from crude bacterial lysates on a GSTrap 
column (Pharmacia).  The protein was dialyzed into 50 mM Tris pH 7.5 plus 100 mM 
NaCl and used in ARF1 pulldown assays using the protocol of Santy and Casanova48.  
 Vero cells were seeded in 10-cm2 dishes and transduced with adenovirus 
expressing ARF1-V5 alone, or co-transduced with virus expressing ARF1-V5 and virus 
expressing GBF1-ML-HA.  After overnight incubation, the cells were washed, 
trypsinized, and seeded into three 25- cm2 flasks each.  The following day, monolayers 
were treated at 37oC for 45 min with media alone, or media containing BFA (10 µg/mL) 
or GCA (10 µM).  The cells were then washed with cold PBS and scraped into 1 mL lysis 
buffer (50 mM Tris pH 7.6, 100 mM NaCl, 2 mM MgCl2, 1 % SDS, 1 % Triton X-100, 
10% glycerol,).   To each sample was added 48 µg of GGA-GST bound to 30 µL of 
glutathione agarose (Pierce Chemical Company).  The samples were incubated with 
rocking at 4oC for 30 min, and the beads were pelleted and washed three times with cold 
GGA wash buffer (50 mM Tris pH 7.6, 100 mM NaCl, 2 mM MgCl2, 1% NP-40, 10% 
glycerol).  SDS-PAGE loading buffer was added, the samples were boiled, and equal 
aliquots separated by SDS-PAGE.  ARF1 was detected by Western blot using anti-V5 
antibody (Invitrogen), followed by enhanced chemiluminescence.  Band intensity was 
determined using the program ImageJ.  The results of duplicate experiments were 
averaged. 
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Molecular Modeling of GBF1-Arf1-GCA complex 
 The GBF1 homology model was built using Prime 2.0 software from 
FirstDiscovery suite (Schrodinger, LLC, Portland, OR) and ARNO coordinates using the 
ARNO-ARF1 complex (PDB id 1r8q) as a template47. Fully flexible ligand docking was 
performed with Glide 5.0 (Schrodinger, LLC, Portland, OR). The protein was prepared 
for grid generation and subsequent docking using the Protein Preparation Wizard tool 
from FirstDiscovery suite. The default settings for grid calculations and docking were 
used.  Images were created with UCSF Chimera version 1.2540 for Windows64. 
 
Transferrin Recycling Assay 
 Transferrin (Tf) recycling was analyzed by modification of a previously published 
assay for recycling of low density lipoprotein related protein65.  2 x 105 Vero cells were 
seeded per well in seven 12-well dishes.  The following day, media was removed and 
replaced with 500 µL serum-free media containing Tf-488 (Invitrogen) at 5 µg/mL  and 
either no compound or GCA (10 µM).  The samples were incubated at room temperature 
for 60 min to allow Tf transport to recycling endosomes.  Cells were washed twice with 1 
mL PBS, then overlaid with 400 µL media containing 10% FCS, anti-AlexaFluor-488 
antibody (Invitrogen) at 15 µg/mL, and either no compound, BFA (10 µg/mL), or GCA 
(10 µM).  t=0 min samples were maintained at room temperature to prevent recycling.  
The remaining samples were incubated at 37ºC and at various times ranging from 10 to 
60 min.  Media was removed, and 500 µL prewarmed cell release buffer (Sigma) was 
added.  Cell suspensions were mixed with 250 µL 4% paraformaldehyde, and mean 
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fluorescence was determined by FACS on a Becton Dickenson FACSCaliber System.  
Mean fluorescence of the t=0 samples was normalized to 100% fluorescence. 
 
[125I]-albumin degradation 
 Vero cells were seeded in 6-well plates (105 cells/well) and washed twice with 
cold serum-free media.  Media was replaced with prewarmed serum-free medium 
containing 1 µCi/mL [125I]-BSA and incubated at 37ºC for 30 or 60 min.  Supernatants 
were collected, and unlabeled BSA was added to a final concentration of 2 mg/mL.  
Proteins were precipitated by TCA (final concentration 15%) for 30 min on ice, then 
centrifuged at 15,000 x g for 20 min at 4ºC.  TCA-soluble and –insoluble fractions were 
analyzed by the Cobra II γ-counter and analyzed by Prism v4.0 software (2003). 
 
STxB-SS-His Sulfation.   
 A STxB construct containing a tandem of carboxy-terminal sulfation sites and a 
histidine tag for purification (STxB-Sulf2) has been described32.  Vero cells seeded in a 6-
well plate (1 x 106 cells/well) were washed three times in serum-free DMEM lacking 
sulfate (Washington University Tissue Culture Support Center), and then incubated in 
sulfate-free medium for 3.5 h at 37ºC.  After treatment with DMSO (0.5% v/v), BFA (10 
µg/mL) or GCA (10 µM) 30 min at 37ºC, media was replaced with sulfate-free media 
containing these compounds plus STxB-Sulf2 (1 mg/mL) and 1 mCi/mL [35S]O4 for 3 h at 
37ºC.  Wells were washed with cold PBS (pH 7.4) and lysed with PBS containing 1% 
Triton X-100.  Lysates were added to 40 µL Ni-NTA Superflow beads (Qiagen) and 
rotated at 4ºC overnight.  Beads were washed once with PBS containing 1% Triton X-100 
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and twice with PBS, then resuspended in imidazole (1.5 M in PBS).  Eluates were 
resolved on a 10-20% Tris-HCl denaturing gel, treated with EnHance reagent (DuPont), 
dried and exposed to film. Band intensity was determined using ImageJ software. 
 
Statistical analyses 
 All statistical analyses were performed by GraphPad Prism 5.  Toxin 
concentrations were log transformed prior to curve fitting and statistical analyses.  Toxin-
response curves were generated by nonlinear regression (least-squares fit) to correspond 
to the observed data, and toxin IC50 and compound IC50 values were calculated using the 
fitted curves.  Toxin IC50  values were compared using the extra sum-of-squares F test 
applied to the best-fit curves for the data.  Differences between toxin IC50 values were 
considered highly statistically significant for p≤0.01.  For assessment of ARF1-GTP 
levels, values were considered statistically significantly different for p≤0.05 (*), whereas 
ns denotes a non-significant difference (p>0.05). 
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CHAPTER IV 
The MAP kinase activated protein kinase-activated protein kinase 2 (MK2) 
contributes to the STx-induced inflammatory response 
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OVERVIEW 
 Gastrointestinal infection with Shiga toxin (STx)-producing bacteria can lead to a 
toxemic condition known as hemolytic uremic syndrome (HUS).  HUS is clinically 
characterized by hemolytic anemia, thrombocytopenia, and renal failure, and it is the 
leading cause of acute renal failure in children.  HUS primarily results from the action of 
STx on endothelial cells lining intestinal and renal microvasculature, resulting in clot 
formation and occlusion of these small vessels (thrombotic microangiopathy).  The 
mechanisms by which STx produces the pathologic features of HUS are debated, 
however.  While some studies have pointed to a direct, cytotoxic role of STx on 
endothelial cells to explain some of the pathophysiology, recent studies have focused on 
the inflammatory component, suggesting that HUS could be an immunopathologic 
response to STx.  In order to investigate the contribution of the immune response to STx, 
we have characterized the mitogen-activated protein (MAP) kinase-activated protein 
kinase 2 (MK2), a substrate of the p38 MAP kinase identified from a siRNA screen of the 
human kinome.  We demonstrate that STx activates MK2 in vitro in both HeLa and 
human microvascular endothelial cells.  Moreover, genetic and chemical inhibition of 
MK2 significantly decreases the inflammatory response to STx2 in HeLa cells and 
human macrophages.  To correlate our findings to an in vivo model, we will adopt a 
murine model of HUS to compare HUS pathology in wild-type versus MK2-deficient 
mice.      
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SUMMARY 
 Infection with Shiga toxin (STx)-producing bacteria can progress to a toxemic, 
extraintestinal injury cascade known as hemolytic uremic syndrome (HUS), the leading 
cause of acute renal failure in children.  Mounting evidence suggests that STx activates 
stress response pathways in susceptible cells and has implicated the p38 mitogen-
activated protein kinase (MAPK) pathway.  More importantly, some of the pathology 
associated with HUS is believed to be a result of a STx-induced inflammatory response.  
From a siRNA screen of the human kinome adapted to a high-throughput format, we 
found that knock-down of the MAPK-activated protein kinase 2 (MK2), a downstream 
target of the p38 MAPK, protected against Shiga toxicity.  Further characterization of the 
in vitro role of MK2 revealed that STx activates the p38-MK2 stress response pathway in 
both p38- and MK2-dependent manners in two distinct cell lines.  MK2 activation was 
specific to damage to the ribosome by an enzymatically active toxin and did not result 
from translational inhibition per se.  Genetic and chemical inhibition of MK2 
significantly decreased the inflammatory response to STx.  These findings suggest that 
MK2 inhibition might play a valuable role in decreasing the immuopathological 
component of STx-mediated disease. 
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INTRODUCTION 
 Bacterial exotoxins are critical components of bacterial pathogenesis and 
constitute potential vehicles for bioterrorism.  Among the most studied of the bacterial 
toxins are members of the AB family, including the bacterial toxins Shiga toxin (STx) 
and the plant toxin ricin.  These toxins are characterized by their bipartite structure, 
consisting of a pentameric, receptor-binding B moiety that is non-covalently linked to a 
catalytic A subunit.  Following a unique retrograde trafficking pathway that facilitates 
toxin access to the cytosol 1-4, these toxins shut off host protein synthesis by inactivating 
the ribosome through cleavage of a single adenine residue in the 28S rRNA 5-7. 
 STx was initially identified in Shigella dysenteriae type I, though it is now 
commonly associated with strains of STx-producing Escherichia coli (STEC), among 
which E. coli O157:H7 has become the most clinically relevant.  In a subset of patients, 
gastrointestinal infection with STEC may progress to extraintestinal injury, leading to 
hemorrhagic colitis and hemolytic uremic syndrome (HUS).   This toxemic syndrome is 
clinically defined by renal failure, thrombocytopenia, and hemolytic anemia, and it 
remains the leading cause of acute renal failure in children 8,9.  Extraintestinal 
complications of HUS correlate with circulating levels of STx, though the mechanism of 
STx-induced pathology in HUS remains unclear.  One of the hallmarks of HUS is the 
development of thrombotic lesions within the intestinal and renal microvasculature that 
accounts for the associated hemorrhagic colitis, hemolytic anemia, and renal failure 10.  
Though some evidence would suggest a direct role for STx in the thrombotic 
microangiopathy associated with HUS 11,12, various lines of evidence support the view 
that much of the systemic and focal pathology of HUS is immune-mediated 13-17.    
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 In conjunction with the mounting evidence suggesting an inflammatory 
contribution to HUS pathology, various cellular stress pathways have been implicated.  
Perhaps the most studied are members of the mitogen activated protein kinase (MAPK) 
family.  MAPKs are signal-transducing enzymes involved in a variety of regulatory roles 
in eukaryotes, including inflammation, differentiation, and apoptosis 18.  The p38 MAPK 
(p38) plays a critical role in the response to various stresses, such as UV radiation, 
cytokines, and toxic stress 19.  In the context of STx-mediated damage, numerous studies 
have clearly defined the role of p38 in inciting inflammatory cytokine release from toxin-
treated cells 20,21.  One study, for example, showed that sequence-specific damage to 28S 
rRNA by STx stimulated a ribotoxic stress response that resulted in p38 activation 22.      
 Though the mechanisms behind STx activation of these signaling cascades remain 
unclear, a critical component is the function of kinases in propagating the stress signal 
and initiating a cellular response.  As a result, kinases are tempting therapeutic targets for 
limiting STx-mediated cellular injury.  For example, inhibition of p38 activation 
decreased cytokine release following exposure of macrophages to STx 23.  However, p38 
inhibition may have limited therapeutic potential, given the ability of p38 to activate 
various downstream kinases involved in diverse cellular functions.  Indeed, mice 
deficient in p38 are not viable post-natally 24-26, and in human clinical trials p38 
inhibition has been met with unanticipated side effects 27.  Moreover, inhibition of p38 
kinase activity by overexpression of dominant negative p38 isoforms 28 or by treatment 
with chemical inhibitors 29 has made probing of specific p38-dependent signaling 
pathways particularly difficult.  Effectors downstream of p38 might therefore be more 
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specific and functionally relevant to the inflammatory signals induced in response to   
STx 30.    
 The mitogen-activated protein kinase-activated protein kinase 2 (MK2) has been 
recently shown to contribute to the inflammatory response 31.  MK2 is a member of the 
MAPK subfamily of calcium/calmodulin-dependent kinases that was originally identified 
as an in vivo substrate of p38 32.  Activation of MK2 by p38 results primarily in the 
subsequent phosphorylation of its two main substrates, heat shock protein 27 (Hsp27) and 
tristetraprolin (TTP).  Despite evidence demonstrating that STx elicits a p38-dependent 
stress response in vitro 22 and that MK2 has been implicated in an in vivo inflammatory 
response to lipopolysaccharide (LPS) 31, the role of MK2 in STx-mediated toxicity has 
yet to be explored.  From a high-throughput siRNA screen of the human kinome, knock-
down of MK2 was found to protect against Shiga toxicity.  We present evidence 
demonstrating that STx activates MK2 in vitro in a p38-dependent manner and that 
inhibition of MK2 decreases the STx-induced inflammatory cytokine response.  We 
extend our in vitro findings to an in vivo mouse model of HUS33 and present preliminary 
evidence comparing the development of HUS pathology in wild-type and MK2-deficient 
mice.  
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RESULTS 
Knock-down of MK2 protects against Shiga toxicity. 
 Various approaches have been employed to study the biological mechanisms 
underlying toxin-induced cell death.  Of particular interest, high-throughput screens of 
small molecules have been developed to target varying aspects of bacterial toxin 
pathogenesis 34-36.  While small molecule compounds are amenable to high-throughput 
screening and allow for the reversible manipulation of cellular processes, the rate-limiting 
step in these studies is the identification of the compound’s target37.   
 As a result, we adapted an inherently target-based approach to specifically screen 
for kinases involved in Shiga toxicity.  An siRNA library targeting 646 human kinase and 
kinase-associated genes (see Methods) was optimized to a high-throughput format and 
screened for kinases essential to Shiga toxicity in HeLa cells.  A HeLa cell line (HeLa-
Fluc) that constitutively expressed luciferase 38, where light expression served as a 
translational readout (Figure 1C), was transfected with a duplex of each of 646 siRNAs 
targeting the human kinome prior to treatment with STx (1 ng/mL) for 24 h.  Each plate 
incorporated a series of controls to assess the screen for siRNA transfection efficiency 
and discriminatory ability (Figures 1A-B).  We considered a hit any kinase knock-down 
that, in the presence of STx, maintained light levels at least 3 standard deviations above 
mock-transfected, STx-treated controls on replicate plates.   
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Figure 1.  Optimization of the human kinome siRNA screen.  (A) Identification of a positive control for the 
siRNA screen.  Knock-down of the delta isoform of protein kinase C (PKCδ siRNA) protects against STx-induced 
inhibition of protein synthesis.  HeLa-Fluc cells were transfected for 48 h with 100 nM negative control siRNA 
(solid line) or PKCδ siRNA (dotted line) prior to exposure to increasing concentrations of STx for 24 h.  Percent 
protein synthesis denotes luminescence levels in transfected cells at a given STx concentration as a percentage of 
transfected cells lacking toxin treatment.  Data points represent duplicate data (mean ±S.D.) for a given toxin 
concentration from one representative experiment.  Data were analyzed using GraphPad Prism.  Dotted horizontal 
line represents 50% protein synthesis.  (B) GL3 siRNA was confirmed as a control for transfection efficiency.  
Transfection with GL3 siRNA effectively knocks down light levels in the HeLa-Fluc reporter cell line.  HeLa-Fluc 
cells were transfected for 48 h with media alone (black bar), transfection reagent alone (gray bar), or GL3 siRNA 
(100 nM; hatched bar), and light levels were measured.  Percent protein synthesis refers to light levels in 
transfected cells as a percentage of light levels in cells containing media alone.  Data points represent duplicate data 
(mean ±S.D.) from one representative experiment.  (C) The half-life of the Fluc reporter was determined using a 
CHX chase.  HeLa-Fluc cells were treated with CHX (100 µg/mL) for the indicated times, and luminescence levels 
were measured.  A non-linear fit to the duplicate data (mean ±S.D.) using a one-phase exponential decay model 
was performed using GraphPad Prism, and the half-life (t1/2) was calculated.  The horizontal dotted line denotes 
50% of the baseline luminescence signal.  CHX, cycloheximide.  
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 Of six kinase hits identified, the mitogen-activated protein kinase-activated 
protein kinase 2 (MK2) revealed the strongest protective effect (Figure 2), and its role in 
STx-induced cytotoxicity was investigated.   
 
STx activates MK2 in vitro. 
 MK2 is a member of the calcium/calmodulin-dependent superfamily of kinases 
functioning downstream of the p38 MAP kinase 32.  Activation of MK2 by p38 results in 
the subsequent phosphorylation by MK2 of its two main substrates, Hsp27 and 
tristetraprolin (TTP).  Hsp27 phosphorylation has been demonstrated to be completely 
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Figure 2.  Knock-down of MK2 protects against Shiga toxicity.  A siRNA screen of 646 human kinase and 
kinase-associated genes was adapted to a 96-well format (see Methods).  Shown are two representative plates, run 
in duplicate (circles and squares), demonstrating light levels of 80 different kinase siRNAs after a 24-h treatment 
with STx1 (1 ng/mL).  Well number represents each well of HeLa-Fluc cells transfected with 50 nM siRNA 
targeting a specific kinase, and corresponding light levels are shown on the y-axis.  Control wells have been 
excluded (see Figures 1A-B).  A hit was considered any knock-down that maintained luminescence at least 3 
standard deviations above STx1-treated controls (dotted line).  Knock-down of MK2 (siRNA sequence provided in 
Methods) conferred the highest protection against Shiga toxicity.  Mean and standard deviations for each set of 
duplicate plates were determined by GraphPad Prism.  MK2, mitogen-activated protein kinase-activated protein 
kinase 2.  
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dependent on the kinase activity of MK2 39, and we therefore used Hsp27 
phosphorylation as an indicator of MK2 activation.  Since the p38 MAPK pathway has 
been shown to play a critical role in the response to various stresses, including UV 
radiation, cytokines, and toxic stress, we assessed STx activation of MK2 in HeLa cells 
by monitoring Hsp27 phosphorylation.  Treatment with STx resulted in activation of  
MK2 in both a time- and dose-dependent manner.  As early as 60 min following exposure 
to STx, phosphorylation of MK2 and its downstream target, Hsp27, were observed 
(Figure 3A).  Similarly, higher levels of phosphorylated MK2 and Hsp27 were observed 
 A) 
B) 
Figure 3. STx1 induces activation of the p38-MK2 pathway in both HeLa cells and HMVEC in time- and 
dose-dependent manners.  (A) HeLa cells (left) or HMVEC (right) were treated with no toxin or STx1 (10 
ng/mL) for the indicated times, and lysates were probed with the indicated antibodies.  Activation of the p38-MK2 
pathway is observed by 60 min following exposure to STx1, while stimulation of this pathway in HMVEC can be 
seen as early as 30 min.  (B) HeLa cells (left) or HMVEC (right) were treated with either no toxin or increasing 
STx1 concentrations for 2 h.  Lysates were probed as in (A).  For both cell lines, as little as 0.1 ng/mL STx1 was 
able to activate the p38-MK2 pathway.  For (A) and (B), actin staining served as a loading control.  HMVEC, 
human microvascular endothelial cells.  
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with increasing STx concentrations (Figure 3B).  Time- and dose-dependent 
phosphorylation of the p38 MAPK mirrored that of MK2, suggesting activation of the 
p38-MK2 pathway (Figure 3).     
 Some studies have suggested that STxB binding to its receptor can stimulate 
signal transduction cascades following activation of membrane-localized kinases, such as 
Syk 40 and Yes 41, and that these effects were independent of the toxin’s effect on 
ribosome function.  We 
found, however, that 
exposure of HeLa cells to 
the STxB subunit alone did 
not result in Hsp27 
phosphorylation (Figure 4), 
implying that engagement 
of the STx receptor, Gb3, 
by the receptor-binding B 
subunit is insufficient for MK2 activation and that STx’s catalytic activity is necessary 
for induction of this pathway.  Phosphorylation of MK2 in the presence of STx thus 
appears to be specific to an enzymatically active toxin.  In addition, we confirmed that 
MK2 activation was not the result of a LPS contamination of the toxin preparation, as 
heat-inactivated STx (HI-STx) failed to activate MK2 (Figure 4). 
 
 
 
Phospho-Hsp27 
MK2 
Treatment: 
HI- 
STx1 
STxB STx1 STx1 
+ SB202190 
 Figure 4.  Activation of MK2 is specific to catalytically active 
STx.  HeLa cells were pretreated with DMSO (0.5% v/v) or the p38 
inhibitor SB202190 (10 µM) for 1 h prior to a 30-min exposure to 
STx1 (100 ng/mL).  Equal fractions of lysates were probed with the 
indicated antibodies, with MK2 serving as a loading control.  
Inhibition of p38 eliminates STx1-induced MK2 activation.  In 
addition, treatment with 100 ng/mL heat-inactivated STx1 (HI-
STx1) or the STxB subunit (100 ng/mL) did not activate MK2.  Heat 
inactivation of STx1 involved incubating the toxin for 12 h at 95ºC.  
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Activation of MK2 is p38-dependent. 
 To assess the role of p38 on STx-induced MK2 activation, we treated HeLa cells 
with the p38-specific chemical inhibitor, SB202190, prior to STx exposure.  As expected, 
pretreatment with SB202190 blocked Hsp27 phosphorylation, indicating that STx 
specifically activates MK2 through p38 and not through another stress activation pathway 
(Figure 4).  Moreover, pretreatment with other p38 inhibitors (SB 203580, p38 inhibitor 
III) showed a similar effect, while pretreatment with the JNK inhibitor (SP 600125) 
showed no decrease in MK2 activation in the presence of STx (Figure 5).  Taken 
together, these results indicate that STx-induced activation of MK2 is dependent on its 
upstream MAP kinase, p38. 
 
 While we could confirm that STx stimulated the p38 MAPK pathway in HeLa 
cells, we sought to validate these findings in a more physiologically relevant cell line.  
Much of the in vivo systemic pathology resulting from infection with STx-producing 
Figure 5.  STx-induced MK2 activation is p38-specific.  HeLa cells (left) or HMVEC (right) were pretreated 
with the indicated compounds 30 min prior to a 2-h exposure to STx2 (10 ng/mL).  Lysates were probed with 
the indicated antibodies.  Two distinct p38 inhibitors, SB203580 (2.65 µM) and the p38 inhibitor III (0.5 µM), 
prevented STx2-mediated Hsp27 phosphorylation, while the JNK inhibitor SP600125 (25 µM) showed no 
effect, similar to STx2-treated cells treated lacking compound treatment (“STx2 alone”).  “No toxin” refers to 
cells lacking compound and toxin treatment.  β-actin staining served as a loading control.  HMVEC, human 
microvascular endothelial cells. 
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bacteria is related to the effects of circulating levels of STx on microvasculature 42.  STx-
mediated endothelial cytotoxicity is believed to contribute to the thrombotic 
microangiopathy of HUS, and exposure of endothelial cells to STx has been shown to 
induce thrombotic changes to the endothelial cell surface, further contributing to the pro-
coagulant state observed in HUS 43.  We investigated the in vitro effects of STx on 
human microvascular endothelial cells (HMVEC).  As with HeLa cells, STx treatment of 
HMVEC stimulated MK2 activity in a time- and dose-dependent manner (Figures 3A-B), 
and MK2 activation was shown to be p38-dependent (Figure 5).    
 In these experiments, we measured cellular responses to STx1 (Figure 3) and 
STx2 (Figure 5), though we have found that HMVEC cells consistently showed similar 
sensitivity to both STx subgroups in terms of p38 activation (data not shown).  While 
both subgroups differ in their toxicity in mice 44-46, they share indistinguishable toxicity 
in our cultured HMVEC and HeLa cells (not shown), consistent with similar observations 
in Vero cells 47.  However, epidemiological evidence suggests that stx2-producing 
enterohemorrhagic E. coli (EHEC) O157:H7 strains are more frequently associated with 
HUS than are stx1-producing strains 48,49.  We therefore found it relevant to study both 
STx subgroups in the context of p38-MK2 activation. 
 
STx activation of the p38-MK2 pathway is MK2-dependent. 
 Activation of the p38-MK2 pathway by STx was equally found to be dependent 
on MK2 catalytic activity.  Overexpression of a catalytically inactive adenoviral construct 
(MK2-DN) in HeLa cells eliminated STx1-induced Hsp27 phosphorylation compared to 
cells overexpressing wild-type MK2 (MK2-WT) or control vector (pAd-Luc; Figures 6A-
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B).  To validate this finding and further confirm the role of catalytically active MK2 in 
the response to STx, pretreatment of endothelial cells with a recently identified inhibitor 
of MK2, PHA-781089, blocked STx1-induced Hsp27 phosphorylation (Figure 6C).  This 
compound, at a dose of 20 µM, has been previously shown to inhibit Hsp27 
phosphorylation of  LPS-treated U937 macrophage cells  39.  We found a similar dose 
response of PHA-781089 against Hsp27 phosphorylation in STx1-treated  HeLa  cells 
(Figure 6D).  Treatment of HMVEC with 20 µM PHA-781089 resulted in undetectable 
levels of phosphorylated Hsp27, even after 4 h of STx treatment, while  vehicle-treated 
controls demonstrated MK2 activity beginning at 60 mins.  This effect was not the result 
of the MK2 inhibitor on STx transport, as treatment of HeLa cells with PHA-781089 
showed no effects on STxB-488 transport to the Golgi (Figure 6D).  These findings 
suggest that STx stimulates the p38-MK2 pathway in two distinct human cell lines and 
that activation of the p38-MK2 pathway may contribute to the endothelial cellular stress 
response to STx in vivo. 
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Figure 6.  STx activation of the p38-MK2 pathway depends on MK2 activity.  (A) Overexpression of catalytically 
inactive MK2 (MK2-DN) eliminates STx1-induced Hsp27 phosphorylation.  HeLa cells were transduced with 
adenoviral constructs expressing luciferase (pAd-Luc), wild-type MK2 (MK2-WT), or catalytically inactive MK2 
(MK2-DN; see Methods).  Cells were then exposed to STx1 (10 ng/mL) for 6 h, and equal fractions of lysates were 
probed with the indicated antibodies.  (B) Validation of the MK2 adenoviral vectors.  HeLa cells were treated for 24 h 
with various dilutions of adenoviral constructs overexpressing either wild-type MK2 (MK2-WT) or a catalytically 
inactive, dominant negative MK2 (MK2-DN).  Equal fractions of lysates were probed with the corresponding 
antibodies.  Actin served as a loading control.  Undiluted virus (corresponding to an MOI of approximately 100) 
resulted in the greatest level of MK2 expression and was used for all relevant experiments.  (C) HMVEC were 
pretreated with DMSO (0.5% v/v; top) or the MK2 inhibitor PHA-781089 (20 µM; bottom) for 1 h prior to exposure to 
STx2 (1 ng/mL) for the indicated times.  Lysates were probed with the indicated antibodies.  Chemical inhibition of 
MK2 prevents STx-induced Hsp27 phosphorylation.  HI-STx2, heat-inactivated STx2 (1 ng/mL).  For (A) and (B), 
actin staining served as a loading control.  (D) PHA-781089 exhibits maximal MK2-inhibitory activity at 20 µM.  This 
concentration is consistent with a previous report 50.  HeLa cells were treated with increasing concentrations of PHA-
781089 for 1 h prior to the addition of STx1 (10 ng/mL) for 4 h.  Equal fractions of lysates were probed with the 
indicated antibodies.  Actin served as a loading control.  Figure is representative of two independent experiments.   
(E) MK2 inhibition has no effect on the intracellular transport of STxB to the Golgi.  The fate of endocytosed 
fluorescently-tagged STxB (red) was monitored by immunofluorescence in HeLa cells pretreated with DMSO (0.5% 
v/v), PHA-781089 (20 µM), or GCA (10 µM) prior to staining with an anti-giantin antibody (green).  Pretreatment with 
the MK2 inhibitor has no effect on STxB transport to the Golgi compared to DMSO-treated cells, while GCA prevents 
toxin colocalization with a giantin-positive structure.  STxB, Shiga toxin B subunit; blue, nuclei.  
 
 
MK2 activation by STx depends on toxin adherence and intracellular transport. 
 STx, like the plant toxin ricin, follows a retrograde trafficking pathway to reach 
its intracellular target.  Following endocytosis into an early endosome, it is believed that 
these toxins hijack host trafficking mechanisms in order to bypass lysosomal   
degradation 51 and coordinate their rerouting to the ER via the Golgi 36.  The toxins are 
then retrotranslocated across the ER membrane in order to access the cytosol, where they 
can inhibit protein synthesis by directly damaging the ribosome 3,4,52.  To test whether 
MK2 activation relied on STx transport to the cytosol, HMVEC were initially incubated 
with  P1 glycoprotein, a ligand of the Gb3 receptor.  As STx is known to induce its 
uptake following binding to the glycosphingolipid Gb3 53, we would expect that co-
incubation of STx1 with the P1 glycoprotein would prevent toxin endocytosis.  Indeed, 
the P1 glycoprotein reduced cell surface-associated STx1 and protected against STx1-
mediated inhibition of protein synthesis (not shown).  More importantly, the P1 
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glycoprotein was able to protect against STx-induced p38 and Hsp27 phosphorylation, 
suggesting that STx must be internalized to stimulate the p38-MK2 pathway (Figure 7A).  
Similarly, treatment of HMVEC with Golgicide A (GCA), a potent inhibitor of Shiga 
toxicity that arrests STx transport at the early endosome 54, was shown to also prevent 
STx-induced p38 and Hsp27 phosphorylation.  In contrast, GCA had no effect on 
anisomycin, an established p38 agonist 55 that does not rely on intracellular transport and 
that rapidly equilibrates in the cytosol.  If we equally consider that treatment with STxB 
alone did not activate MK2 (Figure 4), these results would collectively suggest that 
transport of catalytically active STx to the cytosol is required to activate the p38-MK2 
pathway. 
 
A) B) 
Figure 7.  Activation of the p38-MK2 pathway by STx depends on toxin adherence and intracellular 
trafficking and appears to be part of a ribotoxic stress response. (A) HMVEC were pretreated with DMSO (0.5% 
v/v), GCA (10 µM), or P1 glycoprotein (1 µg/mL) for 30 min prior to exposure to STx1 (10 ng/mL) or media alone 
(“No Toxin”).  Cells were allowed to internalize toxin for 2 h at 37ºC prior to lysis and probing with the indicated 
antibodies.  Pretreatment with the P1 glycoprotein inhibited STx1-mediated phosphorylation of p38 and Hsp27, and 
GCA treatment similarly blocked activation of the p38-MK2 pathway compared to DMSO-treated cells (“Toxin 
alone”).  Pretreatment with GCA, however, had no effect on activation of this pathway following a 2-h exposure to 
anisomycin (10 ng/mL).  (B) HMVEC were exposed to various translational inhibitors for 2 h, and the 
phosphorylation status of p38 and Hsp27 was assessed by Western blotting.  Only inhibitors that are known to cause 
direct damage to the ribosome (STx1, STx2, and ricin) induced p38 and Hsp27 phosphorylation, while translational 
inhibitors acting through different mechanisms (DT, PE, Puro, CHX) showed little to no activation.  “None” refers to 
cells lacking compound and toxin treatment.  STx1, Shiga toxin 1 (10 ng/mL); STx2, Shiga toxin 2 (10 ng/mL); 
GCA, Golgicide A;  DT, diphtheria toxin (1 µg/mL); PE, Pseudomonas exotoxin A (1 µg/mL); Puro, puromycin (10 
µg/mL); CHX, cycloheximide (100 µg/mL).  For both (A) and (B), actin staining served as a loading control. 
 141 
MK2 activation relies on damage to the ribosome. 
 Following entry into the cytosol, STx and ricin inhibit protein synthesis through 
sequence-specific RNA damage to the α-sarcin loop in the 28S rRNA 56.  Both toxins 
consist of an enzymatic A subunit that has RNA N-glycohydrolase activity and 
depurinates a single adenine residue at position 4324 of the 28S rRNA.  Given that MK2 
activation relied on enzymatically active STx (Figure 4), we examined the possibility that 
MK2 activation was the result of ribosomal damage and not simply a stress response due 
to translational inhibition.  To test this, HMVEC were treated with various inhibitors of 
protein synthesis acting through distinct mechanisms, and activation of the p38-MK2 
pathway was assessed .  As expected, STx and ricin treatments both stimulated p38 and 
Hsp27 phosphorylation (Figure 7B).  In addition, both clinically relevant STx subgroups, 
STx1 and STx2, stimulated a similar response.  These subgroups show approximately 
60% similarity in the A subunits at the amino acid level 10 and share a common 
enzymatic mechanism.  The bacterial exotoxins diphtheria toxin (DT) and Pseudomonas 
exotoxin A (PE), however, were unable to stimulate the p38-MK2 pathway at 
concentrations that have been previously shown to inhibit protein synthesis in HeLa   
cells 57.  Both toxins inhibit protein synthesis by catalyzing the ADP ribosylation of 
elongation factor 2 58,59.  Similarly, the aminonucleoside antibiotic puromycin, which 
arrests translation by causing a premature release of the nascent peptide 60, also failed to 
activate the p38-MK2 pathway, while cycloheximide, which prevents ribosomal 
translocation during translational elongation 60, weakly activated it.  These findings are 
consistent with activation of the p38-MK2 pathway following specific damage to the 
ribosome and not translational inhibition per se. 
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MK2 inhibition decreases the inflammatory response to STx. 
 MK2 has been implicated in a variety of stress responses, most notably 
inflammation 31, though no studies have directly assessed MK2’s role in the context of 
the STx-induced inflammatory response.  Multiple studies have lent an immmunological 
perspective to the pathology of HUS 13,14,17.  Given the activation of the p38-MK2 stress 
response pathway by STx and the contribution of this pathway to inflammation, we 
assessed the role of MK2 in generating an inflammatory response to STx.  HeLa cells 
were transduced with adenoviral constructs expressing wild-type MK2 (MK2-WT) or a 
catalytically inactive MK2 (MK2-DN).  Expression of these constructs was validated 
(Figure 6B) and exhibited the expected effects on STx1-induced MK2 activation (Figure 
6A).  MK2-DN overexpression significantly reduced mRNA levels of the inflammatory 
cytokines IL-6 and TNFα compared to cells overexpressing MK2-WT, as assessed by 
quantitative RT-PCR (qRT-PCR; Figures 8A-B).  This suggests that catalytically active 
MK2 is required for the STx1-induced expression of the inflammatory markers IL-6 and 
TNFα. 
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 To further confirm that MK2 inhibition reduced the cytokine response to STx1, 
HeLa cells were pretreated with DMSO, an MK2 inhibitor, or a p38 inhibitor prior to a 6-
h exposure to STx1.  Chemical inhibition of MK2 significantly reduced IL-6 and TNFα 
mRNA levels (Figures 8C-D), consistent with overexpression of catalytically inactive 
MK2 (Figures 8A-B).  Similarly, chemical inhibition of p38, the kinase upstream of 
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Figure 8.  MK2 inhibition reduces the STx-induced inflammatory response in HeLa cells.  (A) HeLa cells 
were transduced with a control adenoviral construct (pAd-Luc; black bars), a construct expressing wild-type 
MK2 (MK2-WT; gray bars), or a construct expressing a catalytically inactive MK2 (MK2-DN; white bars) for 
24 h prior to treating with STx1 (10 ng/mL) for 6 h.  The levels of IL-6 and TNFα mRNA were determined by 
qRT-PCR and are expressed as a fold change above mRNA levels in transduced cells lacking STx1 (see 
Methods).  Data points represent duplicate data from three independent experiments (mean ±S.D.).  Sample 
means were compared using a two-tailed Student’s t-test for independent samples.  (B) HeLa cells were 
pretreated with DMSO (0.5% v/v; black bars), the MK2 inhibitor PHA-781089 (20 µM; gray bars), or the p38 
inhibitor SB202190 (10 µM; white bars) for 1 h prior to a 6-h exposure to STx1 (100 ng/mL).  The levels of IL-6 
and TNFα mRNA were determined by qRT-PCR and are expressed as a fold change above mRNA levels in 
compound-treated cells in the absence of STx1.  Data points represent duplicate data from three independent 
experiments (mean ±S.D.).  Sample means were compared as in (A).  n.s. denotes no significant change, * 
significant change (p<0.05), ** highly significant change (p<0.01).  
*
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MK2, also significantly reduced the levels of these general inflammatory cytokines 
(Figures 8C-D).  These trends could be duplicated in a human macrophage cell ine, THP-
1.  Chemical inhibition of MK2 in human macrophages (Figure 9A) reduced the levels of 
IL-6 and TNFα transcripts(Figure 9B).  Together, our results collectively show that 
genetic and chemical inhibition of MK2 activity significantly reduces the inflammatory 
response to STx1.  Chemical inhibition of MK2 thus presents a unique opportunity for 
targeting the immunopathological response to STx in vivo. 
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Figure 9.  Chemical inhibition of MK2 reduces the inflammatory response to STx in THP-1 cells.  
(A) THP-1 cells were pretreated with media alone or the MK2 inhibitor PHA-781089 for 1 h prior to a 6-
h exposure to STx2 (100 ng/mL).  Cell lysates were probed with the indicated antibodies.  Staining with    
β-actin served as a loading control.  (B) THP-1 cells were pretreated with media alone (black bars) or the 
MK2 inhibitor PHA-781089 (20 µM; gray bars) for 1 h prior to a 6-h exposure to STx1 (100 ng/mL).  
The levels of IL-6 and TNFα mRNA were determined by qRT-PCR and are expressed as a fold change 
above mRNA levels in compound-treated cells in the absence of STx1.  Data points represent duplicate 
data from three independent experiments (mean ±S.D.).  Sample means were compared as in (A).  n.s. 
denotes no significant change, ** highly significant change (p<0.01).  
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DISCUSSION 
 In an effort to identify kinases involved in Shiga toxicity, we developed and 
adapted a siRNA screen targeting the human kinome to identify kinases essential to STx-
induced cytotoxicity.  Of the 646 kinases tested, six were identified as protective, with 
MK2 exhibiting the greatest protection.  Compared to previous high-throughput screens 
aimed at identifying small molecule inhibitors of microbial toxicity 34-36,54, the siRNA 
approach represents an inherently target-based approach that is not hampered by potential 
intracellular “off-target” effects of small molecules.   
 While previous screens 36,54 focused on inhibitors of toxin trafficking and 
monitored Shiga toxicity over a shorter time period (~ 4-6 h), the siRNA screen relied on 
a 24-h exposure to STx due to the relatively long half-life of the Fluc translational 
reporter.  As a result, we would expect that, following a longer exposure to STx, knock-
down of kinases involved in STx transport as well as those involved in STx-induced cell 
death would show up as protective.  Indeed, knock-down of MK2 exhibited strong 
protection against Shiga toxicity in our screen.  A subsequent assessment of cell viability 
by Alamar Blue staining revealed that wells transfected with MK2 siRNA showed 
relatively higher cell viability (not shown; see reference), which may have accounted for 
the protective effects observed.  The role of MK2 in STx-induced cell death remains 
unclear and is currently under investigation.  
 The central role of the p38 MAPK in propagating various cellular stress  
responses 18 has made specific inhibition of p38-dependent signaling pathways 
particularly difficult.  MK2 thus appears as a tempting target, given that it functions 
downstream of p38 on a smaller set of substrates 32.  More importantly, MK2 has been 
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implicated in the inflammatory response in a lipopolysaccharide (LPS) mouse model 31: 
MK2-deficient mice showed decreased TNFα and IL-6 levels and increased survival to 
LPS-induced shock.  In an experimental asthma model, MK2 was found to be essential to 
Th2-type inflammation through sustained NF-κB activation 61.  Most recently, selective 
MK2 inhibitors have been developed for the treatment of animal models of rheumatoid 
arthritis and other inflammatory conditions mediated by TNFα 50.  The contribution of the 
inflammatory response in HUS remains debated, though several lines of evidence would 
suggest that some of the systemic pathology, namely the development of thrombotic 
lesions within the renal microvasculature, could be an immunopathological    
phenomenon 14,15,62.  Our studies suggest that catalytically active STx activates MK2 as a 
result of ribosomal damage, implicating MK2 in the STx ribotoxic stress response.   
 Biochemical evidence suggests that MK2 contributes to the stability of IL-6 and 
TNFα mRNA through the downstream phosphorylation of TTP in a process that involves 
AU-rich elements (ARE) in the 3’ non-coding regions of these mRNAs 63-67: 
phosphorylation of TTP by MK2 results in TTP sequestration and prevents TTP from 
directing degradation of these mRNAs.  In our studies, MK2 inhibition by genetic and 
chemical means diminished the acute inflammatory response in STx-treated HeLa cells.  
Overexpression of catalytically inactive MK2 significantly decreased the mRNA levels of 
IL-6 and TNFα, and chemical inhibition of MK2 mirrored these effects.      
 Interestingly, HMVEC under the same tissue culture conditions did not exhibit the 
cytokine response that was observed in HeLa cells, despite demonstrating STx-dependent 
activation of the p38-MK2 pathway in vitro.  Our studies utilized HMVEC of dermal 
origin, whose sensitivity to STx is similar to that of Vero cells 68.  Certain human 
 148 
microvascular endothelial cell lines have been shown to mount a STx-dependent cytokine 
response in vitro 69,70, though these responses appear to be cell origin-dependent 71 and 
require pre-sensitization with inflammatory cytokines.  Nonetheless, the observed 
cytokine response in both HeLa cells and human macrophages could be crucial to 
establishing a local inflammatory milieu in vivo.  In particular, decreased in vitro levels 
of the general inflammatory markers TNFα and IL-6 in MK2-inhibited cells is consistent 
with decreased cytokine expression in MK2-deficient mice 31 and could translate to 
decreased immunopathology following exposure to STx.  Inhibition of MK2 thus 
presents a viable therapeutic option in mitigating the toxemic effects of STx-mediated 
disease. 
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MATERIALS AND METTHODS 
Reagents and antibodies 
 Shiga toxin 1 (STx1) and 2 (STx2) were kindly provided by Anne Kane (Tufts 
University) and diluted to 0.5 mg/mL in PBS (pH 7.4).  Aliquots were frozen at -80°C 
until further use.  Ricin, Pseudomonas exotoxin A, and diphtheria toxin were purchased 
from Sigma.  The B subunit of STx1 (STxB) was purified and fluorescently tagged as 
previously described 36.  SB202190, SB203580, SP600125, anisomycin, puromycin, 
cycloheximide, and DMSO were purchased from Sigma, p38 inhibitor III from 
Calbiochem, Golgicide A from ChemDiv, and PHA-781089 from Pfizer.  All chemical 
inhibitors were diluted to 10 mM in DMSO and stored at -20ºC until further use.  All 
antibodies used for Western blotting were purchased from Cell Signaling Technology, 
Inc.  Dulbecco’s modified Eagle’s medium (DMEM), streptomycin, and penicillin were 
from Mediatech, and fetal bovine serum (FBS) was from Hyclone.  Protease inhibitor 
cocktail was from Roche. 
 
Cell culture 
 HeLa cells were obtained from the Tissue Culture Support Center (Washington 
University) and maintained at 37ºC and 5% CO2 in DMEM supplemented with 10% FBS 
and 0.1% penicillin/streptomycin.  HeLa-Fluc cells were kindly provided by David 
Piwnica-Worms (Washington University) and maintained in DMEM supplemented with 
10% FBS, 1% penicillin/streptomycin, and 1 mg/mL G418 (Washington University 
Tissue Culture Support Center).  Human dermal microvascular endothelial cells 
(HMVEC) were purchased from Lonza and maintained in EGM-2MV medium (Lonza) at 
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37ºC and 5% CO2.  293A cells were purchased from Invitrogen and maintained at 37ºC 
and 5% CO2 in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.  
THP-1 cells were obtained from American Type Culture Collection and maintained in 
DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.  For experiments, 
THP-1 cells were seeded at 1 x 106 cells/well in 6-well dishes and subsequently 
stimulated for 48 h with 50 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma).  
Adherent cells were washed twice with DMEM and incubated in fresh medium lacking 
PMA.  Medium was changed every 24 h for 3 additional days, after which cells were 
used for experiments. 
  
siRNA kinome screen   
 The Human Kinase siRNA library set version 2.0 was provided by Qiagen.  Fully 
annealed duplex siRNAs were suspended in 1X annealing buffer (100 mM KOAc, 30 
mM HEPES-KOH, 2 mM MgOAc, pH 7.4) and 0.25 nmol of pooled siRNAs were stored 
at -80ºC until further use.  HeLa-Fluc cells were seeded at 1 x 104 cells/well in thirty-six 
96-well plates (Costar) and grown overnight at 37ºC and 5% CO2.  The next day, each 
well was transfected with a duplex of siRNAs (50 nM) targeting a specific kinase, and 
cells were subsequently incubated for 48 h at 37ºC.  STx1 (1 ng/mL) was added for 24 h, 
and light levels were determined using the PerkinElmer Envision XCite Multilabel 
Reader (1 min delay, 1 s integration).  Following luminescence readings, 10 µL of 
Alamar Blue (440 µM resazurin sodium salt stock; Sigma) were added to each well, and 
plates were incubated for 2 h at 37ºC.  Alamar Blue levels were detected using the 
FluoStar OPTIMA spectrophotometer (BMG Labtech).    
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 Each plate contained a positive control and a series of negative controls, as well 
as a control for transfection efficiency.  Positive controls included siRNA against the 
delta isoform of PKC (PKCδ siRNA, Dharmacon; Figure 1A), whose knock-down has 
been shown to protect against Shiga toxicity 72, or pretreatment for 1 h with GCA (10 
µM), which has been equally shown to be protective against Shiga toxicity 54.  Negative 
controls included cells containing media alone, transfection reagent alone 
(DharmaFECT1, Dharmacon), negative control siRNA (Dharmacon), scrambled siRNA 
(Qiagen), and GFP siRNA (Qiagen).    Transfection efficiency was controlled for by 
transfecting cells with siRNA targeting the luciferase reporter (GL3 siRNA; Dharmacon) 
and ensuring >75% drop in light levels (Figure 1B).  All controls were validated prior to 
incorporating them in the screen.  MK2 duplex siRNA sequences provided in the Qiagen 
library were as follows:  5’-CGCCATCATCGATGACTACAA-3’ and 5’-
CTACGAGCAGATCAAGATAAA-3’. 
 
siRNA kinome library 
 The Human Kinase siRNA library set version 2.0 (Qiagen) consisted of  1292 
HPP-grade siRNA duplexes targeting 646 human kinase and kinase-associated genes 
(two siRNA duplexes/gene).  Targeted kinase genes included tyrosine kinases and 
tyrosine kinase-like kinases, calcium/calmodulin-dependent protein kinases, members of 
the protein kinase C family, cyclin-dependent protein kinases, mitogen-activated protein 
kinases, casein kinases, receptor guanyl cyclases, atypical kinases, and other less-
characterized kinases.  The siRNA kinase gene list can be found at 
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http://www1.qiagen.com/Products/GeneSilencing/LibrarySiRna/SiRnaSets/HumanKinase
siRNASet.aspx?ShowInfo=1. 
 
Western blotting   
 Following compound and toxin treatments, cells were lysed in lysis buffer (20 
mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 
mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/mL 
leupeptin, 1X protease inhibitor cocktail) and resolved on a 4-15% Tris-HCl gel (Biorad) 
prior to transfer onto PVDF membranes (Invitrogen).  Membranes were probed with 
corresponding primary antibodies (1:1000) and anti-rabbit alkaline phosphatase-
conjugated secondary antibodies (Invitrogen).  Membranes were washed and developed 
using the Western Breeze kit protocol (Invitrogen).  For experiments comparing multiple 
phospho-proteins, membranes were washed and reprobed with additional antibodies. 
Where indicated, equal fractions of lysates from the same experiment were run on 
separate gels and probed with the corresponding primary antibodies.   
 
Overexpression of MK2-WT and MK2-DN 
 Recombinant wild-type MK2 (MK2-WT) and catalytically inactive MK2 (MK2-
DN) adenoviruses were purchased from Cell Biolabs, Inc. and amplified in 293A cells 
using the manufacturer’s protocol.  The pAd-Luc adenoviral construct has been 
previously reported and validated 57.  Viral stocks were stored at -80ºC until further use.  
Confluent HeLa cells were transduced for 24 h prior to a 6-h expsoure to STx1 (10 
ng/mL).  Lysates were probed by Western blotting with antibodies to MK2, phospho-
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Hsp27, and β-actin.  For cytokine mRNA measurements, HeLa cells were transduced for 
24 h, exposed to STx1 for 6h, and RNA was harvested using the RNeasy Mini Kit 
(Qiagen), according to the manufacturer’s protocol. 
 
Immunohistochemistry 
 HeLa cells were seeded at 2.5 x 104cells/well and grown overnight on coverslips 
(Labtek) at 37ºC.  The next day, cells were treated with DMSO (0.5% v/v), PHA-781089 
(20 µM), or GCA (10 µM) prior to treatment with STxB-488 (1 μg/mL; Molecular 
Probes).  Cells were kept at 4ºC, prior to internalization of STxB-488 for 1 h at 37ºC.  
Cells were fixed in 4% paraformaldehyde for 15 min at room temperature, washed with 
PBS, then permeabilized for 30 min at room temperature with permeabilization buffer 
(PBS, 2% bovine serum albumin, 0.5% Triton X).  Cells were washed and blocked in 
blocking buffer (PBS, 2% bovine serum albumin, 0.1% Triton X) for 30 min at room 
temperature prior to staining with rabbit anti-giantin antibody (1:500; Covance) for 1 h at 
room temperature.  Coverslips were washed and subsequently stained with AlexaFluor-
488 donkey anti-rabbit IgG (1:200; Molecular Probes) for 45 min at room temperature.  
Cells were washed with PBS and mounted with SlowFade reagent (with DAPI; 
Molecular Probes) for epifluorescence microscopy using a Zeiss microscope. 
        
Quantitative RT-PCR (qRT-PCR)   
 For cells overexpressing MK2 adenoviral constructs, HeLa cells were transduced 
for 24 h, exposed to STx1 for 6h, and RNA was harvested using the RNeasy Mini Kit.  
For experiments involving chemical inhibition of MK2, HeLa cells were pretreated with 
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DMSO, PHA-781089, or SB202190 at the indicated concentrations for 1h at 37ºC.  Cells 
were then left untreated or were exposed to STx1 (100 ng/mL) for 6 h.  Cells were 
washed once with cold PBS, and RNA was extracted using the RNeasy Mini Kit.  cDNA 
was synthesized in duplicate from 200 ng of each sample using commercially available 
primers for GAPDH, IL-6, and TNFα (Applied Biosystems).  For each qRT-PCR run, the 
calculated threshold cycle (Ct) was normalized to the threshold cycle of the GAPDH 
gene amplified from the corresponding sample.  The fold change was calculated using the 
2-ΔΔCt method 73 and represents the fold change above adenovirally-transduced or 
compound-treated cells lacking STx1 treatment.  
 
Statistical analyses   
 Data were processed and analyzed using GraphPad Prism version 5.00 for 
Windows (GraphPad software).  Cytokine mRNA levels were compared using the two-
tailed Student’s t-test (VassarStats, http://faculty.vassar.edu/lowry/tu.html) for three 
independent experiments.  Differences were considered significant for p<0.05 and highly 
significant for p<0.01. 
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CHAPTER V 
 
Conclusions and Future Directions 
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CONCLUSIONS 
 The study of Shiga toxin (STx) pathogenesis is inherently an investigation into 
host intracellular transport as well as into the activation of host stress response pathways.  
The unique trafficking mechanism of this bacterial exotoxin makes it an ideal probe for 
uncovering the host mechanisms underlying its transport.  In addition, the development of 
hemolytic uremic syndrome (HUS) following Shiga toxicity highlights the need to 
understand the initiation and regulation of the host stress response in order to limit toxin-
mediated systemic injury.  Our studies have focused on inhibiting STx pathogenesis 
through a multi-faceted approach.  A high-throughput screen aimed at identifying small 
molecules that block intracellular STx transport identified three potential inhibitors, one 
of which enhanced our understanding into the role of GBF1 in mediating anterograde and 
retrograde host transport.  A subsequent siRNA screen adapted to a high-throughput 
format led us to pursue the role of the MAP kinase-activated protein kinase 2 (MK2) in 
mediating the inflammatory response to STx.  The major conclusions of this work 
include:  (i) small molecules are amenable to screens for inhibitors of STx transport, (ii) 
compounds 75 and 134 inhibit Shiga toxicity by blocking toxin transport at distinct stages 
along the STx retrograde trafficking pathway, (iii) Golgicide A (GCA) yielded insights 
into the role of GBF1 in mediating anterograde transport of soluble and membrane-bound 
proteins as well as endosome-to-TGN transport of STx, (iv) activation of MK2 is part of 
a ribotoxic stress response following exposure to STx, and (v) MK2 contributes to the 
acute inflammatory response to STx. 
 In terms of STx transport, characterization of small molecule inhibitors revealed 
that all three compounds studied protected against Shiga toxicity through perturbations in 
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Golgi structure.  As compound 75 also protected against diphtheria toxicity and likely 
acted at the endosome-to-TGN stage of STx transport, it nonetheless disrupted Golgi 
architecture, possibly through an inhibition in bidirectional membrane recycling between 
endosomes and TGN.  More importantly, the block in intra-Golgi transport consistently 
protected against Shiga toxicity, suggesting that STx must primarily transit through an 
intact Golgi in order to access the endoplasmic reticulum (ER).  It therefore seems 
unlikely that a significant amount of STx can bypass the Golgi and reach the ER from an 
endosome, as has been previously suggested 1.   
 The discovery and functional characterization of GCA allowed for the study of 
intra-Golgi vesicular trafficking and clearly defined the role of GBF1 in mediating 
anterograde and retrograde transport.  Previous experiments aimed at probing transport 
through the Golgi have relied on treatment with brefeldin A, and often the promiscuous 
effects of this small molecule on cis/mediali- and trans-Golgi have made specific 
dissection of transport through one of these Golgi compartments particularly difficult.  
We expect that GCA will serve as an effective tool for elucidating the mechanisms of 
COPI-dependent transport through the Golgi. 
 The siRNA screen of the human kinome led us to focus on the host stress 
response to STx.  While the contribution of the immune system to HUS pathology 
remains unclear, MK2 appears to play a significant role in cytokine expression and 
stabilization as part of an acute inflammatory response to STx.  MK2 represents a viable 
therapeutic candidate for the treatment of STx-mediated disease. 
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FUTURE DIRECTIONS 
 The use of small molecules to investigate STx transport has been shown to be an 
effective approach.  Despite gaining insight into the host transport mechanisms that are 
exploited by STx, our studies have revealed additional complexity regarding intracellular 
retrograde transport.  Similarly, the activation of MK2 following STx damage to the 
ribosome raises additional questions about the initiation and regulation of the 
inflammatory response to STx.  The following section outlines some possible directions 
for strengthening the conclusions of these studies and enhancing our understanding of 
STx pathogenesis at the levels of toxin transport and host stress response. 
 
Define a proteomic and lipidomic signature of toxin-containing vesicles 
 Perhaps the most understudied aspect of bacterial toxin trafficking is the 
recruitment of host molecules to the plasma membrane prior to the internalization of the 
toxin-receptor complex.  A more detailed understanding of this process will help define 
the host molecules essential to this process.  Moreover, as these membrane-bound toxins 
manage to bypass targeting to the lysosome for degradation, the composition of endocytic 
vesicles likely provides the localization signal to direct transport from endosomes to the 
TGN.  The recruitment, and exclusion, of host factors determines the fate of endocytosed 
toxin.  While studies have been undertaken to define host components of endosome-to-
TGN transport2, it remains unclear how bacterial toxins exploit host trafficking and 
dictate their transport.  
 We had previously shown that Vero cells treated with the fluorescently-tagged B 
subunits of Shiga toxin or cholera toxin (STxB-594 and CTxB-488, respectively) 
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internalize both toxins, and that these toxins, for the most part, colocalize to endocytic 
compartments previously shown to be early/recycling endosomes3.  However, a small 
proportion of vesicles contained only one of the toxins (Figure 1A).  These findings 
suggested that STx and CTx are internalized into similar vesicles, but the mechanisms by 
which these toxins reach this common compartment and the composition of these 
endosomes remain to be determined.  In addition, the endosomes containing only one 
toxin could be of importance and suggest a different endosomal composition compared to 
dually-labeled endosomes. 
 
 In an effort to define the composition of toxin-containing endosomes, our lab 
attempted to isolate fluorescently-tagged vesicles by fluorescent-activated cell sorting 
STxB 
CTxB 
Merge 
A) B) 
Figure 1.  Isolation of toxin-containing vesicles.  (A) STxB and CTxB converge on early endosomes.  Vero 
cells were treated with fluorescently-tagged STxB or CTxB for 1 h at 4ºC, then allowed to internalize toxin at 
22ºC for an additional hour.  Cells were fixed and developed for immunofluorescence.  (B) CTxB-488 vesicles 
can be isolated by FACS.  CTxB was allowed to bind to Vero cells for 1 h at 4ºC, after which toxin was 
internalized for 1 h at 22ºC.  Vesicles were isolated and sorted on a Dako MoFlo sorter, as outlined in the text.  
Approximately 6% of vesicles from toxin-treated cells were gated (R2) and collected, compared to 0.02% of 
vesicles falling into the R2 gate in untreated cells (not shown).  STxB, Shiga toxin B subunit; CTxB, cholera 
toxin B subunit; FACS, fluorescent-activated cell sorting.   
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(FACS) and characterize their composition by proteomics and lipidomics.  Isolation and 
purification of ligand-containing endosomes by FACS has proven difficult4, as the small 
size of these vesicles are not amenable to detection using forward and side scatter.  With 
the help of William Eades at the Cell Sorting Facility at Washington University, we were 
able to isolate CTxB-488-containing vesicles from Vero cells held at 22ºC, a temperature 
known to block endosome-to-TGN transport3.  The isolation could be achieved if the 
modular sorter was reconfigured with a smaller tip and rewired for detection on 
fluorescence instead of forward and side scatter.  Compared to untreated cells, CTxB-
488-containing cells showed an increased number of detectable vesicles in the gated 
region (see region R2 in Figure 1B; untreated cells not shown).  Given the ability to 
isolate and purify these vesicles, the proteomic and lipidomic composition of toxin-
containing vesicles can be determined.   
 This methodology could be extended to studying the composition of various 
ligand-containing endosomes to define their signature compositions.  For example, STxB 
and CTxB are known to reach transferrin-positive endosomes; the transferrin-transferrin 
receptor complex reaches recycling endosomes, where the receptor dissociates from its 
ligand and is recycled to the cell surface.  A comparison of STxB- or CTxB-containing 
endosomes to transferrin-positive endosomes would establish the host factors that 
constitute and distinguish these vesicles.  In addition, the composition of ligands known 
to be targeted to lysosomes could also be compared to STxB- or CTxB-positive vesicles 
in order to identify host factors that may be excluded from toxin-containing vesicles to 
avoid lysosomal degradation.  The composition of toxin-containing endosomes could also 
be studied for different cell lines and under various physiologic conditions (e.g., 
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cholesterol depletion).  As opposed to traditional immunofluorescence methods to define 
endosomal markers, this method provides a higher resolution of vesicle composition and 
could theoretically be applied to any fluorescently-tagged ligand. 
 
Structural characterization of GCA inhibition of GBF1 ARFGEF activity  
 The mechanism by which the Sec7 domain of GBF1 catalyzes GDP/GTP 
exchange on ARF1 has been elucidated through studies with BFA.  A crystal structure of 
the ARF1-Sec7-BFA complex revealed that BFA binds and stabilizes an abortive, ternary 
complex consisting of inactive ARF1-GDP, the Sec7 domain of GBF1, and BFA5.  The 
mechanism by which GCA inhibits GBF1 catalytic activity is not known, though our 
studies implicated the essential role for a tripeptide loop unique to the Sec7 domain of 
GBF16 and responsible for GCA’s selectivity for GBF1.  The function of this loop in 
mediating the interaction of ARF1 with the Sec7 domain of GBF1 is not known but is 
amenable to investigation using GCA. 
 Preliminary studies would attempt to crystallize a complex of GCA with ARF1 
and the GBF1 Sec7 domain.  Previous structures that captured this complex relied on 
BFA binding to ARF1-GDP complexed to the Sec7 domain of the Gea1, the yeast 
homologue of GBF1.  However, a sequence alignment of GBF1 with Gea1 reveals the 
absence of the GCA-susceptible tripeptide loop in Gea17.  As a result, crystallographic 
studies must rely on purification of recombinant GBF1 to accurately assess the 
significance of the tripeptide loop and the position of GCA in a putative complex. 
 It seems equally possible that GCA, like BFA, could stabilize an abortive 
complex of inactive ARF1-GDP with the Sec7 domain of GBF1.  The current model for 
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the mechanism of GBF1-catalyzed GDP/GTP exchange on ARF1 argues that a 
conformational change in the hinge region of the GBF1 Sec7 domain releases the Sec7-
ARF1 complex from the budding vesicle membrane following GTP exchange on ARF18.  
BFA is believed to block this process and maintain the association between ARF1-GDP 
and GBF1.  Since the hinge region on GBF1 contains the binding site of GCA, it is 
possible that GCA could function in a similar manner, given that it reduces intracellular 
levels of ARF1-GTP6.  One could pull down GBF1 and probe by Western for the 
presence of ARF1 in cells overexpressing epitope-tagged constructs of GBF1 and ARF1.  
We would expect to see increased levels of ARF1 associated with GBF1 in GCA-treated 
cells compared to untreated cells, as has been seen in BFA-treated cells8.  We would 
assume that ARF1 detected by this method would represent inactive ARF1-GDP.  
However, it is possible that GCA could stabilize a complex of GBF1 with active ARF1-
GTP.  In this instance, we would pull down ARF1-GTP using GST-GGA3, a specific 
probe for assessing levels of activated ARF1 in vivo 6, and look for GBF1 by Western 
blotting.  This possibility seems less likely, as GCA has been shown to specifically target 
GBF1 and reduce ARF1-GTP levels by an amount proportional to the expected 
contribution of GBF1 to GDP/GTP exchange on ARF16.    
 
Proteomic characterization of the STx-induced stress response 
 The activation of the host stress response by STx raises an interesting paradox.  
Given that STx inhibits host protein synthesis by inactivating the ribosome, how does the 
host manage to mount a stress response despite a drastically reduced translational rate?  
One hypothesis would be that the host cell diverts its remaining translational output to 
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preferentially translate host mRNAs related to the stress response.  Our studies have 
consistently observed that, even at the highest toxin concentrations (0.1 – 1 µg/mL), de 
novo protein synthesis is not completely shut off 6,9.  This implies that a small pool of 
ribosomes maintains a low level of translation despite an overall reduction in protein 
synthesis.  Host mRNAs relevant to the stress response would be preferentially targeted 
for translation or stabilized following the translational insult.  Our evidence suggests that 
certain inflammatory cytokine mRNAs (IL-6, TNFα) are increased following STx 
exposure.   
 Some studies have looked at the transcriptional profile following STx exposure 
and not surprisingly found increases in transcripts primarily associated with apoptosis 
and the immune response10,11.  However, these studies do not definitively address 
whether these transcripts are translated.  Certain transcripts could be preferentially 
translated at sub-lethal STx doses, when a greater proportion of active ribosomes are 
available.  Of particular importance in post-transcriptional mRNA regulation is the 
coordination of mRNA decay.  MK2 has been shown to indirectly contribute to the 
stability of cytokine mRNAs containing AU-rich elements (ARE) in their 3’untranslated 
regions, including the acute inflammatory cytokines IL-6 and TNFα12.  MK2 
phosphorylates the cytokine-destabilizing protein tristetraprolin (TTP).  Phosphorylated 
TTP is sequestered through its interaction with 14-3-3 proteins to stress granules, 
cytoplasmic foci where inactive components of the translational machinery accumulate 
under conditions of environmental stress.   
 To investigate the characteristics of proteins translated during ribotoxic stress, we 
would compare the proteomic profiles of cells treated with STx to those exposed to 
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catalytically inactive STxB.  This would control for non-specific effects of STx transport 
and would focus on the ribotoxic response.  Proteomic profiles could be compared to 
transcriptional data to identify the components of these mRNAs (e.g., AU-rich elements) 
responsible for their translation under conditions of toxic stress.  The identity of these 
proteins and transcriptional elements would not only provide a catalog of STx-induced 
proteins but would also enhance our understanding of how these transcripts are targeted 
for translation or stabilization.   
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